Official Title of Study: 
A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, 
in Men With Metastatic Castration-resistant Prostate Cancer 
Study ID: [REMOVED] 
Document Date (Date in which document was last revised): September 22, 2023 
Page: 1
Protocol  Number: CA2097DX
IND Number: 135,845
EUDRACT Number : 2019-002030-36
Date :
25-Jul- 2019
Revised Date: 22-Sep-2023
CLINICAL PROTOCOL CA2097DX
A Phase 3 Rando mized, Double -Blind Study  of Nivol umab or Pl acebo in Combinat ion with 
Docetaxel, in Men with Metastatic Castration
-resistant Prostate Cancer (CheckMate 7DX: 
CHECKpo int pathway  and nivo luMAB clinical Trial Evaluat ion 7DX)
Short Title:
A Study  of Nivo lumab or Placebo in Combinatio n with Docetaxel  in Men with Metastati c 
Castration-resistant Prostate Cancer
Protocol Amendment 04
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
3401 Princeton Pike 
Lawrenceville, NJ 08648 USARoute de Perreux 1
Boudry , Swi
tzerland
Telephone (office): Telephone (m obile): 
Email: Email: 
24-hr Emergency Telephone Number
USA: 
International: 
Bristol -Myers Squibb Company
Route 206 & Province Line Road
Lawrenceville, NJ 08543
Avenue de Finlande 4
B
-1420 Braine -l‚ÄôAlleud, Belgium
1-2-1 Otematchi, Chiyoda - ku
Toky o 100 -0004, Japan
This document is the confidential and proprietary information of Bristol -Myer s Squibb 
Company and its global affiliates (BMS). By reviewing this document, you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the propo sed BMS sponsored 
study. Any permitted disclosures will be made only on a confidential "need to know" basis 
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Protocol Amendment No.: 0 4
Date: 22-Sep-2023 2within your organization or to your independent ethics committee(s). Any other use, copying, 
disclosure or dissemination of this information is strictly prohibited unless expressly 
authorized in writing by BMS. Any supplemental information (eg, amendments) that may 
be added to this document is also confidential and proprietary to BMS and must be kept in 
confidence in the same manner as the contents ofthis document. Any person who receives 
this document without due authorization from BMS is requested to return it to BMS or 
promptly destroy it. All other rights reserved. References to BMS in this protocol may apply 
to partners to which BMS has transferr ed obligations, eg, a Contract Research Organization 
(CRO).
¬© 2023 Bristol -Myers Squibb Company
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Protocol Amendment No.: 0 4
Date: 22-Sep-2023 3DOCUMENT HISTORY
Document Date of Issue Summary of Change
Protocol 
Amendment 0422-Sep -2023The purpose of this protocol amendment is to formally incorporate 
guidance provided in the ‚ÄúDear Investigator‚Äù letters from 27
-Jul-2023 and 
10-Aug -2023, and further clarify participant management and study 
procedures as the study proceeds toward termination due to one of the 
primary  efficacy endpoints not meeting the success criterion and the 
implausibility of success of the other primary endpoint. The decision to 
terminate the study was not based on any safety  concerns or issues. On 
26-Jul -2023 the study independent Data Moni toring Committee convened. 
Based on a clinical data cutoff of 01 -Jun-2023, the addition of nivolumab 
to docetaxel plus prednisone did not result in a statistically significant 
improvement in radiographic progression -free survival (rPFS) (hazard 
ratio 0.96;99% confidence interval [CI] 0.77, 1.19) at final analy sis and 
overall survival (OS) at the first interim analy sis (hazard ratio 1.09; 
99.41% CI 0.84, 1.43) compared to placebo added to docetaxel plus 
prednisone. A Sponsor Executive Oversight Committee (EOC) requested 
to be unblinded to the study results. Further evaluation of OS results 
showed no plausible scenario of reaching OS statistical significance at 
subsequent, planned statistical analy ses, including the second interim 
analy sis and final analy sis. Given the lack of clinical benefit from 
nivolumab added to docetaxel plus prednisone for the dual primary 
efficacy endpoints of rPFS and OS, the Sponsor EOC decided to terminate 
the study. Unblinding of study treatment assignment to full study teams 
and i nvestigato rs occurred on 03 -Aug -2023.
Dear Investigator 
Letter10-Aug - 2023 Study termination details and topline data .
Dear Investigator 
Letter27-Jul -2023 Notification of study termination.
Protocol 
Amendment 0313-Sep -2022Major changes:
ÔÇ∑Changes to the statistical analysis section, in which the population for 
radiographic progression -
free survival (rPFS) analysis has been 
changed from the first 544 participants randomized to all randomized 
and the number of events from 433 to 530 rPFS even ts.
ÔÇ∑Changes to clarify censoring rules for rPFS .
ÔÇ∑Increase d overall survival (OS) event sfrom 615 to 690.
ÔÇ∑Clarification of pharmacokinetic sampling at follow -up visits .
ÔÇ∑Clarification of SARS -CoV -2 serology at follow -up as optional.
Administrative 
Letter 0520-Oct -2021 Study Personnel Updated
Administrative 
Letter 0325-Mar - 2021 Study Personnel updated
Protocol 
Amendment 0217-Mar - 2021Major changes:
 
ÔÇ∑Rem oved exclus ion criterio nfor prior radium -223 exposure.
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Protocol Amendment No.: 0 4
Date: 22-Sep-2023 4Document Date of Issue Summary of Change
ÔÇ∑Aligned dose modification criteria and immuno -oncology (IO) agent 
management algorithms with National Cancer Institute Common 
Terminology Criteria for Adv erse Event s (NCI CTCAE) version 5 . 
ÔÇ∑Added serologic testing for severe acute respiratory syndrome 
coronavirus 2 (SARS -CoV -2) status.
ÔÇ∑Incorpo rated additional updates in order to improve alignment 
between protocol sections and clarify remote monitoring, prior 
malignancy window, thyroid testing ,and male contraception 
requirements . 
Revised Protocol 
0106-May -2020Major changes: 
 
 
ÔÇ∑C
larifiedthe inclusion criteria for current evidence of metastatic 
disease and prior treatment with NAT .
ÔÇ∑Lesions that do not qualify as visceral dis ease clarified .
ÔÇ∑Frequency of tumor assessment revised to enhance precision of the 
radiographic progression -free survival (rPFS) endpoint ,and the 
criteria for stable disease (SD) was revised based on frequency of 
tumor assessments .
ÔÇ∑The statistical sectio n now specifies sample size for rPFS and corrects 
the number of events needed for analysis of rPFS.
ÔÇ∑Revisions  have been 
incorporated (France, Germany, Italy, Singapore, Czech Republic, 
US, N. Zealand) .
ÔÇ∑Changes of Administrative Letters 02 and 01 now incorporated .
Administrative 
Letter 0210-Dec -2019Additional corrections were identified and corrected in administrative 
letter.
Administrative 
Letter 0109-Nov -2019Discrepancies in the protocol were corrected and clarification sto 
language were made to ensure proper alignment throughout all sections 
of the protocol. 
Original Protocol 25-Jul-2019 Not applicable .
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
OVERALL RATIONALE FO R PROTOCOL AMENDMENT 04:
The purpose of this protocol  a mendment is to formally incorporate guidance provided in the ‚ÄúDear 
Invest igator‚Äù letters from 27-Jul- 2023 and 10-Aug -2023, and further clarify  participant 
management and study  procedures as the study  proceeds toward terminat ion due to one of the 
primary  efficacy  endpoints not meet ing the success criterion and the implausibilit y of success of
the other primary endpoint. The decision to terminate the study  was not based on any safety 
concerns or issues. On 26 -Jul-2023 the study  independent Data Monitoring Committee convened. 
Based on a clinical data cutoff of 01-Jun- 2023 , the addition of nivolumab to docetaxel plus 
prednisone did not result in a statistically significant improvemen t in radiographic progressi on-
free survival (rPFS) (hazard rati o 0.96; 99% confidence interval [CI] 0.77, 1.19) at final analysis 
and overall survival  (OS) at the first interim analysis (hazard ratio 1.09; 99.41% CI 0.84, 1.43) 
compared to placebo added todocetaxel plus prednisone. A Sponsor Executive Oversight 
Committee (EOC) requested to be unblinded to the study  resul ts. Further evaluation of OS results 
showed no plausible scenari o of reaching OS statistical significance at subsequent, planned 
statist ical analyses, including the second interim analysis and final analysis. Given the lack of 
clinical benefit from nivolumab added to docetaxel  plus prednisone for the dual  primary  efficacy 
endpo ints of rPFS and OS, the Sponsor EOC deci ded to terminate the stu dy. Unblinding of study 
treatm ent assi gnment to full  study  team s and investi gators occurred on 03 -Aug-2023.
SUMMARY OF KEY CHANG ES FOR PROTOCOL AMENDMENT 
04
Section Number & Title Description of Change Brief Rationale
Title Page Rem oved Clinical Scientist information. Updated per Sponsor 
requirements.
Protocol Summary
Section 3.1: Overall 
Rationale for Protocol 
Amendment 0 4and Study 
TerminationAdded the following text:
‚ÄúPer Protocol Amendment 0 4, the independent Data 
Monitoring Committee (DMC) convened on 26 -Jul-2023 
for a prespecified review of all available study data based 
on a clinical data cutoff of 01 -Jun-2023 . After reviewing 
the final analysis of the primary efficacy endpoint of 
radiographic progression -free survival (rPFS) per Blinded 
Independent Central Review (BICR) and the first interim 
analy sis of the primary efficacy endpoint of overall 
survival (OS), the DMC agreed that the study did not meet 
the prespecified boundaries for declaring statistical 
significance for either endpoint. Although the number of 
events for OS at the second interim analysis and final 
analy sis of OS had not been attained, based on the first 
interim analysis results for OS, the DMC determined that 
the prespecified boundaries for declaring significance were 
unlike ly to be met. No new safety concerns were 
identified. ASponsor Executive Oversight Committee 
(EOC) requested to be unblinded to the study results and 
decided to terminate the study. F ull study  teams and 
investigators were unblinded to study treatment 
assignment on 03-Aug-2023 .Provide an 
explanatio n for study 
termination.
Protocol Amendment No.: 04
Date: 22-Sep-2023 5
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
SUMMARY OF KEY CHANG ES FOR PROTOCOL AMENDMENT 04
Section Number & Title Description of Change Brief Rationale
Protocol Amendment 0 4reflects changes in study conduct. 
For participants who are deemed appropriate to continue 
on nivolumab or docetaxel therapy through  the 
CA2097DX study, re -consent will be required. ‚Äù
Protocol Summary
Section 5.1: Overall 
Design
Figure 5.1 -1: Study Design 
Schematic
Section 5.1.2: Treatment 
Phase
Section 7: Treatment
Table 7-1: Study 
Treatments for CA2097DX
Section 7.1: Treatments 
Administered
Table 7.1 -1: Selection and 
Timing of Dose
Section 7.1.1: Nivolumab 
or Placebo Combined with 
Docetaxel
Section 7.1.2: Nivolumab 
or Placebo Dosing
Section 7.4: Dos age
Modification
Table 7.4 -1: Adverse 
Event Criteria to Delay, 
Resume, or Discontinue 
Nivolumab/PlaceboClarified that participants assigned to Arm B will no 
longer receive placebo.Investigators and 
study teams have 
been unblinded to 
study treatment 
assignment as a result 
ofstudy termination
due to lack of 
efficacy benefit for 
nivolumab added to 
docetaxel plus 
prednison e compared 
to placebo added to 
docetaxel plus 
prednisone .
Protocol Summary
Section 5.1.2: Treatment 
PhaseClarified that decisions on docetaxel treatment will be 
based on the clinical judgment of the treating physician 
and o n shared decision making with t he participant. 
Participants who are not able to access local therapy may 
continue on study -provided docetaxel until local access is 
available. In the event that the investigator deems a 
participant is deriving clinical benefit from nivolumab 
therapy  and, together with the counseled participant, 
wishes to continue treatment, this may be possible 
following discussion with the Medical Monitor to ensure a 
clinical rationale exists that justifies continuation of 
nivolumab treatment. Ensure that 
participants cu rrently 
receiving study -
provided docetaxel 
do not undergo 
treatment 
interruptions.
Protocol Summary
Section 5.2: Data 
Monitoring Committee and 
Other External CommitteesNoted that the Data Monitoring Committee is no longer 
applicable.No longer relevant 
due to study 
termination.
Protocol Amendment No.: 04
Date: 22-Sep-2023 6
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
SUMMARY OF KEY CHANG ES FOR PROTOCOL AMENDMENT 04
Section Number & Title Description of Change Brief Rationale
Protocol Summary
Table 10.1 -1: Sample Size 
Determination ; footnote b
Section 10.3.7.1: Interim 
Analy sis for OSClarified that the second interim analysis for OS and final 
analy sis for OS will not be performed, and the first inter im 
analy sis will be considered as the final analysis. At the 
time of study closeout, an updated descriptive OS analysis 
will be provided to report all death events.Study termination.
Table 2-2: On -Study 
Treatment and Follow -up 
Procedural Outline for 
Arms A and B 
(CA2097DX)
Section 5.1.2: Treatment 
Phase
Section 5.1.3: Follow -up 
Phase
Section 7.7.5: Re -
assessment Following 
Initial Assessment of 
Progression
Section 9: Study 
Assessments and 
Procedures
Section 9.1.1: Imaging 
Assessment for the Study
Section 9.1.1.2: Imaging 
and Clinical Assessment
Section 9.1.2: BICR 
Confirmation of 
Progression 
Section 9.1.3: Patient -
Reported Outcomes
Section 9.1.4: The Brief 
Pain Inventory -Short 
Form
Section 9.1.5: The 
Functional Assessment of 
Cancer Therapy -Prostate 
Cancer (FACT -P)
Section 9.1.6: The 5-Level 
EQ-5D
Section 9.2: Adverse 
Events
Section 9.2.5: Pregnancy
Section 9.2.6: Laboratory 
Test Result Abnormalities.Provided clarification for on -treatment and follow -up 
assessments:
ÔÇ∑Safety
Only applicable to:
Participants continuing study -provided 
nivolumab.
Participants up to 100 days after their last
nivolumab infusion.
All other participants will be discontinued from 
the study  and switched to local standard of care 
for metastatic castration -resistant prostate cancer, 
outside of the study.
ÔÇ∑Adverse events (AEs)
After completion of the 100-day safety follow -up 
requirement and resolution or stabilization of AEs, 
nivolumab -treated participants will be discontinued 
from the study. 
ÔÇ∑Subsequent cancer therapy is no longer applicable.
ÔÇ∑PSA is no longer applicable.
ÔÇ∑Labora tory tests
Will include local safety laboratory tests only and 
will exclude tests such as PSA,  and 
pharmacokinetics. In addition, the requirement 
for local safety laboratory tests will ONLY be 
applicable to:
Participants continuing study -provided 
nivolumab. 
Participants up to 100 days from their last 
nivolumab infusion.
All other participants will be discontinued from 
the study  and switched to local standard of care 
for metastatic castration -resistant prostate cancer, 
outside of the study.
ÔÇ∑Efficacy is no longer applicable.
ÔÇ∑Radiographic tumor assessments per BICR and 
following Prostate Cancer Working Group 3 criteria 
are no longer applicable.
All participants receiving study treatment will 
have radiographic tumor assessmen ts based on 
the clinical judgment of the treating investigator 
and following local imaging tumor assessment Study termination.
Protocol Amendment No.: 04
Date: 22-Sep-2023 7
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
SUMMARY OF KEY CHANG ES FOR PROTOCOL AMENDMENT 04
Section Number & Title Description of Change Brief Rationale
Section 9.2.7: Potential 
Drug Induced Liver Injury 
(DILI)
Section 9.2.8: Other Safety 
Considera tions
Section 9.4: Safety Section 
9.4.4: Clinical Safety 
Laborato ry Assessments
Section 9.5: 
Pharmacokinetics Section 
 
 
 
 
 
 
 
 
Section 9.8.2: Additional 
Research Collection
Section 9.8.3: 
Immunogenicity 
Assessments
 
Section 9.9: Healthcare 
Resource Utilization and 
Health Economics 
Appendix 5: Prostate 
Cancer Working Group 3 
(PCWG3) Guidelines (with 
Modified Response 
Evaluatio n Criteria in Solid 
Tumo rs (RECIST) Criteria 
for Soft Tissue Lesion 
Assessment)guidelines for metastatic castration -resistant 
prostate cancer . . 
ÔÇ∑Submission of tumor imaging assessments for central 
review will no longer apply.  
ÔÇ∑Collection of survival data is no longer applicable. 
 
 
ÔÇ∑Health outcomes are no longer applicable.
ÔÇ∑The Brief Pain Inventory -Short Form (BPI-SF) is no 
longer applicable.
ÔÇ∑The Functional Assessment of Cancer Therapy -
Prostate Cancer (FACT -P)is no longer applicable.
ÔÇ∑The 5 -Level EQ -5D i s no longer applicable.
ÔÇ∑Pregnancy is only applicable to female partner sof 
male participant scontinuing study -provided 
nivolumab, and female partner sof male participants 
up to 100 days after the last infusion of nivolumab. 
ÔÇ∑Potential DILI assessments are only applicable to 
participants continuing study -provided nivolumab, 
and participants up to 100 days after the last infusion 
of nivolumab.
 
ÔÇ∑Additional research collection is no longer applicable
ÔÇ∑Healthcare resource utilization and health economics 
are no longer applicable.
ÔÇ∑Laborato ry test result abnormalities are only 
applicable to participants continuing study -provided 
nivolumab, and participants up to 100 days after the 
last infusion of nivolumab.
ÔÇ∑Overdose is only applicable to participants continuing 
study-provided nivolumab, and participants up to 100 
days after the last infusion of nivolumab.
Protocol Amendment No.: 04
Date: 22-Sep-2023 8
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
SUMMARY OF KEY CHANG ES FOR PROTOCOL AMENDMENT 04
Section Number & Title Description of Change Brief Rationale
Table 2-2 : On-Study 
Treatment and Follow -up 
Procedural Outline for 
Arms A and B 
(CA2097DX)
Section 5.1.3: Follow -up 
PhaseClarified that the follow -up phase o nly applies to 
participants up to 100 days after the last infusion of 
nivolumab. After 100 days of follow -up have been 
completed,  t he nivolumab -treated participants will be 
permanently discontinued from the study. Clarified participants 
applicable to the 
follow -up phase 
following study 
termination.
Section 5.1: Study Design Added the following text:
Per Protocol Amendment 04, full study teams and 
investigators were unblinded to study treatment 
assignment on 10 -Aug -2023 and 11 -Aug -2023, 
respectively, due to lack of rPFS and OS benefit from 
nivolumab added to docetaxel plus prednisone compared 
to placebo added to docetaxel plus predni sone.Clarified unblinding 
of study teams and 
investigators due to 
study termination.
Section 5.4: End of Study 
Definitio nClarified that the first interim analysis will be considered 
the final analysis. and that the study will end whenthe last 
participant receiving study -provided nivolumab completes 
100 days of safety follow -up after their last nivolumab 
infusion. 
Updated the total duration of the study from the date of 
first participant treated to the final analysis of both 
primary  endpoints to approximately 31 months.
Deleted the definition of the start of the study, and that the 
survival analysis may be conducted for up to 5 years after 
treatment initiation.Clarified the end of 
study definition 
following study 
termination.
Section 7.2: Blinding Noted that blinding is no longer applicable. Investigators and full 
study teams have 
been unblinded to 
treatment assignment 
due to study 
termination.
Section 7.7.4: Treatment 
Beyond ProgressionNoted as no longer applicable. Study termination.
Section 7. 8: Treatment 
After the End the of StudyClarified that BMS recommends discontinuation of 
nivolumab in all participants receiving this study 
treatment. In the event that the investigator deems a 
participant is deriving clinical benefit from nivolumab 
therapy  and, together with the counseled participant, 
wishes to continue nivolumab, this may be allowed 
following discussion with the Medical Monitor.
Deleted the following text:
At the conclusion of the study, participants who continue 
to demonstrate clin ical benefit will be eligible to receive 
BMS supplied study treatment for the maximum treatment 
duration specified in protocol Section 5.Clarify  the potential 
continued use of 
nivolumab following 
study termination.
Protocol Amendment No.: 04
Date: 22-Sep-2023 9
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
SUMMARY OF KEY CHANG ES FOR PROTOCOL AMENDMENT 04
Section Number & Title Description of Change Brief Rationale
Section 8.1.2: Post Study 
Treatment -Study Follow -
up
Section 8.2: 
Discontinuation from the 
StudyClarified that only participants who received study -
provided nivolumab and are up to 100 days after the last 
nivolumab infusion will have post -study treatment safety 
follow -up. After completion of the 100 -day safety follow -
up requirement and resolution or stabilization of AEs, 
nivolumab -treated participants will be discontinued from 
the study . All other participants currently on safety or 
survival follow -up with resolutio n or stabilization of AEs 
will be discontinued from the study. Clarified the post -
study follow -up and 
discontinuation from 
the study  as a result 
of study termination.
Section 8.3: Lost to 
Follow -upNoted that this section is no longer applicable. Study termination.
Section 10.3: Statistical 
Analy ses
Section 10.3.1: Efficacy 
Analy ses
Section 10.3.3: 
Pharmacokinetic Analyses
Section 10.3.4: 
Immunogenicity Analyses
Section 10.3.5: Outcomes 
Research AnalysesNoted as not applicable. Study termination.
All Minor formatting and edits. These changes are 
minor and, therefore, 
have not been 
summarized.
Protocol Amendment No.: 04
Date: 22-Sep-2023 10
6.0
Approved
930142083
5.0
v
Approved
1.0
v
7$%/(2)&217(176
7,7/(3$*( 
'2&80(17+,6725< 
29(5$//5$7,21$/()2535272&2/$0(1'0(17 
6800$5<2).(<&+$1*(6)2535272&2/$0(1'0(17 
7$%/(2)&217(176 
6<1236,6 
6&+('8/(2)$&7,9,7,(6 
,1752'8&7,21 
2YHUDOO5DWLRQDOHIRU3URWRFRO$PHQGPHQWDQG6WXG\7HUPL QDWLRQ
6WXG\5DWLRQDOH 
5HVHDUFK+\SRWKHVLV 
%DFNJURXQG 
%DFNJURXQG,QGLFDWLRQDQG7UHDWPHQW/DQGVFDSH 
1LYROXPDE0HFKDQLVPRI$FWLRQ 
'RFHWD[HO0HFKDQLVPRI$FWLRQ 
%HQHILW5LVN$VVHVVPHQW 
2%-(&7,9(6$1'(1'32,176 
678'<'(6,*1 
2YHUDOO'HVLJQ 
6FUHHQLQJ3KDVH 
7UHDWPHQW3KDVH 
)ROORZXS3KDVH 
'DWD0RQLWRULQJ&RPPLWWHHDQG2WKHU([WHUQDO&RPPLWWHHV 
1XPEHURI3DUWLFLSDQWV 
(QGRI6WXG\'HILQLWLRQ 
6FLHQWLILF5DWLRQDOHIRU6WXG\'HVLJQ 
5DWLRQDOHIRU3RSXODWLRQ 
5DWLRQDOHIRU,PPXQRWKHUDS\LQP&53& 
5DWLRQDOHIRU&KRLFHRI(QGSRLQWV 
5DWLRQDOHIRU6DPSOH6L]H'HWHUPLQDWLRQ 
5DWLRQDOHIRU'XUDWLRQRI6WXG\7UHDWPHQW 
1LYROXPDE 
'RFHWD[HO 
5DWLRQDOHIRU1LYROXPDE0LQXWH,QIXVLRQ 

-XVWLILFDWLRQIRU'RVH 
-XVWLILFDWLRQIRU1LYROXPDE'RVH 
678'<3238/$7,21 
,QFOXVLRQ&ULWHULD 
([FOXVLRQ&ULWHULD 
/LIHVW\OH5HVWULFWLRQV 
6FUHHQ)DLOXUHV 
5HWHVWLQJ'XULQJ6FUHHQLQJ 
75($70(17 


































Clinical Protocol
BMS-936558CA2097DX
nivolumab
Protocol Amendment No.: 04
Date: 22-Sep-2023 11
6.0 Approved 930142083 5.0 v Approved 1.0 v
7UHDWPHQWV$GPLQLVWHUHG 
1LYROXPDERU3ODFHER&RPELQHGZLWK'RFHWD[HO 
1LYROXPDERU3ODFHER'RVLQJ 
%OLQGLQJ 
0HWKRGRI7UHDWPHQW$VVLJQPHQW 
'RVDJH0RGLILFDWLRQ 
1LYROXPDERU3ODFHER 
'RFHWD[HO'RVH5HGXFWLRQ 
'RVH'HOD\&ULWHULD 
&ULWHULDWR5HVXPH6WXG\7UHDWPHQW 
0DQDJHPHQW$OJRULWKPVIRU1LYROXPDE 
7UHDWPHQWRI5HODWHG,QIXVLRQ5HDFWLRQV 
'RFHWD[HOUHODWHG+\SHUVHQVLWL YLW\5HDFWLRQV 
3UHSDUDWLRQ+DQGOLQJ6WRUDJH$FFRXQWDELOLW\ 
5HWDLQHG6DPSOHVIRU%LRDYDLODELO LW\%LRHTXLYDOHQFH%LRFR PSDUDELOLW\
7UHDWPHQW&RPSOLDQFH 
&RQFRPLWDQW7KHUDS\ 
3URKLELWHGDQGRU5HVWULFWHG7UHDWPHQWV 
$OO3DUWLFLSDQWV 
1LYROXPDE&RPELQHGZLWK'RFHWD[HO 
,PDJLQJ5HVWULFWLRQDQG3UHFDXWLRQV 
3HUPLWWHG7KHUDS\ 
3DOOLDWLYH/RFDO7KHUDS\ 
7UHDWPHQW%H\RQG3URJUHVVLRQ 
5HDVVHVVPHQW)ROORZLQJ,QLWLDO$VVHVVPHQWRI3URJUHVVLRQ 
7UHDWPHQW$IWHUWKH(QGRIWKH6WXG\ 
',6&217,18$7,21&5,7(5,$ 
'LVFRQWLQXDWLRQIURP6WXG\7UHDWPHQW 
'LVFRQWLQXDWLRQRI6SHFLILF6WXG\7UHDWPHQWV 
3RVW6WXG\7UHDWPHQW6WXG\)ROORZXS 
'LVFRQWLQXDWLRQIURPWKH6WXG\ 
/RVWWR)ROORZ8S 
678'<$66(660(176$1'352&('85(6 
(IILFDF\$VVHVVPHQWV 
,PDJLQJ$VVHVVPHQWIRUWKH6WXG\ 
0HWKRGVRI0HDVXUHPHQW 
,PDJLQJDQG&OLQLFDO$VVHVVPHQW 
%,&5&RQILUPDWLRQRI3URJUHVVLRQ 
3DWLHQW5HSRUWHG2XWFRPHV 
7KH%ULHI3DLQ,QYHQWRU\6KRUW)RUP 
7KH)XQFWLRQDO$VVHVVPHQWRI&DQFHU7KHUDS\3URVWDWH&D QFHU)$&7
3 
7KH/HYHO(4' 
$GYHUVH(YHQWV 
7LPH3HULRGDQG)UHTXHQF\IRU&ROOHFWLQJ$(DQG6$(,QIRU PDWLRQ
0HWKRGRI'HWHFWLQJ$(VDQG6$(V 




































Clinical Protocol
BMS-936558CA2097DX
nivolumab
Protocol Amendment No.: 04
Date: 22-Sep-2023 12
6.0 Approved 930142083 5.0 v Approved 1.0 v
)ROORZXSRI$(VDQG6$(V 
5HJXODWRU\5HSRUWLQJ5HTXLUHPHQWVIRU6$(V 
3UHJQDQF\ 
/DERUDWRU\7HVW5HVXOW$EQRUPDOLWLHV 
3RWHQWLDO'UXJ,QGXFHG/LYHU,QMXU\',/, 
2WKHU6DIHW\&RQVLGHUDWLRQV 
2YHUGRVH 
6DIHW\ 
3K\VLFDO([DPLQDWLRQV 
9LWDOVLJQV 
(OHFWURFDUGLRJUDPV 
&OLQLFDO6DIHW\/DERUDWRU\$VVHVVPHQWV 
,PDJLQJ6DIHW\$VVHVVPHQW 
3KDUPDFRNLQHWLFV 
3KDUPDFRG\QDPLFV 
3KDUPDFRJHQRPLFV 








$GGLWLRQDO5HVHDUFK&ROOHFWLRQ 
,PPXQRJHQLFLW\$VVHVVPHQWV 

+HDOWKFDUH5HVRXUFH8WLOL]DWLRQDQG+HDOWK(FRQRPLFV 
67$7,67,&$/&216,'(5$7,216 
6DPSOH6L]H'HWHUPLQDWLRQ 
3RSXODWLRQVIRU$QDO\VHV 
6WDWLVWLFDO$QDO\VHV 
(IILFDF\$QDO\VHV 
6DIHW\$QDO\VHV 
3KDUPDFRNLQHWLF$QDO\VHV 
,PPXQRJHQLFLW\$QDO\VHV 
2XWFRPHV5HVHDUFK$QDO\VHV 
%3,6) 
)$&73 
(4'/ 
2WKHU$QDO\VHV 
,QWHULP$QDO\VHV 
,QWHULP$QDO\VLVIRU26 
5()(5(1&(6 
$33(1',&(6 
$33(1',;$%%5(9,$7,216$1'75$'(0$5.6 




































Clinical Protocol
BMS-936558CA2097DX
nivolumab
Protocol Amendment No.: 04
Date: 22-Sep-2023 13
6.0 Approved 930142083 5.0 v Approved 1.0 v
$33(1',;678'<*29(51$1 &(&216,'(5$7,216 
$33(1',;$'9(56((9(176$1 '6(5,286$'9(56((9(176
'(),1,7,216$1'352&('85(6) 255(&25',1*(9$/8$7,1*
)2//2:83$1'5(3257,1* 
$33(1',;:20(12)&+, /'%($5,1*327(17,$/'(),1,7,216$1'
0(7+2'62)&2175$&(37,21 
$33(1',;35267$7(&$1&(5 :25.,1**52833&:*
*8,'(/,1(6:,7+02',),('5(63216((9$/8 $7,21&5,7(5,$,1
62/,'7802565(&,67&5,7(5,$)2562)77,668(/(6,21
$66(660(17 
$33(1',;0$1$*(0(17$/*2 5,7+06)25678',(681'(51&,
&7&$(9(56,21 
$33(1',;&<3$67521*,1+,%,725$ 1',1'8&(5*8,'$1&( 
$33(1',;(&2*3(5)250$1&(67$786 
$33(1',;&28175<63(&,),&$0(1' 0(176+,97(67,1* 
$33(1',;35272&2/$0(1' 0(176800$5<2)&+$1*(+,6725<
  








Clinical Protocol
BMS-936558CA2097DX
nivolumab
Protocol Amendment No.: 04
Date: 22-Sep-2023 14
6.0 Approved 930142083 5.0 v Approved 1.0 v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
1 SYNOPSIS
Protocol Title: A Phase 3 Randomized, Double -Blind Study of Nivolumab or Placebo in 
Combination with Docetaxel, in Men with Metastatic Castration -resistant Prostate Cancer 
(CheckMate 7DX: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7DX)
Short Title:
A Study  of Nivo lumab or Placebo in Combinatio n with Docetaxel  in Men with Metastati c 
Castrati on-resist ant Prostate Cancer (mCRPC)
Study Phase: 3
Rationale:
Prostate cancer tumor cells have been shown to have low tum or expressio n of programmed deat h 
ligand -1 (PD-L1), suggesting that treatm ents directed at the programmed death -1 (PD1 )/PD-L1 
interact ion are unlikely to be successful as monotherapi es.1This was confirmed by early clinical 
trials, where unselected men with mCRPC did not respond to PD-1 blockade as monotherapy .2
However, several studi es show that PD-L1 expressio n can be up-regul ated in response to 
inflammatory  cytokines, a phenom enon which has been term ed ‚Äúadapt iveimmune resistance .3,4,5
This suggests that if prostate cancer treatments (ie, chemotherapy, androgen ablat ion) can increase 
PD-L1 expressio n on tumor cells by attracting infiltrating immune cells and triggering an adaptive 
immune response, there is a rationale for combining such therapies with immune check -point 
inhibitors .6,7,8,9The rationale for combining chem otherapy  and immunotherapy  is based on the 
findings that cytotoxi c treatm ents such as chem otherapy  may modulate tumor/immune -system 
interact ions i
n favor of the immune system . Chemotherapy  can resul t in tumor cell  death as part 
of its intended therapeut ic effect with a resul tant increase in tumor antigen delivery to antigen -
present ing cells.
These findings have led to the development of clinical trials evaluating the combinat ion of 
docetaxel and PD1/PDL1 inhibitors which has shown promising act ivity in pat ients with mCRPC 
previously treated with second -generati on hormonal therapi es as described in Rationale for 
Popul ation Section of the Protocol.
NCC N guidelines reco mmend to use docetaxel (category 1) as the preferred 1st line chemotherap y 
in men with symptom atic mCRPC and in patients with signs of rapid progressi on or viscera l 
metastases despite lack of  symptoms. In addi tion, docetaxel has a category 1 recommendat ion in 
second -line after prior enzalutamide/abiraterone .
The current study  aims to demonstrate that treatm ent with docetaxel  in combinat ion with 
nivolumab will be efficaci ous in participants with mCRPC. Addit ional object ives of the study 
include characteri zation of safety and tolerabili ty, as well as pharmacokinet ics,  
 and changes in patient reported outcomes for qualit y of life assessments.
Per Protocol Amendment 04, the independent Data Monitoring Committee (D MC) convened 
on 26-Jul- 2023 for a prespecified review of all available study data based on a clinical data 
Protocol Amendment No.: 04
Date: 22-Sep-2023 15
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
cutoff of 01 -Jun-2023 . After reviewing the final analysis of the primary efficacy endpoint of 
radiographic progression -free survival (rPFS) per Blinded Independent Central Review 
(BICR) and the first interim analysis of the primary efficacy endpoint of overall survival 
(OS), the DMC agreed that the study did not meet the prespecified boundaries for declaring 
statistical significance for either endpoint . Although the number of events for OS at the 
second interim analysis and final analysis of OS had not been attained, based on the first 
interim analysis results for OS, the DMC determined that the prespecified boundaries for 
declaring significance were unlikely to be met. No new safety concerns were identified. A
Sponsor Executive Oversight Committee (EOC) requested to be unblinded to the study 
results and decided to terminate the study. Full study teams and investigators were 
unblinded to study treatmen t assignment on 03 -Aug-2023.
Protocol Amendment 04 reflects changes in study conduct. For participants who are deemed 
appropriate to continue on nivolumab or docetaxel therapy through the CA2097DX study, 
re-consent will be required.
Study Population:
Male participants ages 18 or local age of maj ority.
Key Inclusion Criteria:
ÔÇ∑Histologic confirmat ion of adenocarcino ma of the prostate. Diagnosis must be stated in a 
pathol ogy report and confirmed by  the investi gator
ÔÇ∑Current evidence of metastatic disease docum ented by eit her bone lesio ns on radionuclide bone 
scan and/or soft tissue lesio ns on CT/MRI. Metastases may be in regional lymph nodes (N1 
per AJCC staging criteria, 8th edition) and/or distant metastases (M1 perAJCC staging criteria, 
8th edit ion). 
ÔÄ≠Parti cipants whose disease spread is limited to regional pelvic lymph nodes (N1) measuring 
at least 2 cm  in short axi s will be considered eligible.
ÔÇ∑Ongo ing ADT with a
 gonadotropi n-releasing horm one (GnRH) analogue or bilateral 
orchi ectomy  (ie, surgical or medical castration) confirm ed by  testosterone level ‚â§ 1.73 nmol/L 
(50 ng/dL) at the screening visit. Castrate levels of testosterone must be maintained by surgica l 
or medical means (luteinizing horm one-releasing horm one [LHRH]/ GnRH analogues) 
throughout the conduct of the study. For participant s who have not had an orchiectomy , this 
therapy  must have been initiated at least 4 weeks prior to first dose of study treatm ent and 
treatm ent m ust be continued throughout the s tudy
ÔÇ∑Docum ented prostate cancer progressi on as per PCWG3 criteria within 6 months prior to 
screening with at least one of the fo llowing:
ÔÄ≠PSA progressi on defined by a minimum of 2 rising PSA levels with an interval ofÔÇ≥1week 
between each determinat ion. The PSA value at the screening visit shoul d be ÔÇ≥2Œºg/L (2 
ng/mL).
Note: Participants who received an anti-androgen must have PSA progression after 
withdrawal (ÔÇ≥4weeks since last flutamide administrati on orÔÇ≥6 weeks since last 
bicalutamide or nilutamide administration)
Protocol Amendment No.: 04
Date: 22-Sep-2023 16
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
ÔÄ≠Radiographic disease progression in soft tissue based on RECIST 1.1 criteria. 
ÔÄ≠Radiographic disease progression in bone defined as appearance of 2 or more new bone 
lesions on bone scan
ÔÇ∑Parti cipants who a re chemotherapy -na√Øve for mCRPC and have received at least 1 but no more 
than 2 second -generat ion hormonal manipulat ions (also known as novel antiandrogen therapies 
[NAT] eg, including but not limited to abiraterone acetate, enzalutamide, apalutamide, and
darol utamide) in the recurrent non metastati c setting and/or the metastati c setting*(no more 
than 1 prior Novel Androgen Therapy  (NAT) is allowed in the mCRPC setting), or have 
beco me intolerant of the drug. Patients must have progressed during or after NATs or have 
docum ented intolerance to the drug (ie, unacceptabl e toxicity in spite of comprehensive 
supportive therapy ).
* If the same NAT was given more than once in the context of a different di sease setting or if 
intervening therapy  was administered, then these NAT will be considered as separate NAT 
regimens.
ÔÇ∑Parti cipants already receiving agents for the management of skeletal -related events (SREs) are 
allowed to continue with anti-bone resorptive therapy  (including, but not limited to,
bisphosponate or receptor acti vator of  nuclear factor kappa ligand inhibitor) if on stable dose 
for more than 28 days prior to start of study  treatm ent.
ÔÇ∑Prior prostate cancer vaccine therapy (eg, sipuleucel -T), radium -223, second -generat ion 
horm onal manipulat ions (eg, abiraterone acetate, enzalutamide, apalutamide, and 
darol utamide) , antiandrogens (eg, flutamide), ketoconazole, and diethylst ilbestrol (DES) or 
other estrogens, are allowed if treatm ent was com pleted at l east28 days prior to start of study 
treatm ent. Note : bicalutamide or nilutamide must be discont inued at least 6 weeks prior to the 
start of study  treatm ent.
ÔÄ≠Parti cipants wi th a history  of response to an ant iandrogen or adrenal  androgen -producti on 
inhibitor and with subsequent progre ssion while receiving that antiandro gen shoul d be 
assessed for antiandrogen withdrawal  response for 4 weeks, and must demonstrate 
progression as described inInclusion Criterion 2e in the protocol  and have stopped 
receiving the ant iandrogen prior to start of study  treatm ent.
ÔÄ≠For participants w ho have never responded to anti androgens, observat ion for antiandrogen 
withdrawal  response is not necessary .
 
 
 
 
 
 
 
 
Protocol Amendment No.: 04
Date: 22-Sep-2023 17
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
 
Key Exclusion Criteria:
Medical Conditions:
ÔÇ∑Parti cipants with active brain metastases. Participants with brain metastases are eligible to 
enroll in this study  if brain metastases have been treated and there is no magnetic resonance 
imaging (MRI except where contraindicated in which case CT scan is acceptable) ev idence of 
progression for at least 4 weeks after treatm ent is complete and within 28 days prior to first 
dose of study drug administration. Such cases shoul d be discussed with the BMS Medical 
Moni tor or designee . Previously irradiated brain lesio ns are not considered measurable disease .
ÔÇ∑Parti cipants must have recovered from the effects of major surgery  requiring general  anesthesia 
or significant traumat ic injury  at least 14 days befo re start of study  treatm ent.
ÔÇ∑Prior radiat ion therapy  within 2 weeks prior to start of study treatment. Patients should have 
recovered (ie, Grade ÔÇ£1 or at baseline) from radiatio n-related toxi cities.
ÔÇ∑All toxicities attributed to pri or anti -cancer therapy  other than al opecia and fatigue must have 
resolved to Grade 1 or baseline before administration of study treatment. Participants with 
toxicities attributed to prior anti -cancer therapy  that are not expected to res olve and resul t in 
long-lasting sequelae, such as peripheral  neuropathy  after platinum based therapy , are 
permitted to e nroll. Parti cipants who have ÔÇ≥Grade 2 peripheral neuropathy  are excluded.
ÔÇ∑Parti cipants wi th an act ive, known, or suspected autoimmune disease. Participants with ty pe I 
diabetes mellitus, hypothy roidism  only requi ring horm one replacement, skin disorders (such 
as vit iligo, psoriasis, or alopecia) not requiring systemic treatment, or condit ions not expected 
to recur i n the absence of an external trigger are permitted to enroll.
ÔÇ∑Parti cipants who have received a live / attenuated vaccine within 30 days of first dose in the 
study .
ÔÇ∑Dem entia, altered mental  status, or any psychiatri c condi tion that woul d prohibit the 
understanding or rendering o f informed consent or completing QoL questionnaire.
ÔÇ∑Known history  of a posit ive test for human immunodeficiency virus (HIV) or known acquired 
immunodeficiency  syndrom e (AIDS). NOTE: Testing for HIV must be perform ed at all sites 
in Germany and where mandated locally. (see Appendix 9) .
ÔÇ∑Parti cipants with serious or uncontrolled medical disorders that, in the opinio n of the
investigator, would impair the abilit y of the parti cipant to receive protocol  therapy or obscure 
the interpretation of AEs, such as a condit ion associated with frequent diarrhea.
ÔÇ∑Uncontrolled intercurrent illness including, but not limited to, ongoing or active infect ion, 
history  of congest ive heart failure, unstable angina pectoris, cardiac arrhyt hmia, or psychiatric 
illness/social situat ions that woul d limit co mpliance wi th study  requi rements. Addit ionally , in 
the case of prior severe acute respiratory  syndrome coronavirus 2 (SARS -CoV -2)infect ion, 
acute symptoms must have resolved and based on investigator assessment in consultat ion with 
the Medical Monitor, there are no sequelae that would place the participant at a higher risk of 
receiving invest igational treatment (see Section 6.4.1) .
Protocol Amendment No.: 04
Date: 22-Sep-2023 18
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
ÔÇ∑Parti cipants with superscan on technecium -99m radionuclide bone scans are not eligible for 
the study. Superscan is defined as a bone scan which demo nstrates markedly increased skeletal 
radioisotope uptake relative to softtissue in associ ation with absent orfaint renal activity 
(absent ki dney  sign).
ÔÇ∑Concurrent malignancy (present during screening) requiring treatm ent or history of prior 
malignancy active within the previous 2 years prior to randomization (ieparticipants with a 
history  of prior malignancy are eligible if treatment was completed at least 2 years before 
rando mizat ion and the participant has no evidence of disease). Participants with history of prior 
early stage basal/squamous cell skin cancer or non-invasive or in situ cancers that have 
undergone definit ive treatment at any  time are also eligible. 
Prior/Concomitant Therapy:
ÔÇ∑Parti cipants wi th a condit ion requiring systemic treatment with either corticosteroids (> 10mg 
daily  prednisone equivalent) or other immunosuppressive medications wi thin 14 days of start 
of study  treatm ent. Inhaled or topical steroids, and adrenal replacement steroid doses > 10mg 
daily  prednisone equivalent, are permitted in the absence of act ive auto immune disease.
ÔÇ∑Prior treatm ent wi th an anti -PD-1, anti -PD-L1, anti -PD-L2,or anti -CTLA -4 ant ibody , or any 
other antibody  or drug specifically targeting T -cell co -stimulat ion or checkpoint pathways .
ÔÇ∑Prior treatm ent with docetaxel or another chemotherapy agent for metastatic castrati on-
resistant prostate cancer. Prior docetaxel for metastatic castration -resistant prostate cancer is 
allowed if ÔÇ≥12months elapsed fro m last dose of docetaxel.
ÔÇ∑Treatment with complementary  medicat ions (eg,herbal supplements or tradit ional Chinese 
medicines) to treat the disease under study  within 2 weeks prior to start of study treatm ent.
Such medicat ions are permitted if they are used as supporti ve care (refer to Secti on 7.7.1 for 
other prohibited therapies ).
ÔÇ∑Parti cipants currently in other intervent ional trials, including those for coronavirus disease 
2019 (COVID -19), may not participate in BMS clinical  trials until the protocol -specific 
washout period is achieved. If a study  participant has received an invest igational COVID -19 
vaccine or other investigational produ ct designed to treat or prevent COVID -19 prior to 
screening, enrollment must be delayed until the biologic impact of the vaccine or 
investigat ional product is stabilized, as determined by discussio n between the Invest igator and 
the Medi cal Monitor .
Objectives and Endpoints:
Objective Endpoint
Primary
ÔÇ∑To compare the rPFS (using PCWG3) of 
nivolumab in combination with docetaxel 
to placebo in combination with docetaxel, 
inmen with metastatic castration -resistant 
prostate cancer (mCRPC).ÔÇ∑rPFS for randomized participants is the time between 
randomization and the first date of documented progression 
or death due to any cause, whichever occurs first. The 
radiographic progr ession will be assessed by Blinded 
Independent Central Review (BICR) per PCWG3 . The 
rPFS will be censored at the last tumor assessment up to the 
start of subsequent systemic cancer therapy.
Protocol Amendment No.: 04
Date: 22-Sep-2023 19
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Objective Endpoint
ÔÇ∑To compare the OS of nivolumab in 
combinatio n with docetaxel to placebo in 
combinatio n with docetaxel inmen with 
metastatic castration -resistant prostate 
cancer (mCRPC) .ÔÇ∑OS for all randomized participants is the time between 
randomization and the date of death from any cause. For 
participants who are alive, their survival time will be 
censored at the last date that they  were known to be alive. 
OS will be censored for participants at the date of 
randomization if they had no follow -up. 
Secondary
ÔÇ∑To assess the antitumor activity  of 
nivolumab in combination with docetaxel .ÔÇ∑Objective Response Rate per PCWG3 (ORR -PCWG3) is 
the proportion of participants who have a confirmed 
complete or partial best overall response (BOR) per 
PCWG3 among randomized participants who have 
measurable disease at baseline. The BOR is defined as the 
best response designation, as determined by the BICR, 
recorded between the date of randomization and the date of 
objectively documented progression per PCWG3 or the date 
of subsequent systemic cancer therapy , whichever occurs 
first. For partici pants without documented progr ession or 
subsequent systemic cancer therapy , all available response 
assessments will contribute to the BOR assessment.
ÔÇ∑Time to Response per PCWG3 (TTR -PCWG3) is the time 
from randomization to the date of the first documented CR 
or PR per PCWG3, as determined by BICR. 
ÔÇ∑Duration of Response per PCWG3 (DOR -PCWG3) is the 
time between the date of first response (CR/PR per 
PCWG3) tothe date of first documented radiographic 
progression per PCWG3, as determined by  BICR, or death 
due to any  cause. Participants who neither progress nor die 
will be censored at the last tumor assessment up to the start 
of subsequent systemic cancer therapy.
ÔÇ∑PSA Response Rate (PSA -RR) is the proportion of 
randomized participants with a 50% or greater decre ase in 
PSA from baseline to the lowest post-baseline PSA result. 
A second consecutive value obtained 3 or more weeks later 
is required to confirm the PSA response. PSA response will 
be calculated for all participants with PSA values at baseline 
and at least one post -baseline assessment.
ÔÇ∑Time to PSA Progression (TTP -PSA) is the time between 
randomization to the date of PSA progression per PCWG3 
in randomized participants. For participants with an initial 
PSA decline from baseline, the date of PSA progr ession is 
the date that an increase of 25% or more and an absolute 
increase of 2 ng/mL or more from the nadir are documented 
and confirmed by a second consecutive PSA value at least 
3 weeks later. For participants with no PSA decline from 
baseline, the date of PSA progression is the date that an 
increase of 25% or more and an absolute increase of 2 
ng/mL or more from baseline are documented beyond Week 
13. TTP-PSA will be censored at the date of last PSA 
evaluation prior to the start of subsequent systemic cancer
therapy . The time will be censored at the date of 
Protocol Amendment No.: 04
Date: 22-Sep-2023 20
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Objective Endpoint
randomization for participants with no post-baseline PSA 
evaluation .
ÔÇ∑To characterize the safety and tolerability of 
nivolumab in combination with docetaxel.ÔÇ∑Overall safety and tolerability will be measured by the 
incidence ofAEs, SAEs, AEs leading to discontinuation, 
immune-mediated AEs, select AEs, deaths, and laboratory 
abnormalities and changes from baseline .
ÔÇ∑To evaluate the progression of pain during 
treatment .ÔÇ∑Median time to pain progression as assessed by Brief Pain 
Inventory -Short Fo rm (BPI -SF).
Exploratory
ÔÇ∑To investigate the time to initiatio n of 
subsequent systemic therapy (TT -SST) .ÔÇ∑TT-SST is the time from randomization to the start of 
subsequent systemic therapy, including hormonal therapy , 
chemotherapy, immunotherapy, or investigational therapy.
ÔÇ∑To investigate the t ime to first symptomatic 
skeleta l event (TT -SSE ).ÔÇ∑TT-SSE is the time between randomization and the date of 
first symptoma tic fracture, radiatio n or surgery to bone, or 
spinal cord compression .
ÔÇ∑To evaluate the change inpain intensity and 
health -related cancer related symptoms and 
quality  of life .ÔÇ∑Change in mean scores as assessed by BPI -SF
ÔÇ∑Median time to deterioratio n and change in mean scores as 
assessed by FACT -P total score and subscales .
ÔÇ∑To assess the participant‚Äôs quality of life 
and overall health status .ÔÇ∑Change in scores in both the EQ-5D-5L utility index and 
visual analog scale.
ÔÇ∑To investig ate the time to and duration of 
PSA response .ÔÇ∑Time to PSA response (TTR -PSA) is defined for PSA
responders as the time from randomization to the date of the 
first PSA r esponse. Duration of PSA response (DOR -PSA)
is defined for PSA responders as the time between the date 
of firstresponse and the date of PSA progression. 
Participants who neither progress by PSA nor die will be 
censored on the date of last PSA evaluation.
ÔÇ∑To evaluate the pharmacokinetics of 
nivolumab when administered in 
combinatio nwith docetaxel . To explore 
exposure response relatio nships between
select exposure measures, and safety, and 
efficacy endpoints, as appropriate .ÔÇ∑Parameter estimates from Population PK analysis and 
exposure -response analysis, if data permit .
ÔÇ∑To characterize the immunogenicity of 
nivolumab when administered in 
combinatio nwith docetaxel.ÔÇ∑Immunogenicity will be determined by measurement of 
anti-drugantibody (ADA) in serum and samples with 
positive ADA response may be analy zed for neutralizing 
ADA response to nivolumab .
Protocol Amendment No.: 04
Date: 22-Sep-2023 21
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Objective Endpoint
ÔÇ∑To assess the impact of SARS -CoV -2 
serologic status on participants with 
metastatic castration -resistant prostate 
cancer who are rec eiving nivolumab plus 
docetaxel ,  
.ÔÇ∑Explo ratory  measurements of SARS -CoV -2 serology (anti -
SARS -CoV -2 total or Immunoglobulin G [IgG ]), from 
serum samples collected at baseline and during the study, 
and the potential association between these measurements 
and selected endpoints related to safety, efficacy,  
. 
Overall Design:
CA2097DX is a Phase 3 randomized, double -blinded, multi-center clinical trial comparing 
nivolumab or pl acebo in combinat ion with docetaxel, in men with metastati c castrati on-resistant 
prostate cancer.
Randomization will be stratified according to the foll owing baseline factors:
ÔÇ∑1 prior Novel  Antiandrogen Therapy (NAT) for mCRPC vs 1 prior NAT for non-metastati c 
castration -resistant prostate cancer (nmCRPC) or metastatic castrati on-sensi tive prostate 
cancer (mCSPC) vs 2 prior NAT
ÔÇ∑Visceral  disease (Y vs N)
Visceral  disease status will be assessed by invest igator based on the tum or assessment perform ed 
during screening. Visceral disease is defined as the presence of metastatic disease in the liver, lung, 
adrenal, peritoneum, brain or other internal organs. Bone,lymph node metastases and prostate 
lesion (or bladder/rectum if fro m direct invasion from prostate) are not considered visceral disease .
The study  design schemat ic is presented in Figure 1 -1.
Protocol Amendment No.: 04
Date: 22-Sep-2023 22
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Figure 1-1: Study Design Schematic
Per Protocol Amendment 0 4, participants assigned to Arm B will no longer receive placebo. 
Per Protocol Amendment 04, decisions on docetaxel treatment will be based on the clinical 
judgment of the treating physician and on shared decision making with the participant. 
Participants who are not able to access local therapy may continue on study -provided 
docetaxel until local access is available. In the event that the investigator deems a participant 
is deriving clinical benefit from nivolumab 
therapy and, together with the counseled 
participant, wishes to continue treatment, this may be possible following discussion with the
Medical Monitor to ensure a clinical rationale exists that justifies continuation of nivolumab 
treatment.
Number of Participants: 
Assum ing a 25% screen failure rate, it is estimated that approximately 1312 participants with 
mCRPC will be enro lled in order to randomize approximately 984 participants .
The sample size determinati on of this study  is based on a comparison of the rPFS and OS 
distribution between participants rando mized to nivolumab in combinat ion with docetaxel and 
participants randomized to placebo in co mbinat ion with docetaxel . 
These endpo ints will be evaluated for treatment effect using the fo llowing testing strategy : 
ÔÇ∑The analysis for rPFS will occur after enrollment for the study has completed and  
approximately  530 rPFS events are observed in all rando mized global subjects. The number of 
events was estimated assuming an exponent ial distribut ion of rPFS for the Docetaxel arm (Arm 
B) and a piecewise exponent ial distribut ion with a 2-months delayed treatment effect for the 
Nivo lumab + Docetaxel arm (Arm A). This number of events provi des 90% power to de tect 
an average HR of 0.67 (Arm A vs Arm B in all randomized global partic ipants) with a 2 -sided 
alpha of 0.01. The average HR of 0.67 resulted from an assumed targeted hazard ratio of 1 for 
the init ial 2 mo nths fro m rando mization and a targeted hazard ratio of 0.58 for the time beyond 
2 months f rom randomizat ion.
ÔÇ∑The analysis for OS has two planned interim analyses and a final analysis. The first interim 
analysis will occur at the time of rPFS analysis, the second interim analysis is planned at 
Protocol Amendment No.: 04
Date: 22-Sep-2023 23
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
approximately  80% of  the total  events, and the final  analysis is planned at approxima tely 690 
events among all rando mized global participants. The number of events was estimated 
assuming an exponent ial distribut ion of OS for the Docetaxel arm (Arm B) and a piecewise 
exponent ial distribut ion with a 3-monthdelayed treatm ent effect for the Nivolumab + 
Docetaxel arm (Arm A). This number of events provides 92% power to detect an average HR 
of 0.76 (Arm  A
 vs Arm B in all randomized partici pants) with a 2-sided alpha of 0.04. The 
average HR of 0.76 resulted fro m an assumed targeted hazard ratio o f 1 fo r the initial 3 mo nths 
from randomizat ion and a targeted hazard ratio of 0.72 for the time beyo nd 3months from 
rando mizat ion.Per Protocol Amendment 04, given the decision to terminate the study 
early, the second interim analysis for OS and final analysis for OS will no longer be 
performed, and the first interim analysis will be considered as final. At the time of study 
closeout, an updated descriptive OS analysis will be provided to report all death events.
ÔÇ∑The stopping boundaries for OSat the interim and final analyses will be based on the actual 
number of events at the time of the analysis using Lan-DeMets alpha -spending funct ion with 
O‚ÄôBrien -Fleming boundaries, taking into account any alpha that was passed from the rPFS 
analysis (if a pplicable).
ÔÇ∑These primary endpoints will be tested separately and if significant, the alpha allocated to each 
endpo int will be recycled to the other endpoint. For example, if rPFS is significant at the 0.01 
level, then 0.01 will be transferred to the OS an alysis for testing at 0.05 level.
Treatment Arms and Duration:
Per Protocol Amendment 04,full study teams and investigators were unblinded tostudy
treatment assignment on 03-AUG - 2023 due to lack of rPFS and OS benefit from nivolumab 
added to docetaxel p lus prednisone compared to placebo added to docetaxel plus prednisone. 
Participants in the placebo arm will discontinue placebo and may be able to continue
docetaxel for up to 10 cycles through the study if the participant is in the combination phase, 
and local access to docetaxel outside the study is not available. In addition, all participants 
should receive standard of care treatment for mCRPC per local guidelines.
Arm A:
ÔÇ∑Combinat ion Phase (m aximum 10 cy cles, 1 cy cle is 3 weeks):
ÔÄ≠Docetaxel 75 mg/m ¬≤IV Q3W + Prednisone 5 mg PO BID + Nivo 360 mg IV Q3W
ÔÇ∑Monotherapy  Phase (1 cy cle is 4 weeks):
ÔÄ≠Nivo lumab 480 m g IV Q4W
Arm B:
Per Protocol Amendment 04, participants assigned to Arm B will no longer receive placebo. 
ÔÇ∑Combinat ion Phase (m aximum 10 cy cles, 1 cycle is 3 weeks)
ÔÄ≠Docetaxel 75 mg/m ¬≤IV Q3W + Prednisone 5 mg PO BID + Placebo IV Q3W
ÔÇ∑Monotherapy  Phase (1 cy cle is 4 weeks):
ÔÄ≠Placebo IV Q4W
Protocol Amendment No.: 04
Date: 22-Sep-2023 24
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Study Treatment :
Selection and Timing of Dose
Study Treatment Unit dose strength(s)/
Dosage level(s)Dosage formulation
Frequency of AdministrationRoute of 
Administration
Arm A
Nivolumaba 360mg Every 3 weeks Intravenous
Prednisone 5mg Twice daily (BID ) Oral
Docetaxel 75mg/m2Every 3 weeks through cycle 10 Intravenous
Arm B
Prednisone 5mg Twice daily (BID ) Oral
Docetaxel 75mg/m2Every 3 weeks through cycle 10 Intravenous
Not applicable per Protocol 
Amendment 0 4:
PlaceboNot applicable Every 3 weeks Intravenous
aNivolumab or placebo will be administered as combination therapy with docetaxel and prednisone for maximum 
10 cycles, followed by nivolumab monotherapy (480 mg Q4W) orplacebo until progression, unacceptable toxicity 
or withdrawal of Consent.
Data Monitoring Committee: 
Not applicable per Protocol Amendment 04.
To provide independent oversi ght of safety, efficacy , and study  conduct, an independent Data 
Moni toring Committee (DMC) will be established to provide oversight on safet y and efficacy 
considerations. Details of the DMC responsibili ties and procedures will be specified in the DMC 
charter. 
A Study Steering Commit tee (consisting of selected participating invest igators) will meet regul arly 
to advise BMS regarding study -related issues, including safet y concerns.
When requi red, adjudicated events will be submitted to the DMC and Health Authorities for review 
on a specified timeframe in accordance with the adjudicat ion documentation.
References:
1Martin AM, Nirschl TR, Nirschl CJ, et al. Paucit y of PD-L1 expressio n in prostate cancer: Innate 
and adapt ive immune resistance. Prostate Cancer and Prostatic Diseases. 2015;18(4):325 -332.
Protocol Amendment No.: 04
Date: 22-Sep-2023 25
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
2Topalian SL, Hodi FS, Brahmer JR, et al. Safet y, activit y, and immune correl ates of anti-PD-1 
antibody  in cancer. N Engl J Med. 2012;366:2443 -54.
3Dong H, Strome SE, Sal omao DR, et al . Tum or-associ ated B7 -H1 prom otes T -cell apoptosi s: a 
potenti al mechanism of immune ev asion. Nat Med. 2002;8:793-800.
4Dong H, Zhu G, Tamada K, et al. B7- H1, a thi rd member of the B7 family, co -stimulates T -cell 
proliferat ion and interleukin -10 secreti on. Nat Med. 1999;5:1365 -69.
5Pardoll D and Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med. 
2012;209:201 -9.
6Gannon PO, Poisson AO, Delvo ye N, et al. Characteri zation of the intra-prostati c immune cell 
infiltrat ion in androgen -deprived prostate cancer patients. J Immuno l Methods. 2009;348:9 - 17.
7Mercader M, Bodner BK, Moser MT, et al. T cell infiltrat ion of the prostate induced by androgen 
withdrawal  in pat ients with prostate cancer. Proc Natl Acad Sci USA. 2001;98:14565 -70.
8Aragon -Ching JB, Williams KM, Gulley JL. Impact of androgen -deprivat ion therapy  on the 
immune system: implicat ions for combinat ion therapy of prostate cancer. Front Biosci. 2007;12
.
9Drake CG. Prostate cancer as a model for tumour immunotherapy. Nature Rev Immuno l. 
2010;10:580 -93.
Protocol Amendment No.: 04
Date: 22-Sep-2023 26
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
2 SCHEDULE OF ACTIVITI ES
Table 2-1: Screening Procedural Outline (CA2097DX)
Proced
urea Screening 
VisitNotes
All windows are on calendar days.
Eligibility Assessments
Informed Consent XRegister in Interactive Response Technology (IRT) system to obtain participant number. 
Study permits re -enrollment of a participant who has discontinued the study as a pre -
treatment failure (ie, participant has not been treated). If re -enrolled, the participant must be 
re-consented.
Inclusion/Exclusion Criteria X Must be confirmed prior to randomization in IRT .
Medical History XAll medical history relev ant to the disease under study.
Includes clinical stage and Gleason score at initial diagnosis .
Prior Medicatio ns/Radiatio n for Cancer X Details and dates of prior therapy including all hormonal therapies .
Body Imaging XTechnicium -99m bone scans, c ontra st enhanced CT of the chest, CT/MRI of the abdomen, 
pelvis, and all other known and/or suspected sites of disease, within 28 days prior to 
randomization . Section 9.1.1 for further details .
Please refer to Appendix 5 for PCWG3 guidelines for tumor assessments.
Brain Imaging XMRI of the brain without and with contrast is required for participants with known or 
suspected brain metastases, unless participant has completed an imaging study of the brain 
within 28days prior to randomization.
CT of the brain without and with contras t can be performed if MRI is contraindicated. 
See Section 9.1for further details.
Safety Assessments
Full Phy sical Examination XHeight, Weight, ECOG Performance Status ( Appendix 8) within 14 days prior to 
randomization .
Vital signs (BP, heart rate, RR, temperature) to be measured at screening visit and within 
72hours prior to first dose.
Assessment of Signs and Symptoms X Within 14 days prior t orandomization .
Prior/Concomitant Medication Use X Within 14 days prior to randomization .
Protocol Amendment No.: 04
Date: 22-Sep-2023 27
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 2-1: Screening Procedural Outline (CA2097DX)
Procedu
rea Screening 
VisitNotes
All windows are on calendar days.
Serious Adverse Event (SAE) Assessment XSAEs collected from time of consent (see Section 9.2).All AEs (SAEs or non serious AEs) 
associated with SARS -CoV -2 infection collected from time of consent. AEs are graded per 
NCI CTCAE v . 5.0
12 lead ECG X Within 14 days prior t o randomizati on
Laboratory Tests
Clinical Laboratory Tests
CBC with differential, c hemistry panel, thyroid 
testing XMust be performed within 14 days p rior to randomization .
Refer to Section 9.4for list of laboratory tests to conduct 
The following must be performed up to 6 weeks prior to first dose:
PSA ( See Section 6.1, inclusion criteria)
Testosterone (See Section 6.1, inclusion criteri a).
Review of Pathology ReportHistologic confirmation of adenocarcinoma of the prostate. Diagnosis must be stated in a 
pathology report and confirmed by the investigator. See Section 6.1(Inclusion Criteria).
Protocol Amendment No.: 04
Date: 22-Sep-2023 28
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 2-1: Screening Procedural Outline (CA2097DX)
Procedurea Screening 
VisitNotes
All windows are on calendar days.
SARS -CoV -2 Serology XSerum collected to be used for potential future measurements of anti -SARS -CoV -2 serology 
(anti-SARS -CoV -2 total o r IgG , central lab ).
IRT
RandomizationX Once a participant is deemed eligible for the study, the IRT system must be contacted to 
randomize the participant to a treatment group.
aSome of the  assessments referred to in this section may  not be captured as data in the eCRF. They  are intended to be used as safet y monitoring by the treating 
physician. Additional testing or assessments may be performed as clinically necessary or where require d by institutional or local regulations. If a dose is delayed, 
the procedures scheduled for that same time point should also be delayed to coincide with when that time point‚Äôs dosing actua lly occurs .
Protocol Amendment No.: 04
Date: 22-Sep-2023 29
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 2-2: On-Study Treatment and Follow -up Procedural Outline for Arms A and B (CA2097DX)
Pro
cedureaCombination Phase 
Max 10 Cycles
(1 Cycle = 3weeks)
Day 1Monotherapy 
Phaseb
(1 Cycle = 4 weeks)
Day 1Safety Follow -
upc
(30 days [FU1]
and 100 days
[FU2] )Survival 
Follow -
updNotes
Study Treatment
Dispense Study 
TreatmentX XFirst dose to be administered within 3 calendar days 
following randomization .e
Safety Assessments
Per Protocol Amendment 04, safety assessments will be applicable ONLY to:
ÔÇ∑Participants continuing study -provided nivolumab
ÔÇ∑Participants up to 100 days after their last nivolumab infusion
All other participants will be discontinued from the study and switched to local standard of care for metastatic castration -resistant prostate cancer, 
outside of the study.
Targeted Physical 
Examination and 
Vital SignsX X XWithin 72 hours prior to dosing :
Weight, BP, HR , RR, and Temperature 
ECOG Performance Status .
Adverse Event and 
Serious Adverse 
Event Assessment ContinuouslyPer NCI CTCAE v ersion 5
Record at each visit.
All AEs (SAEs or nonserious AEs), including those 
associated with SARS -CoV -2 infection, must be 
collected continuously during the treatment period
and for a minimum of 100 days following 
discontinuation of dosing.
*Beyond 100 days from the last dose of study 
therapy , participants will be followed for drug -
related AE s/SAEs until resolution, return to 
Protocol Amendment No.: 04
Date: 22-Sep-2023 30
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 2-2: On-Study Treatment and Follow -up Procedural Outline for Arms A and B (CA2097DX)
Pr
ocedureaCombination Phase 
Max 10 Cycles
(1 Cycle = 3weeks)
Day 1Monotherapy 
Phaseb
(1 Cycle = 4 weeks)
Day 1Safety Follow -
upc
(30 days [FU1]
and 100 days
[FU2] )Survival 
Follow -
updNotes
baseline, deemed irreversible, or participant is lost 
to follow -up or withdraws study consent.
See Section 9.2(Adverse Events ).
Concomitant 
Medica tion UseX Record at each visit .
Not applicable per 
Protocol 
Amendment 04: 
Subsequent Cancer 
TherapyInclude documentation of subsequent cancer 
therapy  (ie,systemic therapy, tumor -directed 
surgery , or radiation therapy).
Laboratory Tests
Per Protocol Amendment 04, laboratory tests will include local safety laboratory tests only and will exclude tests such as PSA,  and 
pharmacokinetics. In addition, the requirement for local safety laboratory tests will ONLY be applicable to:
ÔÇ∑Partici pants continuing study -provided nivolumab 
ÔÇ∑Participants up to 100 days after their last nivolumab infusion
All other participants will be discontinued from the study and switched to local standard of care for metastatic castration -resistant prostate cancer, 
outside of the study.
Clinical Laboratory 
Tests
CBC with 
differential, 
chemistry  panel, 
thyroid testingX(see note s) X (see notes) X(see notes )For the first dose visit, labs need not be repeated if 
performed within 72 hours and results are av ailable 
and have been reviewed for eligibility.
Laborato ry tests may  be performed within 72 hours 
prior to dosing for each cycle.
See Section 9.4for list of laboratory tests.
Protocol Amendment No.: 04
Date: 22-Sep-2023 31
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 2-2: On-Study Treatment and Follow -up Procedural Outline for Arms A and B (CA2097DX)
Proce
dureaCombination Phase 
Max 10 Cycles
(1 Cycle = 3weeks)
Day 1Monotherapy 
Phaseb
(1 Cycle = 4 weeks)
Day 1Safety Follow -
upc
(30 days [FU1]
and 100 days
[FU2] )Survival 
Follow -
updNotes
Specific l abs required at Safety FU 2 only  if toxicity 
is present are noted in Section 9.4.
Not applicable per 
Protocol 
Amendment 04: 
(Local) PSA Perform on D1 of ever y cycle. Participants who 
discontinue study treatment without PSA 
progression or radiographic progression will
continue to have PSA performed at FU1, at FU2 
and every 12 weeks thereafter. PSA collection will 
continue until PSA progression, radiographic 
progression or end of study treatment, whichever 
occurs last. Additional PSA collection outside of 
this sched ule is encouraged to confirm PSA 
progression as needed ,during prolonged dose 
delay sor if clinically indicated.
Continuous 
Assessment of 
Skeletal Events 
(SSE)X (see notes)Assessed from treatment initiation to first 
symptomatic f racture, radiation or surgery to bone, 
orspinal cord compression.
Protocol Amendment No.: 04
Date: 22-Sep-2023 32
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 2-2: On-Study Treatment and Follow -up Procedural Outline for Arms A and B (CA2097DX)
Pr
ocedureaCombination Phase 
Max 10 Cycles
(1 Cycle = 3weeks)
Day 1Monotherapy 
Phaseb
(1 Cycle = 4 weeks)
Day 1Safety Follow -
upc
(30 days [FU1]
and 100 days
[FU2] )Survival 
Follow -
updNotes
Efficacy Assessments
Not applicable per Protocol Amendment 04. . All participants receiving study treatment will have radiographic tumor assessments based on the 
clinical judgment of the treating investigator and following imaging tumor assessment local guidelines for mCRPC.
Body ImagingTechnicium -99m Bone Scans, Contrast enhanced 
CT of the chest, CT/MRI of the abdomen, pelvis, 
and all other known an d/or suspected sites of 
disease . Tumor a ssessments should occur ever y 9 
weeks (ÔÇ±7 days) from first dose, regardless of 
treatment schedule or dose delays for first 54 
weeks. Thereafter switch to every 12 weeks ( ÔÇ±7 
days). Imaging must continue until radiographic 
progression per PCWG3 is assessed by investigator 
and confirmed by BIC R, or study treatment is 
discontinued, whichever occurs later .In case 
subsequent therapy has begun, imaging must 
continue until radiographic progression per PCWG3 
is confirmed by BICR .
See Section 9.1.1 and Section 9.1.2 .
Brain Imaging Participants with a history of brain metastasis or 
symptoms should have a surveillance MRI study 
per standard of care (approximately every 12 
weeks), or sooner if clinically indicated. CT of the 
brain without and with contrast can be performed if 
MRI is co ntraindicated. Imaging must continue 
until radiographic progression per PCWG3 is 
assessed by investigator and confirmed by BICR, or
study treatment is discontinued, whichever occurs 
later. See Section 9.1.1 for further details.
Protocol Amendment No.: 04
Date: 22-Sep-2023 33
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 2-2: On-Study Treatment and Follow -up Procedural Outline for Arms A and B (CA2097DX)
Proce
dureaCombination Phase 
Max 10 Cycles
(1 Cycle = 3weeks)
Day 1Monotherapy 
Phaseb
(1 Cycle = 4 weeks)
Day 1Safety Follow -
upc
(30 days [FU1]
and 100 days
[FU2] )Survival 
Follow -
updNotes
Survival StatusDuring safety follow -up and every  3months (clinic 
visit or by telephone) during survival phase. Include 
documentation of subsequent therapy.
Health Outcomes
Not applicable per Protocol Amendment 04.
BPI-SF At Safety  FU1 only. 
Questionnaire should be completed after 
randomization but prior to dosing or prior to safety 
labs at safety follow-up visits.FACT -P
FACT -P PCSFor survival follow -up visits, only  the Prostate 
Cancer Subscale (PCS) portion of the FACT -P 
should be administered. Can be administered by 
telepho ne if needed.
EQ-5D-5LQuestionnaire should be completed after 
randomization but prior to dosing or prior to safety 
labs at safety follow -up visits.
During survival follow -up visits, the questionnaire 
canbe administered by phone if needed .
Healthcare Resource 
Utilizatio nHealthcare resource utilization data will be 
collected at each visit by study site staff using the 
case report form (CRF).
Protocol Amendment No.: 04
Date: 22-Sep-2023 34
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 2-2: On-Study Treatment and Follow -up Procedural Outline for Arms A and B (CA2097DX)
Pr
ocedureaCombination Phase 
Max 10 Cycles
(1 Cycle = 3weeks)
Day 1Monotherapy 
Phaseb
(1 Cycle = 4 weeks)
Day 1Safety Follow -
upc
(30 days [FU1]
and 100 days
[FU2] )Survival 
Follow -
updNotes
 
SARS -CoV -2 
SerologySerum collected approximately every 6 months 
during study treatment to be used for potential 
future measurements of anti -SARS -CoV -2 serology 
(anti-SARS -CoV -2 total o r IgG). 
Serum should also be collected approximately 4 
weeks after a documented or suspected SARS -CoV -
2 infection . If a documented or 
suspected SARS -CoV -2 infection occurs within 4 
weeks of the 6- month sampling time point, a single 
serum sample will be collected to satisfy the 
requirements for both the every 6 month and 
approximately 4 week safter infection time points.
Protocol Amendment No.: 04
Date: 22-Sep-2023 35
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 2-2: On-Study Treatment and Follow -up Procedural Outline for Arms A and B (CA2097DX)
ProcedureaCombination Phase 
Max 10 Cycles
(1 Cycle = 3weeks)
Day 1Monotherapy 
Phaseb
(
1 Cycle = 4 weeks)
Day 1Safety Follow -
upc
(30 days [FU1]
and 100 days
[FU2] )Survival 
Follow -
updNotes
Pharmacokinetic (PK) and Immunogenicity (IMG) Assessments
Not applicable per Protocol Amendment 04.
Collect blood 
samples for PK/IMG
aSome of the assessments referred to in this section may  not be captured as data in the eCRF. They  are intended to be used as safety monitoring by the treating 
physician. Additional testing or assessments may be performed as clinically necessary or where required by institutional or local regulations. If a dose is delayed, 
the procedures scheduled for that same time point should also be delayed to coincide with when that time point‚Äôs dosing actually occurs .
bMonotherapy Phase will start 3 weeks ÔÇ±3 days from last combination dose. If a dose is delayed, the procedures scheduled for that same time point (except tumor 
scans) should also be delayed to coincide with when that time point‚Äôs dosing actually occurs. Nivolumab will be given up to a maximum duration of 24 months 
from date of first dose .
cParticipants must be followed for at least 100 day s after last dose of study  treatment. Safety  Follow-up Visit 1 (FU 1) should occur 30 day s from the last dose 
(ÔÇ±7days)or can be performed on the date of discontinuation if that date is greater than 30days from last dose. Specific labs required at Safety FU2 only if 
toxicity is present are noted in Section 9.4. Safety Follow -up Visit #2 (FU2) occurs approximately 100 days ( +7 days) from last dose of study drug. Both Safety 
Follow -up visits should be con ducted in person .
dPer Protocol Amendment 04, the follow -up phase only applies to participants up to 100 days after the last infusion of nivolumab. After 100 days of 
follow -up ha sbeen completed, the nivolumab -treated participants will be permanently discontinued from the study .
eNo dose escalatio n or reductions of nivolumab are allowed. For Q3W and Q4W dosing cy cles, all partic ipants may be dosed within a ¬± 3-day window. For the  
Q3W dosing cycle, par
ticipants may be dosed no less than 18 days after the prior dose. Refer to Section 7.1.
Protocol Amendment No.: 04
Date: 22-Sep-2023 36
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
3 INTRODUCTION
CA2097DX is a Phase 3, rando mized, global study assessing the efficacy and safet y of nivo lumab 
or nivolumab placebo combined with standard of care docetaxel  chemotherapy , in men with 
metastati c castration -resistant prostate cancer (mCRPC) who have progressed after second -
generat ion horm onal manipulat ion, also known as Novel Ant iandrogen Therap y (NAT ), and have 
not received chemotherapy  for mCRPC. 
The study  aims to dem onstrate that treatment wi th nivo lumab combined with docetaxel improves 
clinical efficacy in terms of overall survival (OS) or radiographic progression -free survival (rPFS), 
when co mpared to docetaxel alone.
A detailed descript ion of the chemistry, ph armacology , efficacy, and safet y of the study treatments 
is provided in the respective Invest igator Brochures (IBs) and package inserts.
3.1 Overall Rationale for Protocol Amendment 0 4 and Study Termination
Theindependent Data Monitoring Committee (DMC) convened on 26 -Jul-2023 for a prespecified 
review of all  available study  data based on a clinical  data cutoff of 01-Jun-2023. Af ter reviewing 
the final analys is of the primary efficacy endpo int of radiographic progression -free survival (rPFS) 
per Blinded Independent Central Review (BICR) and the first interim analysis of the primar y 
efficacy endpo int of overall survival  (OS), the DMC agreed that the study  did not meet the 
prespecified boundari es for declaring statistical significance for either endpo int. Although the 
number of events for OS at the second interim analysis and final analysis of OS had not been 
attained, based on the first interim analysis resul ts for OS, the DMC determined that the 
prespecified boundaries for declaring significance were unlikely to be met . No new safet y concerns 
were ident ified. ASponsor Execut ive Oversight Committee (EOC) requested to be unblinded to 
the study  resul ts and decided to terminate the study . Full study  team s and investigators were 
unblinded to study  treatment as signment on 
03-AUG -2023.
Protocol  Amendment 04reflects changes in study conduct. For participants who are deemed 
appropriate to continue on nivolumab or docetaxel therapy  through  the CA2097DX study , re-
consent will be required.
3.2 Study Rationale
Prostate c ancer tumor cells have been shown to have low tumor expression of programmed deat h 
ligand -
1 (PD-L1), suggesting that treatm ents directed at the programmed death (PD-1)/PD-L1 
interact ion are unlikely to be successful as monotherapi es.1This was confirmed byearly clinical 
trials, where unselected men with mCRPC did not respond to PD-1 blockade as monotherapy .2
However, several studi es show that PD-L1 expressio n can be up-regul ated in response to 
inflammatory  cytokines, a pheno menon which has been term ed ‚Äúada ptive immune resistance‚Äù3,4,5
This suggests that if prostate cancer treatments (ie, chemotherapy, androgen ablat ion) can increase 
PD-L1 expressio n on tumor cells by attracting infiltrating immune cells and triggering an adaptive 
immune response, there is arationale for combining such therapies with immune check -point 
inhibitors.6,7,8,9The rationale for combining chem otherapy  and immunotherapy  is based on the 
findings that cytotoxi c treatm ents such as chem otherapy  may modulate tumor/immune -system 
Protocol Amendment No.: 04
Date: 22-Sep-2023 37
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
interact ions in favor of the immune system . Chemotherapy  can resul t in tumor cell  death as part 
of its intended therapeut ic effect with a resul tant increase in tumor antigen delivery to antigen -
present ing cells.
Tumor cell death may also lead to a reducti on in soluble and membrane -bound factors inhibi ting 
tumor-infiltrat ing T -cells and disrupt immune system regulatory networks by decreasing numbers 
of T-regul atory  cells. Docetaxel has been reported to increase the production o f pro -inflammatory 
cytokines which may e nhance the immune response. These findings have led to the devel opment 
of several clinical  trials evaluat ing the combinati on of docetaxel  and PD1/PDL1 inhibitors 
([STUDY_ID_REMOVED], NCT 03834506, [STUDY_ID_REMOVED] ).10Preliminary results fro m Keynote -36510have 
demonstrated promising act ivity with this co mbination in patients with mCRPC previously treated 
with NAT(s) as described in Section 5.5.1 (Rationale for Populat ion).
The current study  aims to demonstrate that treatm ent with docetaxel  in combinat ion with 
nivolumab will be efficaci ous in participants with mCRPC. Addit ional object ives of the study 
include characteri zation of safety and tolerabili ty, as well as pharmacokinet ics,  
 and changes in patient reported outcomes for qua lity of life assessments.
3.2.1 Research Hypothesis
1)The administration of nivolumab in combinat ion withdocetaxel  will improve radiographic 
progression -free survival (PFS) assessed by BICR compared with docetaxel  in participants
with mCRPC
2)The administration of nivolumab in co
mbinat ion with docetaxel  will improve overall survival 
(OS) com pared wi th docetaxel  in participants wi th mCRPC
3.3 Background
3.3.1 Background Indication and Treatment Landscape
Prostate cancer is a leading cause of cancer mortalit y in men worldwide,11with an estimated 
incidence of 1,276,106 new cases and 358,989 deaths globally12and 164,690 new cases and 
29,430 deaths in US in 2018.13Prostate cancer is the most frequently diagnosed cancer and second 
most frequent cause of cancer deaths in US males. In the US, prostate cancer accounted for almost  
1 in 5 new diagnoses of cancer in men in 2018. In Europe, prostate cancer was the most comm on 
primary  sites in men in 2018 (21.8% of the total), with 450,000 new cases and 107,000 deaths 
from prostate can cer being reported in that y ear.14
In 1941, Huggins and Hodges first noted the beneficial effects of castrati on and inject ion of 
estrogens in participants wi th metastatic prostate cancer. Over time, androgen deprivation therap y 
(ADT), defined as medical castrat ion when it is administered as neoadj uvant, concomitant or 
adjuvant therapy  in combinat ion with radiation, became the cornerstone of treatm ent for patients 
with metastatic disease, as well as for patients with localized or locally advanced prostate cancers . 
ADT resul ts in disease remissio n in 90% of  metastati c prostate cancer parti cipants, evi denced by 
a decline in levels of prostate-specific antigen (PSA). Nevertheless, most participants become 
Protocol Amendment No.: 04
Date: 22-Sep-2023 38
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
resistant, with disease progression occurring within a median of 18 to 24 months of continuous 
horm onal manipulat ion.
In 1996, mitoxantrone plus prednisone was approved for the treatm ent of patients with mCRPC 
based on improvement in pain palliat ion.Docetaxel became the first chemotherapeutic agent to 
show an OS benefit in mCRPC in two randomized controlled clinical trials (TAX 32715and 
SWOG 99-1616), and was approved in combinat ion with prednisone for this indicat ion in the US 
in 2004. Since 2010, 6 new therapeut ic agents wit h diverse mechanisms o f action have been a dded 
to the therapeuti c armamentari um, 5 of which (sipuleucel -T, cabazitaxel, abiraterone, 
enzalutamide, and radium-223) have been approved for the treatm ent of mCRPC based on 
improvement in median overall survival (OS). 
Cabazitaxel is another taxane -based chem otherapy that was approved by the FDA, in 2010, in 
patients with mCRPC previously treated with docetaxel.17In the FIRSTANA trial,18which studi ed 
cabazitaxel vs docetaxel as first -line therapy in chemotherapy -na√Øve mCRPC, different dosages of 
cabazita xel did not show superiorit y over docetaxel . 
Sipuleucel -T19was the first immunotherapy to receive FDA approval in men wi th asymptom atic 
mCRPC based on the Phase III IMPACT trial which showed a median survival o f 25.8 m onths vs 
21.7 months (placebo arm). Two androgen -directed therapi es, abiraterone acetate and 
enzalutamide, were approved by the FDA for post chemotherapy20,21and chemotherapy -na√Øve22,23
mCRPC patients. Furtherm ore, bone targeting alpha
-emitting radionuclide radium-223 chloride 
(radium-223)24was approved in men with symptomati c bone metastases but no visceral disease, 
based on data from the ALSYMPCA trial which showed a median OS benefit (HR, 0.7; 14.9 vs 
11.3 months; P <0.001). However, cross -resistance has been observed between some of these 
agents (ie, enzalutamide and abiraterone; abiraterone and docetaxel) and a lack of consensus 
currently exists on optimal sequencing of these therapies in mCRPC. 
The use of some of these agents has now expanded into earlier stages of the disease, with 
docetaxel25and abiraterone26,27demonstrating a significant OS improvement in metastati c 
cstrati on-sensi tive prostate cancer (
mCSPC) which led to their approval  in this setting. 
Enzalutamide has also been tested in in men with m CSPC 28and recently showed to s ignificant ly 
improve rPFS and other efficacy endpo ints compared to ADT alone. Furtherm ore, both 
enzalutamide29and apal utamide30, another second -generat ion antiandrogen that is an irreversible 
AR antagonist, showed improved metastasis -free survival in non-metastati c CRPC and were 
approved in 2018. More recently, darolutamide31, an AR antagonist related to enzalutamide and 
apalutamide, but with a high affini ty for AR and low affinit y for GABA receptors, has 
demonstrated a significant improvement of metastasis -free survival (MFS) in M0 CRPC (HR 0.41; 
40.4 m onths wi th darol utamide vs 18.4 months with pl acebo; P <0.0001). It i s unknown if using 
chemotherapy and AR-directed agent therapy  for the upfront treatm ent of mCSPC and in 
non-metastatic CRPC will alter disea se bio logy, clinical course, and sequencing of these agents in 
the mCRPC setting.
Protocol Amendment No.: 04
Date: 22-Sep-2023 39
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
Significant progress has been made in the last few years in the treatment and understanding of the 
biology of CRPC and mole cular classificat ion is likely to guide future treatment strategies. 
Olaparib and rucaparib are two examples of PARP inhibitors that are being invest igated in a 
molecularly  defined mCRP C subgroup and received FDA breakthrough therapy  designation in 
2016 and in 2018, respectively. Olaparib as a treatment for BRCA1/2 or ATM-mutated mCRPC 
in pat ients who have received a prior taxane -based chemotherapy and at least one hormonal agent, 
either enzalutamide or abiraterone based on the initial results o f Phase 2 TOPARP -A32trial, which 
found that 88% of participants with DNA -repai r defects (DRD) (n=16) had a response (composite 
response endpoint including PSA response, objective response, and CTC conversi on) to ol aparib 
vs 6% of patient without DRD. Rucaparib as a treatment for BRCA1/2 -positive mCRPC fo llowing 
at least 1 androgen receptor ‚Äìdirected therapy  and taxane -based chem otherapy based on the 
ongoing TRITON -
233Phase II study , which showed that 44.0% (11/25) of patients with a 
BRCA1/2 al terati on had a confirmed radi ographic response. Recently, findings of TOPARP -B,34
the second stage of the trial where 98 patients were pre-selected based on the detecti on of DNA 
repai r defects, showed a response rate (combined primary endpo int) of 54% overall in the 400 mg 
olaparib cohort and 37% in the 300 mg cohort. Radiographic re sponses based on specific geno mic 
alterati ons were 42.4% in patients with a  B RCA1/2, PALB2 ‚Äì33.3%, ATM ‚Äì8.3%, and no 
responses in CDK12 or other geno mic alterations. 
While the availabilit y of these new treatm ent options allows for tailoring therapy to patient  
characterist ics such as presence or absence of symptoms, prior treatm ents, patient preferences, and 
life expectancy , none of these therapi es resul t in durable clinical responses. Despite high initial 
response rates, remissio ns following second -gene ration hormone therapies are temporary  due to 
the occurrence of resistance mechanisms, including androgen receptor (AR) reactivat ion. At this 
time, with judici ous sequencing and use of available new therapies, participants with established 
mCRPC have a life expectancy inthe range of  12 to 35 m onths. Thus mCRPC remains a disease 
with a lethal outcom e with the urgent need for treatment options that will provide durable disease 
control  and l ong term  survival.
3.3.2 Nivolumab Mechanism of Action
Cancer immunotherapy rests on the premise that tum ors can be recognized as foreign rather than 
as self and can be effect ively attacked by an activated immune system . An effective immune 
response in this setting is thought to rely  on immune surveillance of tum or anti gens expre ssed on 
cancer cells that ultimately resul ts in an adapt ive immune response and cancer cell death. 
Meanwhile, tumor progression may depend upon acquisit ion of traits that allow cancer cells to 
evade immunosurveillance and escape effective innate and adapti ve immune responses.35,36,37
Current 
immunotherapy  efforts attem pt to break the apparent tol erance of the immune system  to 
tumor cells and antigens by mechanisms such as introducing cancer antigens by therapeutic 
vaccination or by  modulating regul atory  checkp oints of the immune system . T-cell stimulat ion is 
a complex process involving the integrati on of numerous positive as well as negative co-
stimulatory  signals in addit ion to antigen recognit ion by the T -cell receptor (TCR).38Collect ively, 
these signals gove rn the balance between T- cell activat ion and tol erance.
Protocol Amendment No.: 04
Date: 22-Sep-2023 40
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
PD-1 is a member of the CD28 family of T -cell co -stimulatory  receptors that also includes CD28, 
CTLA 4, ICOS, and BTLA.39PD-1 signaling has been shown to inhibit CD28 -mediated 
upregul ation of interleukin (IL)-2, IL-10, IL-13, interferon-gamma (IFN -Œ≥) and Bcl-xL. PD-1 
expressio n has also been noted to inhibi t T-cell activat ion, and expansi on of  previ ously activated 
cells. Evidence for a negative regulatory role of PD -1 comes from studies of PD -1 deficie nt mice, 
which devel op a variet y of autoimmune phenoty pes.40These resul ts suggest that PD-1 blockade 
has the potenti al to activate anti-self T-cell responses, but these responses are variable and 
dependent upon various host genet ic factors. Thus, PD-1 deficiency or inhibit ion is not 
accompanied by a universal loss of tolerance to self -antigens.
In vitro, nivolumab (BMS -936558) binds to PD -1 with high affinit y (EC50 0.39 -2.62 nM), and 
inhibits the binding of PD-1 to its ligands PD-L1 and PD-L2 (IC50 ÔÇ±1 nM). Nivo lumab binds 
specifically to PD -1 and not to related members o f the CD28 family  such as CD28, ICOS, CTLA 
4 and BTLA. Blockade of the PD -1 pathway by nivo lumab results in a reproducible enhancement 
of both proliferat ion and IFN-Œ≥ release in the mixed lymphocy te reacti on (MLR). Using a 
cytomegalovirus (CMV) re-stimulation assay with human peripheral blood mononuclear cells 
(PBMC), the effect of nivolumab on antigen specific recall response indicates that nivolumab 
augm ented IFN-Œ≥ secre tion fro m CMV spec ific memory T cells in a dose -dependent manner versus 
isoty pe-matched control. In vivo blockade of PD -1 by a murine analog of nivo lumab enhances the 
anti-tumor immune response and resul t in tumor rejection in several  immunocom petent mouse 
tumor models (MC3 8, SA1/N, and PAN02).41
3.3.3 Docetaxel Mechanism of Action
Docetaxel is an anti -neopl astic chem otherapeuti c agent which acts by  disrupting the microtubular 
network that is essenti al for mitotic and interphase cellular functions. See the current prescribing 
information for docetaxel  (Sm PC, USPI, or country -specific label) for more informat ion.42
3.4 Benefit/Risk Assessment
Although multiple new agents have been approved for mCRPC over the last decade, benefits 
remain modest and the median survival o f patients with mCRPC is unsat isfactory  at approximately 
12 to 35 months .43,44,45,46,47It is clear that there is an urgent need for new therapeutic options that 
offer further improvement in cancer control and overall survival .
Nivo lumab has demonstrated significant clinical benefit in the treatm ent of advanced solid 
(eg,melanoma, renal cell carcino ma [RCC], and non-small cell lung cancer [NSCLC]) and 
hematol ogic (eg, classical Hodgkin Lympho ma [cHL]) malignancies as monotherapy  or in 
combinat ion with other agents such as ipilimumab, depending on the malignancy. Details of the 
clinical act ivity in these various malignancies are provided in the USPI48and SmPC49.
Overall, the safet y profile of nivo lumab is manageable and generally consistent across completed 
and ongo ing clinical t rials wi th no maximum  tolerated dose (MTD) reached at any dose tested up 
to 10 mg/kg. Most adverse events (AEs) were low -grade (Grade 1 to 2) with relat ively few related 
high-grade (Grade 3 to 4) AEs. There was no pattern in the incidence, severit y, or cau sality of AEs 
with respect to nivol umab dose l evel.
Protocol Amendment No.: 04
Date: 22-Sep-2023 41
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
A pattern of immune -mediated adverse events (IMAEs) associ ated with nivolumab has been 
defined, for which management algorithms have been developed; these are provided in Appendix 
6. Most high-grade event s were manageable with the use of corticosteroi ds or horm one 
replacement therapy  (in the case of endocrinopathy) as instructed in these algorithms. 
Addit ional details on the safet y profile o f nivolumab, including results fro m other clinical studies, 
are a lso available in the nivo lumab IB.
Notwi thstanding that there have been several immunotherapy  failures in prostate cancer, the 
approval  of cancer vaccine si puleucel -T in the US, together wi th the promising act ivity shown by 
the recent early phase trials ofPD-1 inhibitors in combination withanti-CTLA -4 inhibitors or,
with other non-immunotherapy  agents (ie,docetaxel, enzalutamide and olaparib) have provided 
support for further exploring the use of immune thera pies in prostate cancer.50,51,52,53As outlined 
inSection5.5.2 the purpose of combinat ion immune therapies is to enhance anti
-tumor T-cell 
responses and several lines of evidence support combinat ion of immune therapi es with 
chemotherapy in men with mCRPC. 
Docetaxel has a well-characteri zed AE profile as a cytotoxic chem otherapy, including the potenti al 
of pancytopenia, fluid retent ion, peripheral neuropathi es, diarrhea, nausea and vomiting. 
Prelimi nary data from a NSCLC study  suggest that nivolumab in combinat ion with platinum 
doubl et chemotherapy has additive anti-tumor activit y in participants regardless of PD-L1 
expressio n, but wi th a numeri cally higher ORR observed in non-squamous NSCLC.54The sa fety 
profile of nivolumab plus platinum -doublet chemotherapy reflected additive toxicities of the 
individual agents, which were manageable using established safet y guidelines. In addition, the 
safet y and tol erabilit y of docetaxel  in combinat ion with pembro lizumab in patients with mCRPC 
appeared to be acceptable.55Grade 3 -5 treatment -related AEs occurred in 27 (38%) pts, including 
2 deaths from treatm ent-related AEs (pneumo nitis). The most commo nly reported grade 
ÔÇ≥3treatm ent-related AEs were febrile neutropenia (12%), decreased neutrophil count (6%), colitis 
(4%), and pneumonit is (4%). Most immune -mediated AEs were low grade with the most commo n 
being infusio n-related reactions (11%) and colitis (10%).55Docetaxel is being tested in 
combinat ion with nivolumab in Arm B of the ongoing Phase 2 CA209 -9KD study 
([STUDY_ID_REMOVED]). Enrollment has been completed (n = 84) and preliminary result s from the inter im 
analysis have demonstrated promis ing anti-tumor activit y with nonew safet y concerns and as 
described in Section 5.5.2 (Rationale for Immunotherapy in mCRPC) .
To assure an ongoing favorable risk/benefit assessment for participants enrolled into the present 
study , the f ollowing safet y measures will be emplo yed throughout the conduct of the study :
ÔÇ∑Institution of a Data Moni toring Committee (DMC) to provide independent oversight of safety, 
study  conduct and efficacy of nivolumab in combinat ion with docetaxel .In addi tion, a Study 
Steering Committee (consi sting of selected participating invest igators) will meet regularly to 
advise BM S regarding study -related i ssues, including safet y concerns.
ÔÇ∑Rigorous safet y monitoring by BMS to ensure participants‚Äô safet y including regul ar and 
system atic review of  safety  data, cl ose follow-up of  reported safety  events, and intensive site 
and study  invest igator training/education on the implementation of the nivolumab toxicity 
Protocol Amendment No.: 04
Date: 22-Sep-2023 42
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
management algorithms and toxicity management of docetaxel . A BMS Safet y Management 
Team  will review and evaluate all emerging data across the program for potential safet y signa l
assessment in a timely manner. 
ÔÇ∑Risks will be further minimized by adherence to inclusion and exclusio n select ion criteria (see 
Secti on 6), avoidanc e of prohibited medicat ion (see Secti on 7.7.1 ), close safety  monitoring 
(see Section 9.2Adverse Events and Secti on9.4Safety), and dose adjust ment guidelines (see 
Secti on7.4Dose Modificat ions). These w ill also be clearly discussed and highlighted during 
site visi ts.
In concl usion, treatment of nivolumab in combination with docetaxel in men with mCRPC is 
expected to be tolerable, and toxicities of the treatment are expected to be manageable and 
reversi ble upon dose reduction, treatment interruption, or discont inuat ion. The overall risk -benefit  
of thecombinat ion is deemed acceptable.
Detailed informat ion about the known and expected benefits and risks and reasonably  anticipated 
AEs of nivolumab may be found in their respective IBs. Similar information is provided for 
docetaxel in the associ ated Patient Inform ation Leaflet, USPI, country -specific label, Devel opment 
Safety Update Report, or SmPC.
4
OBJECTIVES AND ENDPOI NTS
Table 4-1: Objectives and Endpoints
Objective Endpoint
Primary
ÔÇ∑To compare the rPFS (using 
PCWG3) of nivolumab in 
combinatio n with docetaxel to 
placebo in combination with 
docetaxel, in men with metastatic 
castration resistant prostate cancer 
(mCRPC).ÔÇ∑rPFS for randomized participants is the time between 
randomization and the first date of documented progression or death 
due to any cause, whichever occurs first. The radiographic 
progression will be assessed by Blinded Independent Central 
Review (BICR) per PCWG3 . The rPFS will be censored at the last 
tumor assessment up to the start of subsequent systemic cancer 
therapy .
ÔÇ∑To compare the OS of nivolumab in 
combinatio n with docetaxel to
placebo in combination with 
docetaxel ,in men with metastatic 
castration resistant prostate cancer 
(mCRPC).ÔÇ∑OS for all randomized participants is the time between 
randomization and the date of death from any cause. For 
participants who are alive, their survival time will be censored at 
the last date that they  were kno wn to be alive. OS will be censored 
for participants at the date of randomization if they  had no follow -
up.
Secondary
ÔÇ∑To assess the antitumor activity of 
nivolumab in combination with 
docetaxel .ÔÇ∑Objective Response Rate per PCWG3 (ORR -PCWG3 )is the 
proportion of participants who have a confirmed complete or partial 
best overall response (BOR) per PCWG3 amongrandomized
participants who have measurable disease at baseline .The BOR is 
defined as the best response designation, as determined by the 
BICR, recorded between the date of randomizatio n and the date of 
objectively documented progr ession per PCWG3 or the date of 
subsequent systemic cancer therapy, whichever occurs first. For 
participants without documented progr ession or subsequent 
Protocol Amendment No.: 04
Date: 22-Sep-2023 43
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
Table 4-1: Objectives and Endpoints
Objective Endpoint
systemic cancer therapy , all available response assessments will 
contribute to the BOR assessment.
ÔÇ∑Time to Response per PCWG3 (TTR -PCWG3 )is the time from 
randomization to the date of thefirst documented CR or PR per 
PCWG3 , as de termined by BICR . 
ÔÇ∑Duration of Response per PCWG3 (DOR -PCWG3 )is the time
between the date of first response (CR/PR per PCWG3) to the date 
offirst documented radiographic progression per PCWG3 , as 
determined by BICR, or death due toany cause. Participant s who 
neither progr ess nor die will be censored at the last tumor 
assessment up to the start of subsequent systemic cancer therapy.
ÔÇ∑PSA Response Rate (PSA -RR) is the proportion of randomiz ed 
participants with a 50% or greater decrease in PSA from baseline to 
the lowest post-baseline PSA result. A second consecutive value 
obtained 3 or more weeks later is required to confirm the PSA 
response. PSA response will be calculated for all participants with 
PSA values at baseline and at least one post -baseline asses sment.
ÔÇ∑Time to PSA Progression (TTP -PSA ) is the time between 
randomization to the date of PSA progr ession per PCWG3 in 
randomized participants. For participants with an initial PSA 
decline from baseline, the date of PSA progr ession is thedate that 
an incr ease of 25% or more and an absolute increase of 2 ng/mL or 
more from the nadir are documented and confirmed by asecond 
consecutive PSA value at least 3 weeks later. For participants with 
no PSA decline from baseline, the date of PSA progression is the
date that an increase of 25% or mo re and an absolute increase of 2
ng/mL or more from baseline are documented beyond Week 13.
TTP-
PSA will be censored at the date of last PSA evaluation prio r 
to the start of subsequent systemic cancer therapy. The time will be 
censored at the date of randomization for participants with no post -
baseline PSA evaluation.
ÔÇ∑To characterize the safety and 
tolerability of nivolumab in 
combinatio n with docetaxel.ÔÇ∑Overall safety and tolerability will be measured by the incidence of
AEs, SAEs, AEs leading to discontinuation, immune -mediated 
AEs, select AEs, deaths, and laboratory abnormalities and changes 
from baseline .
ÔÇ∑To evaluate the progression of pain 
during treatment .ÔÇ∑Median time to pain progr ession as assessed by Brief Pain 
Inventory -Short Fo rm (BPI -SF).
Exploratory
ÔÇ∑To investigate the t ime to initiatio n 
of subsequent systemic therapy  
(TT-SST) .ÔÇ∑TT-SST is the time from randomization to the start of subsequent 
systemic therapy, including hormonal therapy, chemotherapy,
immunotherapy, or investigational therapy.
ÔÇ∑To investigate the time to first
symptomatic skeleta l event (TT-
SSE) .ÔÇ∑TT-SSE is the time between randomization and the date of first
symptomatic fracture, radiatio n or surgery to bone, or spinal cord
compression .
ÔÇ∑To evaluate the change inpain 
intensity  and health -related cancer ÔÇ∑Change in mean scores as assessed by BPI -SF.
Protocol Amendment No.: 04
Date: 22-Sep-2023 44
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
Table 4-1: Objectives and Endpoints
Objective Endpoint
related symptoms and quality of 
life.ÔÇ∑Median time to deterioration and change in mean scores as assessed 
by FACT -P total score and subscale s.
ÔÇ∑To assess the participant‚Äôs quality 
of life and overall health status .ÔÇ∑Change in scores in both the EQ-5D-5L utility index and visual 
analog scale .
ÔÇ∑To investig ate the time to and 
duration of PSA response .ÔÇ∑Time to PSA response (TTR -PSA) is defined for PSAresponders 
as the time from randomization to the date of the first PSA r esponse . 
Duration of PSA response (DOR -PSA) is defined for PSA 
responders as the time between the date of first response and the 
date of PSA progression. Participants who neither progress by PSA 
nor die will be censored on the date of last PSA evaluation.
ÔÇ∑To evaluate the pharmacokinetics 
of nivolumab when administered in 
combinatio nwith docetaxel . To 
explore exposure response 
relatio nships between select 
exposure measures, and safety , and 
efficacy endpoints, as appropriate .ÔÇ∑Parameter estimates from Population PK analy sis and exposure -
response analysis, if data permit .
ÔÇ∑To characterize the 
immunogenicity of nivolumab  
when administered in combination
with docetaxel .ÔÇ∑Immunogenicity will be determined by measurement of anti-drug
antibody (ADA) in serum and samples with positive ADA response
may be analy zed for neutralizing ADA response to nivolumab .
ÔÇ∑To assess the impact of SARS -
CoV-2 serologic status on 
participants with metastatic 
castr ation-resistant prostate cancer 
who are receiving study treatment
 ÔÇ∑Explo ratory  measurements of SARS -CoV -2 serology (anti-SARS -
CoV-2 total or IgG), from serum samples collected at baseline and 
during the study, and thepotential association between these 
measurements and selected endpoints related to safety, efficacy, 
Protocol Amendment No.: 04
Date: 22-Sep-2023 45
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
5 STUDY DESIGN
5.1 Overall Design
The study  design schema tic is presented in Figure 5.1-1.
CA2097DX is a Phase 3 randomized, double -blinded , multi-center clinical trialcompar ing 
nivolumab or pl acebo in combinat ion with docetaxel , in men with metastati c castrati on-resistant 
prosta tecancer .
The study  will randomize up to approximately  984 participant s 1:1 into 1 of the 2 treatment arms 
(nivo lumab combined with docetaxel  or docetaxel combined with placebo ).The primary  endpo ints 
of the study  are rPFS and OS, as described in Sect ion4.
Per Protocol Amendment 04, full study teams and investigators were unblinded to study 
treatment assignment on 03
-AUG -2023 due to the lack of rPFS and OS benefit from 
nivolumab added to docetaxel plus prednisone compared to placebo added to docetaxel plus 
prednisone. 
Arm A
:
ÔÇ∑Combinat ion Phase (m aximum 10 cy cles, 1 cy cle is 3 weeks) :
ÔÄ≠Docetaxel 75 mg/m¬≤ IV Q3W + Prednisone 5 mg PO BID + Nivo 360 mg IV Q3W
ÔÇ∑Monotherapy  Phase (1 cy cle is 4 weeks) :
ÔÄ≠ Nivo lumab 480 m g IV Q4W
Arm B :
Per Protocol Amendment 04, participants assigned to Arm B will no longer receive placebo. 
ÔÇ∑Combinat ion Phase (m aximum 10 cy cles, 1 cy cle is 3 weeks)
ÔÄ≠Docetaxel 75 mg/m¬≤ IV Q3W + Pre dnisone 5 m g PO BID + Placebo IV Q3W
ÔÇ∑Monotherapy  Phase (1 cy cle is 4 weeks):
ÔÄ≠Placebo IV Q4W
Randomization will be stratified according to the following baseline factors:
ÔÇ∑1 pri or Novel  Antiandrogen Therapy (NAT) for mCRPC vs 1 pri or NAT for non-metastati c 
castration -resistant prostate cancer (nmCRPC) or metastatic castrati on-sensi tive prostate 
cancer (mCSPC )vs 2 prior NAT
ÔÇ∑Visceral  disease (Y vs N)
Visceral  disease status will be assessed by invest igator based on the tum or assessment perform ed 
during screening. Visceral disease is defined as the presence of metastatic disease in the liver, lung, 
adrenal, peritoneum, brain or other internal organs. Bone,lymph node metastases and prostate 
Protocol Amendment No.: 04
Date: 22-Sep-2023 46
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Cli nical Pr ot oc ol C A 2 0 9 7 D X 
B M S - 9 3 6 5 5 8 ni v ol u ma b
lesi o ns ( or bla d der/rect u m if fr o m  d irect i n vasi o n fr o mpr ostate) are n ot c o nsi dere d viscera l 
di sease .
Fi g ure 5. 1 - 1: St u d y Desi g n Sc he m atic 
Per Pr ot oc ol A me n d me nt 0 4, p artici p a nts assi g ne d t o Ar m B will n o l o n ger recei ve pl ace b o. 
T his st u d y  wi ll c o ns ist of  t hree p hases: Scree ni n g, Treat me nt, a n d F ol l o w- u p. F or a c o m plete list  
of  st u d y  r e q ui re d pr oce d ures, pl ease refer t o  Secti o n 2.
5. 1. 1 S cr e e ni n g P h a s e 
P arti ci pa nt s will pr o vi de wri tte n i nf or me d c o nse nt t o partici pate i n t h e st u d y  b ef or e c o m pleti n g 
a n y pr ot oc ol -s pecifie d pr oce d ures or e val uat i o ns n ot c o nsi dere d t o be part of  t he partici pa nts‚Äô 
sta n dar d of care (refer t o Secti o n 2 Sc he d ule of A cti vi ti es f o r details). After si g ni n g t he i nf or me d 
c o nse nt f o r m  ( I C F), partici pa nts will be e val uate d f o r e ntr y  c ri t eri a d uri n g t h e scree ni n g p eri o d 
bef ore a d mi nistrati o n of  s t u d y  d r u g(s). Re -e nr oll me nt aft er scree n fa il ure will be all o we d a n d 
la bs/ pr oce d ures ma y be reteste d (see Secti o n 6. 4. 1 ( Retesti n g D uri n g Scree ni n g or Lea d -I n 
P eri o d). 
T u m o r i ma gi n g is re q uire d wit hi n 2 8 da ys of ra n d o mizat i o n. 
5. 1. 2 Tr e at m e nt P h a s e 
Per Pr ot oc ol A me n d me nt 0 4 a n d t he decisi o n t o ter mi n ate t he st u d y d ue t o a l ac k of effic ac y, 
t he f ull st u d y te a m sa n d i n vesti g at ors h a ve bee n u n bli n de d t o tre at me nt assi g n me nts. 
P arti ci p a nts i n t he pl ace b o ar m will disc o nti n ue pl ace b o a n d m a y be a ble t o c o nti n ue 
d ocet a xel f or u p t o 1 0 c ycles t hr o u g h t he st u d y if t he y are i n t he c o m bi n ati o n p h ase, a n d l oc al 
access t o d ocet a xel o utsi de t he st u d y is n ot a v ail a ble. I n a d diti o n, all p artici p a nts s h o ul d 
recei ve st a n d ar d of c are tre at me nt f or m C R P C per l oc al g ui deli nes. 
Pr ot oc ol A me n d me nt N o.: 0 4 
Date: 2 2- Se p- 2 0 2 3 4 7 
6 . 0 A p p r o v e d 9 3 0 1 4 2 0 8 3 5 . 0 vP PI 
A p p r o v e d 1 . 0 v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
Following confirmation of eligibilit y, partici pants will be randomized to receive nivolumab or 
placebo in combinat ion with docetaxel.
The treatm ent period will consist of a combinat ion phase (nivo lumab or pl acebo in combinat ion 
with docetaxel for up to 10 cycles) and a monotherapy  phase (nivo lumab or placebo) as described 
above in Sect ion 5.1. Treatment with nivo lumab will be given for a maximum of 24 months from 
date of first dose in the absence of disease progressio n, unacceptable toxicity or other reasons 
specified in the protoc ol. See Section 7.1(Treatm ents administered) for details o f treatm ents. 
Not applicable per Protocol Amendment 04: PK sam ples and immun ogenici ty samples will  be 
collected according to schedules in Table 9.5-1
Not applicable per Protocol Amendment 04: Tumor assessments shoul d occur every 9 weeks 
(ÔÇ±7 days) from first dose, regardless of treatm ent schedule or dose delays,for first 54 weeks. 
Thereafter switch to every 12 weeks (ÔÇ±7 days). Imaging must continue until radiographic 
progression per PCWG3 is assessed by invest igator, and confirmed by BICR, or treatm ent is 
discontinued, whichever occurs later. See Section 9.1.1 (Imaging Assessment for the Study ) and 
Secti on 9.1.2 (BICR Confirmation of Progressio n).Per Protocol Amendment 04, all 
participants receiving study treatment will have radiographic tumor assessments based on 
the clinical judgment of the treating investigator and following imaging tumor assessment 
local guidelines for mCRPC.
Per Protocol Amendment 04, decisions on docetaxel treatment will be based on the clinical 
judgment of the treating physician and on shared decis ion making with the participant. 
Participants who are not able to access local therapy may continue on study -provided 
docetaxel until local access is available. In the event that the investigator deems a participant 
is deriving clinical benefit from nivolu mab therapy and, together with the counseled 
participant, wishes to continue treatment, this may be possible following discussion with the 
Medical Monitor to ensure a clinical rationale exists that justifies continuation of nivolumab 
treatment.
Not applicable per Protocol Amendment 04: In certain circumstances, participants with 
progressive disease (PD) per PCWG3, but wit
h otherwi se stable or improved performance and 
clinical status, m ay conti nue to be treated in the ev ent of a perceived benefi t per invest igator; see 
Secti on7.7.4 for treatm ent bey ond progressi on cri teria.
This phase ends when the participant is discont inued fro mstudy  therapy .
5.1.3 Follow -upPhase
Per Protocol Amendment 04, the follow -up phase only applies to participants up to 100 days 
after the irlast infusion of nivolumab. After 100 days of follow -up have been completed, the 
nivolumab -treated participants will be p ermanently discontinued from the study. 
Begins when the decisio n to discontinue a participant from study  therapy is made (no further 
treatm ent with study therapy). Not applicable per Protocol Amendment 04: Every effort should 
be made to continue tumor assessments for participants who discont inue treatm ent for reasons 
other than disease progression or consent withdrawal, according to the schedule in Table 2-2until 
Protocol Amendment No.: 04
Date: 22-Sep-2023 48
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
progression. Not applicable per Protocol Amendment 04: After completion of the first two 
safet y follow-up visits, participants will be followed every 3 months for survival, and include 
docum entati on of  subsequent therapy .
Not applicable per Protocol Amendment 04: BMS may request that survival data be collected 
on all treated participants outsi de of the protocol  defined window as detailed in the Schedule of 
Activities in
 Sect ion 2. At the time of this request, each participant will be contacted to determine 
their survival status unless the participant has withdrawn consent for all contact .
5.2 Data Monitoring Committee and Other External Committees
Not applicable per Protocol Amendment 04 due to study termination.
To provide independent oversi ght of safety, efficacy , and study  conduct, an independent Data 
Moni toring Committee (DMC) will be established to provide oversight on safet y and efficac y 
considerations. Details o f the DMC responsibili ties and procedures will be specified in the DMC 
charter. 
A Study Steering Commit tee (consisting of selected participating invest igators) will meet regul arly 
to advise BMS regarding study -related issues, including safet y concerns.
When requi red, adjudicated events will be submitted to the DMC and Health Authorities for review 
on a specified timeframe in accordance wit h the adjudicat ion documentation.
5.3 Number of Participants
Assuming a 25% screen failure rate, it is estimated that approximately 1,312 participants with 
mCRPC, will be enrolled in order to randomize approximately 984 participants . See Secti on10.1
for a descript ion of the sample size calculat ion.Recrui tment was completed globally as of 13-Jun-
2022. China region will continue enrolling until required number of participants to satisfy 
regul atory  requi rements isachieved ( approximately  15% of  the gl obal partici pants )
.
5.4 End of Study Definition
Per Protocol Amendment 04, the study will be terminated, and the first interim analysis will 
be considered the final analysis. The end of the trial is defined as when the la st participant 
receiving study -provided nivolumab completes 100 days of safety follow -up after their last 
nivolumab infusion . Study  com pletion is defined as the final date on which data for the primar y 
endpo int was or i s expected to be collected, if this is not the same .
The total duration o f the study fro m the date of first participant treated to the final analysis of both 
primary  endpoints i s expected to be approximately 31 months. 
5.5 Scientific Rationale for Study Design
5.5.1 Rationale for Population
Men with metastati c CRPC who have progressed after 1or 2 NATs and have not received 
chemotherapy for mCRPC will be included in this study .Although most patients without 
symptoms are not treated with chemotherapy, the survival benefit reported with docetaxel appli es 
to those wi th or wi thout symptom s. NCCN guidelines recommends to use docetaxel  (category  1) 
Protocol Amendment No.: 04
Date: 22-Sep-2023 49
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
as the preferred 1st line chemotherapy in men with symptomat ic mCRPC and inpatients with signs 
of rapid progressi on or visceral metastases despite lack of sympt oms. Docetaxel also has a cat egory 
1 recommendat ion in second -line after prior enzalutamide/abiraterone. Clinical data from a 
number of small retrospective cohort studies suggests that once participant s with mCRPC progress 
response rates to abiraterone aft er enzalutamide and conversely enzalutamide after abiraterone are 
low and no robust criteria exist clinically to select one drug rather than the other.56
Given that abiraterone and enzal utamide are the preferred 1st line option for men with 
asymptomat ic, ch emotherapy -na√Øve mCRPC and the recent approvals of next gen eration hormonal 
therapi es in mCSPC and M0 CRPC settings, it is expected that most patients will have received 
one of these agents when they develop mCRPC. Therefore, the current study  will include chem o-
na√Øve mCRPC patients who are post-1 or 2 prior lines of second -generat ion horm onal therapies. 
No m ore than 1 prior NAT is allowed in the mCRPC setting. The study  will stratify by prior NAT 
(1 pri or NAT for mCRPC vs 1 prior NAT for nmCRPC/mCSPC vs 2 prior NAT) in order to 
account for potential differences in survival outcomes.
Significant progress made over the last few years in understanding the biology and molecular 
classificat ion of CRPC, wi th Olaparib and rucaparib being two examples of PARP inhib itors that 
are being investigated in a mo lecularly defined mCRPC subgroup, namely pat ients with mutations 
in specific HRD genes, such as BRCA1/2 and ATM. Data from the Phase 2 Check -Mate 650 study 
(NIVO1+IPI3) presented at ASCO -GU in Feb-201957demonstrated clinical activity in mCRPC, 
with ORR of 10% and 25% in chem otherapy -pretreated and chemotherapy -na√Øve patients, 
respectively , and preliminary  evidence of tumor mutati onal burden (TMB) as a biomarker for 
immuno -oncol ogy (IO)activit y in a subgroup of patie nts with tumor sam ples evaluable for whole 
exome sequencing. However, little published data are available on the efficacy  of chemotherapy 
by biomarker status in advanced prostate cancer as several older trials did not include next-
generat ion sequencing of tumor samples.  
5.5.2 Rationale for Immunotherapy in mCRPC
Like most types of cancer, prostate cancer devel ops in an immune -competent environment. 
Immune responses against prostate tumors are noted in the form of intratum oral leukocy te 
infiltrat ion and inflammatory  pathway  activation.58Evidence from animal models and human 
prostate cancer suggests that, despite the prese nce of immune effector cells that recogni ze tumor 
antigens, these cells are act ively tolerized and become incapable o f mediat ing tumor destruction.59
The induct ion of regulatory or suppressor T cells60with increased CD4+CD25+ and CD8+Foxp3+ 
regul atory  T  cells (Treg), detected both within prostate glands and in the peripheral  blood of 
prostate cancer subjects, suggests the presence of active immune suppressio n of antitumor 
immunit y.61,62
An analysis of the prognostic significance of PD-1 and/or PD-L1 expressio nin a cohort of 
535prostate cancer tumors showed that a high densit y of PD-1+ lymphocy tes independent ly 
predi cted shorter clinical failure -free survival .63This may indicate that tumor immune escape, and 
Protocol Amendment No.: 04
Date: 22-Sep-2023 50
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
thus tum or immune eliminat ion, are important m echani sms in prostate cancer and the associ ation 
of pathway mo lecules wit h poor prognosis makes them attractive targets for inhibit ion. These lines 
of evidence support targeti ng the immune system itself, via activati on of  T cells and overcoming 
T-cell tolerance, to resul t in durable ant itumor activit y in prostate cancer.
Two Phase 3 Studi es (CA184043 and CA184095) carri ed out subsequently have failed to show a 
clear-cut surviv al advantage for ipilimumab (10mg/kg) over placebo, although some patients 
achieved sustained co mplete responses and treatment with ipilimumab was associated with longer 
median PFS and higher PSA response rate.64,65More recent ly, the approval  of cancer vaccine 
sipuleucel -T in the US, together with the promising activit y shown by the recent early phase trials 
of immune checkpo int inhibitors66,10 ,52, 53,57have provided support for further exploring the use of 
immun e therapi es in prostate cancer.
The IMPACT study  evaluated sipuleucel -T (Provenge ÔÉí, Dendreon Corp., Seattle, WA), an 
autol ogous therapeuti c vaccine, vs placebo in chemotherapy -na√Øve CRPC participants and reported 
a 4.1-month survival improvement in asymptomat ic or minimally symptom atic 
CRPC participants.67While these data show little overall impact on delaying progressi on of 
disease, the reported benefits in OS m ay be considered ‚Äúproof of concept‚Äù that immunotherapeutic 
agents can play an important role in treati ng advanced prostate cancer.68
Prostate cancer has been shown to have low tumor expressi on of PD-L12and single- agents anti-
programmed death -1 (PD-1)/programmed death ligand 1 (PD-L1) immunotherapies have shown 
limited clinical success in prostate cancer patients, particularly when compared toother cancer 
types such as melano ma and non -small  cell l ung cancers . In a cohort of 17 subjects with mCRPC ,
nivolumab 10 mg/kg showed no object ive responses .69One out of 10 subjects evaluable for PSA 
response demonstrated a PSA reducti on ÔÇ≥50% frombaseline. Prostate tumor samples were 
available in 2 subjects with mCRPC, and tumor PD-L1expressio n was 0% in both subjects.
Atezolizumab monotherapy  was evaluated in a Phase 1a study, including 15 heavily pretreated 
subjects with mCRPC.70There were no objective responses per RECIST 1.1, although 1 subject 
had a PR per immune -related response criteria (irRC). Pembrolizumab was recently evaluated in 
a Phase 2 study  of mCRPC patients previously treated with docetaxel .71Among those with 
measurable diseas e, ORR was 3% and 5% in PD-L1 negat ive (n=66) and positive (n= 133) 
patients, respectively. PSA responses were observed in 11% of evaluable patients (n=193). 
Amo ng 19 patients with so matic aberrations in BRCA1/2 or ATM, ORR was 11%, suggesting that 
DNA repair defects may be associated with anti -tumor activi ty.
However, immunotherapy -based combinat ions couldpotenti ally result inincreasing immune -
mediated anti
-tumor activit y in subjects with prostate cancer. Nivo lumab plus ipilimumab
demonstrated antitumor activity in patients with mCRPC and further evaluat ion of the clinical 
activit y of this combinat ion, as well as the potential  associ ation between biomarkers is current ly 
ongoing in study  CA209650.57In addi tion to this study , an open -label P hase 2 tri al of nivo lumab 
combined with rucaparib, docetaxel, or enzalutamide in patients with mCRPC ([STUDY_ID_REMOVED]) is 
ongoing.
Protocol Amendment No.: 04
Date: 22-Sep-2023 51
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
Other clinical trials are underway evaluat ing the role of PD-1/PDL1 inhibitors in co mbinat ion with 
other agents that work via varied mechanisms of action and are potenti ally synergist ic 
([STUDY_ID_REMOVED], [STUDY_ID_REMOVED], [STUDY_ID_REMOVED], [STUDY_ID_REMOVED], [STUDY_ID_REMOVED], 
[STUDY_ID_REMOVED]). The addition of pembro lizumab upon enzalutamide failure was evaluated in a 
single
-arm, Phase 2 study .66The study  demonstrated meaningful clinical act ivity to PD-1 blockade 
in men wi th mCRPC and no unexpected AEs. Furtherm ore, recent resul ts from other early phase 
studi es combining permbrolizumab with olaparib, docetaxel  or enzalutamide have shown 
acceptable safet y profile and promising ant i-tumor activit y, supportin g further evaluation of the se 
combinat ions in the ongoing Phase 3 studi es ([STUDY_ID_REMOVED], [STUDY_ID_REMOVED], 
[STUDY_ID_REMOVED]).10,52,53
ADT , which has been shown to alter the immune environment in prostate cancer, plays a central 
role in the treatm ent of high-risk early PCa and recurrent or metastati c disease . Therefore, it is 
cruci al that immune -based therapies are compatible and, preferably, show synergist ic activit y.8
For example, neoadj uvant ADT of prostate cancer patients resul ts in increased numbers of 
infiltrat ing CD4 T-cells, CD8 T-cells, natural killer (NK) cells, and macrophages in prostate 
tissues.6,7Similarly, th ere is growing evidence that chemotherapy can induce immuno -modulatory 
effects that could facilit ate the induction o f antitumor immunit y.
Nivolumab in combination with Docetaxel
Docetaxel, a second -generat ion semisynt hetic taxane analog, became the first chemotherapeutic 
agent to show an OS benefit in mCRPC in two randomized controlled clinical trials (TAX 327 and 
SWOG 99 -16), and was approved in combinat ion with predniso ne for this indication in the US in 
2004.15,16In the landmark TAX 327 Phase 3 trial, 1006 participants with mCRPC were 
rando mized to receive daily  prednisone and either mitoxantrone 12 mg/m2 Q3W, docetaxel 
75mg/m2Q3W, or docetaxel  30 m g/m2QW for 5 of  every 6 weeks .15Participants who received 
docetaxel Q3W had a median survival of 19.2 months, compared to 16.3 months in the 
mitoxantrone Q3W and 17.8 months in the docetaxel QW arms. The hazard ratio for th e docetaxel 
Q3W arm was 0.76 (95% confidence interval [CI], 0.62 to 0.94; P =0.009). It is hypothesized that 
chemotherapy may modify the immune response to tum ors by influencing multip le mechanisms, 
including inducing immunogenic cell death, stimulating r elease of tumor antigens and/or deplet ing 
immuno -suppressive Tregs. Chemotherapies (docetaxel, cabazitaxel) can have profound effects 
on the immune system , including acute reducti ons in NK, T, and B cells. Paradoxically , while 
treatm ent with docetaxel may induce lymphocytopenia in pat ients,72upon regenerat ion of immune 
cell populati ons, an enhanced ant i-tumor immune response can occur through a reduction of 
immunosuppressive cell ty pes, including myelo id-derived suppressor cell ( MDSC )suppressio n73
and the s elect ive deplet ion of Treg cells .74In mouse models, the administration of docetaxel after 
vaccine -based immunotherapy  increased the response compared to either treatm ent alone,75
potenti ally as a result of increased T cell response and neoant igen presentati on.76Docetaxel has 
been reported to increase the producti on of proinflammatory  cytokines which may enhance the 
immune response.77In patient studies, evaluat ing immune response to taxanes in breast cancer, 
Protocol Amendment No.: 04
Date: 22-Sep-2023 52
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
increased T-Cell and natural  killer (NK) activat ion is also correlated with the use of  docetaxel .78
These findings indicate that use of immunotherapy may  augment the enhanced immune response 
seen following the use of standard- of-care chemotherapy  and have led to the development of 
clinical trials evaluating the combinat ion of docetaxel and various immune therapy  approaches.
Nivo lumab has been co mbined with docetaxel and other taxane agents, such as paclitaxel, and also 
with other cytotoxi c agents. The combinat ion of nivolumab with platinum -based doubl et 
chemotherapy has shown promising activit y and limited added toxicityin a Phase 1 study in 
NSCLC.79In this study , 14 participants were treated with nivolumab 5 mg/kg (equivalent to a 
360mg flat dose), 200mg/m2paclitaxel, and carbopl atin Q3W for 4 cycles, followed by 
nivolumab alone until disease progressi on or unacceptable toxicity. The most commo n toxicities 
reported wi th the combinat ion were those expected for chem otherapy  aloneand included fatigue, 
nausea, and decreased appet ite. Treatment -related select AEs (those AEs with an immuno logical 
etiology) were slight ly higher than seen with nivolumab monotherapy . Sel ect AEs of skin rash 
occurred in 5 participants (36%, with 1 Grade 3-4 AE), diarrhea in 3 participants (21%, Grade 1 -2), 
acute renal failure in 2 participants (14%, Grade 3-4), and pneumo nitis in 2 participants (with 1 
Grade 3-4). All select AEs were effectively  managed with corticosteroi ds, and none resul ted in 
death. Co mpared to historical controls, the activit y of the combinat ion, even in such a small cohort, 
was encouraging. The ORR was 43%, wit
h 6 participants achieving a partial response (PR). The 
median DOR was 19.6 months, the median PFS was 7.1 months, and the 6-month PFS rate was 
51%. Median OS had not been reached at the time of the database lock, but 1 -year and 2 -year OS 
rates were 86% and 62%, respectively. 
In a Phase 1, open -label, uncontrolled study  of nivolumab in combinat ion with chemotherapy in 
participan ts with Stage IIIB/IV or recurrent NSCLC (ONO -
4538- 04, see the current IB for 
nivolumab for more information), nivolumab 10mg/kg was administered in combinat ion with 
docetaxel in 6 Japanese participants. The most commo n drug-related AEs reported in at least 
2participants were neutrophil count decreased, white blood cell count decreased, lymphocyte 
count decreased and alopecia. AEs leading to nivolumab discont inuat ion were observed in 
3participants (hypothyroidism, lung infect ion, and infusio n
-related rea ction); hypothy roidism and 
infusio n-related reacti on were considered possibly  related to nivo lumab.
In mCRPC, docetaxel  is being tested in combinatio n with nivolumab in Arm B of the ongoing 
Phase 2 CA209 -9KD study  ([STUDY_ID_REMOVED]) in patients who had received up to two prior second -
generat ion horm onal manipulati on in the pre-chemotherapy setting. Enrollment has been 
completed (n =84) and an interim analysis was conducted in 41 patients with at least 16 weeks of 
follow
-up (Database lock date 09 -May-2019). The safet y of the combinat ion was consistent wi th 
the profiles of individual  agents, with 49% of patients experiencing Grade 3-4 treatm ent- related 
adverse events. Preliminary antitumor activit y appeared promising, with ORR being 37%, PSA-
RR 47% and rPFS 8.2 mo nths.
In addition, the combinat ion of pembro lizumab and docetaxel was tested in 72 pts with mCRPC 
who progressed after either abiraterone or enzalutamide .10The preliminary result s showed that the 
combinat ion was generally well tolerated with promising ant i-tumor activit y (ORR 14%; PSA -RR 
Protocol Amendment No.: 04
Date: 22-Sep-2023 53
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
31%; time to PSA progression 5.5 and 7 months for patients with measurable and non -measurable 
disease, respectively; rPFS 8 months; OS NR [12.9 to NR]), and potenti al benefit vs docetaxel 
alone.
Given the well characterized AE profile of docetaxel (ie, pancytopenia, fluid retention, peripheral 
neuropathi es, diarrhea, nausea, and vo miting) and the eviden ce from combinat ion studies showing 
that the safet y profile of nivolumab plus chem otherapy  can be managed using established safet y 
guidelines, the proposed combinat ion of nivolumab and docetaxel is expected to bring clinical 
benefits wit h manageable safet yto men wi th mCRPC.
5.5.3 Rationale for Choice of Endpoints
OS is easily  measured, unambiguous, obj ective, and unaffected by  the timing of  assessment. It i s 
considered the gold standard among efficacy  endpoints (clinically and regul atory  accepted), and 
an appropriate measure of treatment benefit for immune checkpo int inhibitors. However, given the 
availabilit y of effective systemic therapies to treat mCRP C patients in the post-docetaxel setting 
(eg, abiraterone, enzalutamide, cabazitaxel, radium -223), rPFS has been chosen as a second 
primary  endpoint as it will not be confounded by subsequent treatments.
5.5.4 Rationale for Sample Size Determination
The sample size of the study  accounts for the two primary endpo ints: rPFS and OS. The 
assumpt ions of rPFS and OS were derived fro m the following studi es:
ÔÇ∑two Phase 3 studi es that led to docetaxel approval  (TAX32715: OS 19.9 mo; 
SWOG991616:rPFS 6.3 m o; OS 17.5 mo) .
ÔÇ∑two retrospective docetaxel studi es conducted in thepost-abiraterone setting 
(Azad 201480:rPFS 4 mo, OS 11.6 mo; Mezynski 201281: OS 12.5 m o).
Since the pivotal  Phase 3 studi es were conducted approximately  15 years ago prior to novel 
antiandrogen therapi es approval  and survival  outc omes have improved since then, a more recent 
study  evaluat ing 1st line docetaxel vs cabazitaxel (Firstana: rPFS 12. 1 mo derived fro m composite 
PFS endpo int) was also used for rPFS assumpt ions.82
Therefore, the expected rPFS and OS wi th docetaxel  monotherapy  in the chosen popul ation are6 
months and 15 months ,respect ively.
Delayed separat ion of KM curves is included in the alternat ive hypotheses for rPFS and OS 
because a delayed immunotherapy  effect was observed in various tumors.83 84 85 86
See Secti on 10.1 (Sam ple Si ze Determinat ion) for a descript ion of the sample size determinat ion.
5.5.5 Rationale for Duration of Study Treatment
5.5.5.1 Nivolumab
The optimal durat ion of immunotherapy is an important question and continues to be invest igated. 
Clinical trials across different tumors types in the nivolumab and ipilimumab development 
program indicate that m ost of  the responses occur early , with a median time to response of 2 to 4 
Protocol Amendment No.: 04
Date: 22-Sep-2023 54
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
months,87,88,89,90,91and emer ging data suggest that benefit can be maintained in the absence of 
continued treatment. A recent analysis in a melano ma study  suggests the majorit y of patients who 
discontinue nivolumab and/or ipilimumab for toxici ty maintain disease control  in the absence of 
further treatm ent.92Furtherm ore, a limited durat ion of ipilimumab, including only 4 induct ion 
doses, resul ted in long term survival in patients with metastatic melano ma, with a sustained plateau 
in survival starting around 2 y ears after the start of tr eatment.93
Accumulat ing data suggest that 2 y ears of  PD-1 checkpo int inhibitor treatm ent m ay be sufficient 
for long term benefi t. CA209003, a dose-escalat ion cohort expansio n trial evaluat ing the safet y 
and clinical activi ty of nivolumab in patients wit
h previously treated advanced solid tumors 
(including 129 subjects with NSCLC), specified a maximum treatment duration of 2 years. Among 
16 subjects with NSCLC who discont inued nivolumab after completing 2 years of treatment, 
12subjects were alive > 5 years and remained progressi on-free without any subsequent therapy . 
In the CA209003 NSCLC cohort, the OS curve begins to plateau after 2 y ears, wi th an OS rate of 
25% at 2 years and 18% at 3 years.94These survival  outcom es are similar to Phase 3 studi es in 
previo usly treated NSCLC, in which nivolumab treatm ent was continued until progressi on or 
unacceptable toxicity (2 year OS rates of 23% and 29%, and 3 year OS rates of 16% to18% for 
squamous and non -squamous NSCLC, respect ively).95
Similar resul ts have been repor ted in clinical studies of pembro lizumab, another PD-1 inhibitor . 
Keynote -010 was a rando mized Phase 3 trial of pembro lizumab (at either 2 mg/kg or 10 mg/kg 
every 3 weeks) versus docetaxel in subjects with previously treated, PD-L1-posit ive, advanced 
NSCLC which specified a maximum treatm ent durati on of 2 years for pembrolizumab. OS was 
significant ly longer with both pembro lizumab 2 mg/kg (HR 0.72, P = 0.00017) and 
pembro lizumab 10 mg/kg (HR 0.60, P < 0.00001) compared to docetaxel, with an OS plateau 
devel oping beyo nd 2 years in both pembro lizumab arms. Amo ng 690 patients who received 
pembro lizumab, 47patients completed 2 years of pembro lizumab and stopped treatm ent. Most
were able to maintain their response, including those with stable disease, with only 2 pat ients (4%) 
having confirmed progression after stopping at 2 years.96
Keynote -006 was a randomized Phase 3 study  of pembro lizumab versus ipilimumab in patients 
with advanced melano ma, which also specified a maximum 2 year durati on of pembro lizumab 
treatment. 104 (19%) of 556 patients rando mized to pembro lizumab completed 2 years of 
treatm ent. With a median follow -up of 9 months after complet ion of pembrolizumab, the estimated 
risk of progression or death was 9% in these patients.97
Taken together, these data suggest that treatm ent beyo nd 2 years is unlikely to confer additional 
clinically meaningful benefit and that the risk of progression after discont inuing treatm ent at 
2years is low.
In contrast, a shorter duration of nivolumab of only 1 year was associated with increased risk of 
progression in previously  treated pati ents with NSCLC, suggesting that treatm ent beyond 1 year 
is likely needed. In CA209153, patients with previously treated advanced NSCLC who completed 
1 year of nivo lumab therapy were rand omized to either continue or stop treatment, with the option 
Protocol Amendment No.: 04
Date: 22-Sep-2023 55
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
of retreatment upon progression. Amo ng 163 patients still on treatm ent at 1 year and without 
progression, those who were randomized to continue nivolumab had significant improvement in 
progressio n-free survival (PFS) compared to those who were randomized to stop treatm ent, with 
median PFS (post- randomizat ion) not reached vs 10.3 m onths, respect ively; HR=0.42 (95% CI, 
0.25 to 0.71). With a median fo llow-up of 14.9 months post -randomizat ion, there also was a trend 
for pati ents on con tinued treatment to live longer (OS HR =0.63 [95% CI: 0.33 to1.20]). Of note, 
the PFS curves in both groups plateau approximately  1 year af ter randomizat ion (ie, 2 y ears after 
treatm ent init iation), suggest ing that there may be minimal benefit in extending treatment bey ond 
a total  of 2 years.98
Collect ively, these data suggest that there is minimal if any benefi t derived from continuing I -O 
treatm ent beyo nd 2years in advanced tumors. However, even though immunotherapy  is well 
tolerated, patients will be at risk for addit ional toxicit y with longer term treatm ent. Therefore, in 
this study , treatm ent will be given for a maximum of 2 y ears fro m the start of study  treatm ent.
5.5.5.2 Docetaxel
The durati on of treatm ent for docetaxel, shoul d be based on the assessment of benefi t and 
toxicities. In a pivotal trial establishing the survival advantage of docetaxel chem otherapy , 
participants received up to 10 cycles of treatment .15Administering more than 10 cycles of 
docetaxel has not dem onstrated any  further improvement in survival and is associated wi th more 
adverse effects.99,100Therefore, in the present study, docetaxel will be administered for a 
maximum of 10 cycles, or until disease progressio n, unacceptable toxicity, withdrawal  of 
participant consent, or the end of the study , whichever occurs sooner .
Please consult the current prescribing information for docetaxel for further details concerning 
administration. 
5.5.6 Rationale for Nivolumab 30 -Minute Infusion
Long infusio n times place a burden on participants and treatm ent centers. Nivo lumab was 
originally approved in the US wi th a 60 -minute infusio n using 3 mg/kg Q2W body  weight -based 
dosing and is now approved in the US using a 30 minute infusion for the 240 mg Q2 W and 480 mg 
Q4W flat doses. Previous clinical studies show that nivolumab has been administered safely over 
60minutes at doses ranging up to 10 mg/kg over long treatm ent durations. In Study CA209010 
(aPhase 2, randomized, double -blind, dose-ranging study of nivolumab in participants with 
advanced/metastatic clear cell RCC), a dose associat ion was observed for infusio n site react ions 
and hypersensit ivity react ions (1.7% at 0.3 m g/kg, 3.7% at 2 m g/kg, and 18.5% at 10 m g/kg). All 
the events were Grade 1-2 and were manageable. An infusio n durati on of  30 minutes for 360 m g 
or 480 mg doses of nivolumab is not expected to present safet y concerns compared to th e prior 
experience at 10-mg/kg nivolumab dose infused over a 60-minute durati on. Nivo lumab 480 mg 
Q4W an d nivo lumab 360 mg Q3W infused over 30 minutes are also being investigated in several 
ongoing clinical studies. Overall, preliminary  safety  analysis suggests that the safet y profile of 
nivolumab administered IV over 30minutes at 480 mg Q4W or 360 mg Q3W is consistent with 
nivolumab 240 mg Q2W or 3 mg/kg Q2W administered IV over 30 or 60 minutes across mult iple 
tumor types with respect to Grade 3-4 AEs, serious adverse events (SAEs), AEs leading to 
Protocol Amendment No.: 04
Date: 22-Sep-2023 56
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
discontinuat ion, and immune -mediated AEs (IMAEs) including hypersensit ivity/infusio n react ion 
IMAEs. There were no new safet y concerns i dentified. For study  CA2099KD (a Phase 2 study  of 
nivolumab in combinat ion with either rucaparib, docetaxel or enzalutamide in men with mCRPC) , 
the protocol specifies monitoring and management of safety events including nivolumab -related 
infusio n react ions. In summary, nivo lumab 360 mg Q3W or nivo lumab 480 mg Q4W infused over 
30 minutes is expected to provide a comparable safet y profile to that seen with a  60-minute 
infusio n, and i s not expected to present addit ional safet y concerns.
 
 
 
 
 
 
 
 
5.6 Justification for Dose
5.6.1 Justification for Nivolumab Dos e
Nivo lumab will be administered as a flat dose of 360 mg once every 3 weeks (Q3W) in 
combinat ion with docetaxel for a maximum o f 10 cycles , in order to maintain synchronized dosing 
of both agents on the same day and then switch to a nivolumab dose of 480 mg given every 4 
weeks (Q4W) for dosing convenience. 
Nivo lumab PK has been extensively  studied in multiple tumor types, including melanoma, 
NSCLC, RCC, cHL, SCCHN, CRC and urothelial carcino ma and has been safely administered at 
doses up to 10 mg/kg Q2W. Nivo lumab monotherapy  was originally approved as a body -weight 
based dose of 3 mg/kg Q2W, and was recent ly updated to 240 mg Q2 W or 480 mg Q4W in mult iple 
indicat ions.101,102Nivo lumab 360 mg Q3W is also under evaluat ion in monotherapy  and in 
combinat ion therapy  studi es. Less frequent 360 mg Q3W and 480 mg Q4W dosing regimens can 
reduce the burden to patients of frequent, lengthy  IV treatm ents and allow combinat ion of 
nivolumab with other agents using alternat ive dosing regimens. 
The benefit -risk profiles of nivo lumab 240 mg Q2W, 360 mg Q3W and 480 mg Q4W are predicted 
to be comparable to 3 mg/kg Q2W. This assessment is based on a co mprehensive c haracteri zation 
of nivolumab PK, safet y, efficacy, and exposure -response relationships across indicat ions. 
Popul ation PK (PPK) analyses have shown that the PK of nivolumab is linear with proporti onal 
exposures over a dose range of 0.1 to 10 mg/kg; no clini cally meaningful differences in PK across 
ethnicit ies and tumor types were observed. Using the PPK model, the exposures following 
administration of several  dosing regimens of nivolumab administered as a flat dose were 
simulated, including 240 mg Q2W, 360 m g Q3W and 480 mg Q4W. The simulated average serum 
concentration at steady  state [Cavgss] following administrati on of nivolumab 360 mg Q3W and 
Protocol Amendment No.: 04
Date: 22-Sep-2023 57
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
480 mg Q4W are predicted to be similar to those following administrati on of  nivolumab 240 mg 
Q2W and nivolumab 3 mg/kg Q2W administered to parti cipants over a wide body  weight range 
(34to 180kg) across tumor types.
Extensive exposure -response (E-R) analyses of multiple PK measures (maximum  serum 
concentration at Day 1 [Cmax1], average serum concentration at Day 28 [Cavg28], and trough 
serum  concentrati on at Day 28 [Cmin28]) and efficacy  and safet y endpo ints indicated that the 
efficacy of the flat-dose 480 mg IV regimen are similar to that of  3 mg/kg Q2W IV regimen. In 
E-R efficacy analyses for OS and ORR conducted in melano ma, RCC, and NSCLC using Cavg28 
as the exposure measure, probabilit ies of achieving a response and survival probabilit ies at 1 y ear 
and 2 y ears for IV 480 mg Q4W were sim ilar to that of IV 3 mg/kg Q2W. In E-R safet y analyses, 
it was demonstrated that the exposure margins for safet y are maintained following nivolumab 
480mg Q4W, and the predi cted ri sks of  discont inuations due to AEs or death, AE Grade 3+, and 
immune -mediated AEs (IMAEs) Grade 2+ are similar fo llowing nivo lumab 480 mg Q4W relative 
to nivolumab 3 mg/kg Q2W across tumor ty pes. In addition, nivolumab exposures with 240 mg 
Q2W, 360 mg Q3W, and 480 mg Q4W flat-dose IV regimens across tum or ty pes are maintained 
well below the corresponding exposures observed with the well -tolerated 10 mg/kg I V nivo lumab 
Q2W dose regimen.
Addit ional details on nivolumab posol ogies and risk-benefit can be found in the invest igator 
brochure.
6
STUDY POPULATION
For entry  into the study , the f ollowing criteria MUST be met.
6.1 Inclusion Criteria
1)Signed Written Informed C onsent
a)Parti cipants or thei r legally acceptable representative (see Appendix 2) ,must have signed 
and dated an IRB/IEC approved written informed consent form in accordance with 
regul atory  and institutional guidelines. This must be obtained before the performance of 
any protocol -related procedures that are not part of normal pat ient care.
b)Parti cipants m ust be willing and able to comply with scheduled visits, treatment schedule, 
laboratory testing, and other requirements of the study .
2) Type of Participant and Target Disease Characteristics
a)Histologic confirmati on of adenocarcino ma of the prostate without small cell features . 
Diagnosis m ust be stated in a pathology  report and confirmed by the invest igator
b)Current evidence of metastatic disease documented by eit her bone lesio ns on radionuclide 
bone scan and/or soft tissue lesions on CT/MRI. Metastases may be in regional lymph 
nodes (N1 per AJCC staging criteria, 8th edit ion) and/or distant metastases (M1 per AJCC 
staging criteria, 8th edit ion).
i)Parti cipants whose disease spread is limited to regional pelvic lymph nodes (N1) 
measuring at least 2 cm in short axis will be considered eligible.
c)ECOG performance status 0-1
Protocol Amendment No.: 04
Date: 22-Sep-2023 58
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
d)Ongo ingandrogen deprivat ion therapy (ADT )with a gonadotropin -releasing horm one 
(GnRH) analogue or bilateral orchiectomy  (ie, surgi cal or medical castrati on) confirmed 
by testosterone level ÔÇ£1.73 nmol/L (50 ng/dL) at the screening visit. Castrate levels of 
testosterone must be maintained by surgi cal or medical means (luteinizing horm one-
releasing horm one [LHRH]/ GnRH analogues) throughout the conduct of the study. For 
participan ts who have not had an orchiectomy, this therapy must have been init iated at least 
4 weeks pri or to fi rst dose of study  treatm ent and treatm ent m ust be cont inued througho ut 
the study
e)Docum ented prostate cancer progression as per PCWG3 criteria within 6 months prior to 
screening with at least one of the fo llowing:
i)PSA progression* defined by a minimum of 2 rising PSA levels with an interval of 
ÔÇ≥1week between each determin ation. The PSA val ue at the screening visi t shoul d be 
ÔÇ≥2 ÔÅ≠g/L (2 ng/mL).
Note: *Parti cipants who received an anti-androgen must have PSA progressi on after 
withdrawal (ÔÇ≥4weeks since last flutamide administrati on or ÔÇ≥6 weeks since last 
bicalutamide or ni lutamide administration)
ii)Radiographic disease progression in soft tissue based on RECIST 1.1 criteria. 
iii)Radiographic disease progression in bone defined as appearance of 2 or more new bone 
lesions on bone scan
f)Parti cipants who are chem otherapy -na√Øve for mCRPC and have received at least 1 but no 
more than 2 second -generat ion hormonal manipulatio ns (also known as novel antiandrogen 
therapi es [NAT] eg,including but not limited to abiraterone acetate, enzalutamide, 
apalutamide, and darol utamide) in the recurr ent non-metastati c setting and/or the 
metastati c setting (no more than 1 prior Novel Androgen Therapy ( NAT )is allowed in the 
mCRPC setting*), or have beco me intolerant of the drug. Patients must have progressed 
during or after NATs or have docume nted intolerance to the drug (ie,unacceptable toxicit y 
in spite of com prehensive supportive therapy ).
* If the same NAT was given more than once in the con text of a different disease setting or 
if intervening therapy  was administered, then these NAT will be considered as separate 
NAT regimens.
g)Parti cipants already receiving agents for the management of skeletal -related events (SREs) 
are allowed to continue with anti-bone resorptive therapy  (including, but not limited to 
bisphosponate or receptor activator of nuclear factor kappa ligand inhibitor) if on stable 
dose for m ore than 28 days prior to start of study treatment .
 
 
 
 
 
 
i)Prior prostate cancer vaccine therapy (eg, sipuleucel -T), radium -223, second -generat ion 
horm onal manipulat ions (eg, abiraterone acetate, enzalutamide, apalutamide, and 
darol utamide), antiandrogens (eg,flutamide), ketoconazole, and diethylst ilbestrol (DES) 
Protocol Amendment No.: 04
Date: 22-Sep-2023 59
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
or other estrogens, are allowed if treatment was completed at least 28 day s prior to start of 
study  treatm ent. Note: bicalutamide or nilutamide must be discont inued at least 6 weeks 
prior to the start of study  treatm ent.
i)Parti cipants with a history  of response to an ant i-androgen or adrenal androgen -
producti on inhibitor and with subsequent progression while receiving that antiandrogen 
shoul d be assessed for antiandrogen withdrawal response for 4 weeks, and must 
demonstrate progression as described in Inclusion Criterion 2e and have stoppe d 
receiving the ant iandrogen pri or to start of study  treatm ent.
ii)For participants who have never responded to antiandrogens, observat ion for 
antiandrogen withdrawal response is not necessary.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3)Age and Reproductive Status
a)Males, ages 18 or l ocal age of maj ority
b)Males who are sexually active with WOCBP must agree to follow instructi ons for 
method(s) of contrace ption for the duration of treatment with docetaxel plus 5 half -lives o f 
the study  treatm ent pl us 90 days (durati on of  sperm  turnover) f or a total  of 6 months after 
the last dose of docetaxel .In addition, male partici pants must be willing to refrain from 
sperm  donat ion during this t ime.
Protocol Amendment No.: 04
Date: 22-Sep-2023 60
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
Invest igators shall counsel  male participants who are sexually active with WOCBP on the 
importance of pregnancy prevent ion and the implicat ions of an unexpected pregnancy. 
Invest igators shall advise male participants who aresexually active with WOCBP on the use 
of highly  effective methods of contraception (Appendix 4). Highly effect ive methods of 
contrac eption have a failure rate of < 1% when used consistently and correctly.
6.2 Exclusion Criteria
1)Medical Conditions
a)Not applicable per Protocol  
Amendment 02 (see new criterionm) below): Prior 
malignancy active within the previous 3 years (ieparticipants with a history of prior 
malignancy are eligible if treatment was completed at least 3 years before enrollment) 
except for locally curable cancers that have been apparently cured, such as basal or 
squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the breast .
b)Parti cipants with act ive brain metastases. Participants with brain metastases are eligibl e to 
enroll in t his study if brain metastases have been treated and there is no magnet ic resonance 
imaging (MRI except where contraindicated in which case CT scan is acceptable) evidence 
of progressi on for at least 4 weeks after treatm ent is com plete and w ithin 28 days pri or to 
first dose of study drug administration. Such cases shoul d be discussed with the BMS 
Medical Moni tor or designee. Previously irradiated brain lesio ns are not considered 
measurable disease. Parti cipants must have recovered from the effects of major surgery 
requi ring general anesthesia or si gnificant traum atic injury  at least 14 day s before start of 
study  disease .
c)Parti cipants must have recovered from the effects of major surgery  requiring general 
anesthesia or significant traumat ic injury at least 14 day s before start of study  treatm ent.
d)Prior radi ation therapy  within 2 weeks prior to start of study  treatm ent. Pati ents shoul d 
have recovered (ie, Grade ÔÇ£1 or at baseline) fro mradiation-related toxi cities. 
e)All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must  
have reso lved to Grade 1 or baseline before administration of study treatment. Participants 
with toxicities attributed to prior anti-cancer therapy  that are not expected to resolve and 
resul t in lo ng-lasting sequelae, such as peripheral neuropathy after plat inum based therapy, 
are permitted to enroll. Participants who have ÔÇ≥Grade 2 peripheral neuropathy  are 
excluded.
f)Parti cipants with an act ive, known or suspected autoimmune disease. Participants with type 
I diabetes mellitus, hypothy roidism  only requiring horm one replacement, skin disorders 
(such as vit iligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not 
expected to recur in the absence of an external tri gger are permitted to enroll.
g)Parti cipants who have received a live/ attenuated vaccine wit hin 30 days o f first dose in the 
study .
h)Dem entia, altered mental status, or any psychiatri c condi tion that woul d prohibit the 
understanding or rendering o f informed consent or completing QoL questionnaire.
i)Known history  of a positive test for human immunodeficiency virus (HIV) or known 
acqui red immunodeficiency syndrome (AIDS). NOTE: Testing for HIV must be per formed 
at all sites in Germany  and where mandated locally (see Appendix 9) .
Protocol Amendment No.: 04
Date: 22-Sep-2023 61
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
j)Parti cipants with serious or uncontrolled medical disorders that, in the opinion of the 
investigator, would impair the abilit y of the participant to receive protocol  therapy or 
obscure the interpretation of AEs, such as a condi tion associ ated wi th frequent di arrhea.
k)Uncontrolled intercurrent illness including, but not limited to, ongoing or active infect ion, 
history  of congest ive heart failure, unstable angina pectoris, cardi ac arrhy thmia, or 
psychiatric illness/social situations that would limit compliance with study requirements.
Addit ionally , in the case o f prior severe acute respiratory syndrome coronavirus 2 (SARS -
CoV -2)infect ion, acute symptoms must have resol ved and based on invest igator 
assessment in consul tation with the Medi cal Moni tor, there are no sequelae that would 
place the participant at a higher risk of receiving investigational treatm ent (see Section 
6.4.1 ).
l)Parti cipants with superscan on technecium -99m radionuclide bone scans are not eligible 
for the study . Superscan is defined as a bone scan which demonstrates markedly increased 
skeletal  radioisotope uptake rel ative to sof t tissue in associ ation with absent o rfaint renal 
activit y (absent ki dney sign).
m)Concurrent malignancy (present during screening) requiring treatm ent or history  of prior 
malignancy active within the previous 2 years prior to randomizat ion (ie,participants wit h 
a history o f prior mal ignancy are eligible if treatment was co mpleted at least 2 years before 
rando mizat ion and the pat ient has no evidence of disease). Parti cipants with history of prior 
early  stage basal/squamous cell skin cancer or non-invasive or in situ cancers that have 
undergone definit ive treatment at any  time are also eligible.
2)Prior/Concomitant Therapy
a)Parti cipants wit
h a condi tion requi ring systemic treatm ent with either corticosteroi ds 
(>10mg daily prednisone equivalent) or other immunosup pressive medicat ions within 
14days of start of study treatment. Inhaled or topical steroids, and adrenal replacement 
steroi d doses >10 mg daily predniso ne equivalent, are permitted in the absence of active 
autoimmune disease.
b)Prior trea tment with an ant i-PD-1, anti-PD-L1, anti-PD-L2,or anti-CTLA -4 antibody , or 
any other antibody  or drug specifically targeting T-cell co-stimulat ion or checkpo int 
pathways
c)Prior treatm ent with docetaxel  or another chemotherapy agent for metastati c castrati on-
resistant prostate cancer. Prior docetaxel for metastatic castrati on-sensi tiveprostate cancer 
is allowed if ÔÇ≥12 m onths elapsed from last dose of docetaxel .
d) Not applicable per Protocol Amendment 02:Prior treatment with radium -223 or other 
therapeutic radiopharmaceuticals for prostate cancer .
e)Treatment with complementary  medicat ions (eg,herbal supplements or traditional Chinese 
medicines) to treat the disease under study wit hin 2 weeks prior to start of study treatm ent. 
Such medications are permi tted if  they are used as supporti ve care. Refer to Secti on 7.7.1
for other prohibited therapies.
f)Parti cipants currently in other intervent ional trials, including those for coronavirus disease 
2019 (COV ID-19), may not participate in BMS clinical trials until the protocol -specific 
washout period is achieved. If a study  parti cipant has received an investigational COVID -
19 vaccine or other invest igational produ ct designed to treat or prevent COVID -19 prior to 
screening, enrollment must be delayed until the biologic impact of the vaccine or 
Protocol Amendment No.: 04
Date: 22-Sep-2023 62
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
investigat ional product is stabilized, as determ ined by  discussi on between the i nvest igator 
and the Medical Monitor .
3) Physical and Laboratory Test Findings
a)WBC < 2000/ ÔÅ≠L
b)Neutrophils < 1500/ ÔÅ≠L
c)Platelets < 100*103/ÔÅ≠L
d)Hem oglobin < 9.0 g/dL
e)Serum  creatinine > 1.5 x upper limit of normal (ULN ), unless creat inine clearance ÔÇ≥40 
mL/min (measured or calculated using the Cockroft- Gault formula)
f)AST/ALT > 3.0 x ULN
g)Total  bilirubin > 1.0x ULN (except participants with Gilbert Syndro me who must have a 
total bilirubin level of < 3.0 x ULN)
h)Any positive test result for hepatitis B virus or hepatit is C virus indicat ing presence of 
virus, eg Hepatit is B surface antigen (HBsAg, Australia antigen) positive, or Hepati tis C 
antibody  (anti-HCV) posi tive (except if HCV -RNA negat ive)
i)AST and/or ALT > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN . 
Note: Testing for asymptomat ic SARS-CoV -2 infection, eg,by reverse transcri ption polymerase 
chain react ion (RT-PCR )or viral antigen is not required. However, some part icipants may develop 
suspected or confirmed symptom atic SARS -CoV -2 infect ion, or be discovered to have 
asymptomat ic SARS -CoV -2 infect ion during the screening period. In such cases, participants ma y 
be considered eligible for the study  after meet ing all inclusio n/exclusio n criteria related to active 
infect ion, and after meeting the fo llowing cri teria: 
ÔÇ∑At least 10 days (20 days for severe/crit ical illness) have passed since symptom s first 
appeared or posit ive RT -PCR or viral ant igen test result, and
ÔÇ∑At least 24 hours have passed since last fever without the use of fever-reducing 
medicat ions, and
ÔÇ∑Acute symptoms (eg, cough, shortness of breath) have reso lved,and
ÔÇ∑In the opini on of the investi gator, there are no COVID -19-related sequelae that may  place 
the participant at a higher risk of receiving invest igational treatm ent, and 
ÔÇ∑Negative follow
-up SARS -CoV -2 RT-PCR or viral antigen test based on institutional, 
local,or regi onal guidelines .
4)Allergies and Adverse Drug Reactio n
a)History  of allergy  or hy persensi tivity to study  drug com ponents
b)History  of hypersensi tivity to docetaxel  or polysorbate 80
5)Other Exclusion Criteria
a)Prisoners or participant s who are invo luntarily incarcera ted. (Note: under certain specific 
circumstances and only in countries where local regulat ions permit, a person who has 
Protocol Amendment No.: 04
Date: 22-Sep-2023 63
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
been imprisoned may be included or permitted to continue as a participant . Stri ct 
condi tions apply  and Bri stol-Myers Squibb approval is requi red.
b)Parti cipants who are compulsorily detained for treatment of either a psychiatric or physica l 
(eg, infect ious disease) illness .
Eligibilit y criteria for this study  have been carefully considered to en sure the safety  of the study 
participant s and that the resul ts of the study  can be used. It is imperative that participant s fully 
meet all eligibilit y criteria.
6.3 Lifestyle Restrictions
Parti cipants receiving docetaxel  should be advised to use appropriate sun protecti on due to the 
potenti al risk o f photosensit ivity which may  cause sunburn wi th minimal  sun exposure.
6.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but who 
are not subsequent ly randomized in the study /included in the analysis popul ation. A minimal set 
of screen failure informat ion is requi red to ensure transparent reporting of screen failure 
participants, to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requi rements, as applicable, and to respond to queri es from regul atory  authori ties. Minima l 
inform ation includes date of consent, demography, screen failure details, eligibilit y criteria, and 
any serious AEs.
6.4.1 Retesting During Screening 
This study  permits the re-enrollment of a
 participant who has discontinued the study  as a pre-
treatm ent failure (ie, participant has not been treated). If re-enrol led, the participant must be 
re-consented.
Retesting of laboratory  parameters and/or other assessments within any single Screening or
Lead -in period will be perm itted (in addit ion to any parameters that require a confirmatory value).
The most current resul t prior torandomizat ionis the value by which study  inclusio n will be 
assessed, as it represents the participant‚Äôs most current, clinical state.
Laboratory  parameters and/or assessments that are included in Table 2-1Screening Procedural 
Outline may be repeated in an effort to find all possible well-qualified participants. Consultatio n 
with the Medical  Monitor/designee may be needed to ident ify whether repeat testing of any 
particular param eter is clinically relevant.
7 TREATMENT
Study  treatment is defined as any invest igational treatm
ent(s), marketed product(s), placebo or 
medical device intended to be administered to a study participant according to the study 
rando mizat ion or treatment allocat ion
An invest igational product, also known as invest igational medicinal product in some regions, is 
defined a pharmaceut ical form of an active substance or placebo being tested or used as a reference 
in a clinical study, including products already with a market ing authorization but used or 
Protocol Amendment No.: 04
Date: 22-Sep-2023 64
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivoluma b
assembled (formulated or packaged) different ly than the authori zed form, or used for an 
unauthori zed indication, or when used to gain further information about the authorized form.
Other medications used as support or escape medication for preventative, diagnosti c, or therapeutic 
reasons, as components of the standard of care for a given diagnosi s, may be considered as non-
investigat ional products.
Per Protocol Amendment 04, due to lac k of rPFS benefit at the final analysis and OS benefit 
at the first interim analysis for nivolumab added to docetaxel plus prednisone compared to 
placebo added to docetaxel plus prednisone, on 26-Jul-2023, a BMS EOC decided to 
terminate the study. The decision to terminate the study was not based on any safety 
concerns or issues. Full study teams and investigators were unblinded to study treatment 
assignment on 03-A ug- 2023; therefore, no participant receiving study treatment will receive 
placebo .
In thi s protocol , the fo llowing are considered Investigat ional [Medicinal] Product (IP/IMP):
ÔÇ∑Nivo lumab (BMS -
936558)
ÔÇ∑Docetaxel
ÔÇ∑Not applicable per Protocol Amendment 04: Nivo lumab -Placebo (0.9% Sodium Chloride 
Inject ion, USP, or 5% Dextrose Injection)
Solutions used as placebo (ie, 0.9% Sodium Chloride Inject ion or 5% Dextrose Injection) or as
diluent should be sourced by  invest igative sites.
In this protocol , the following isconsidered as aNon-invest igational [Medicinal] Product (Non -
IP/Non -IMP):
ÔÇ∑Prednisone
Protocol Amendment No.: 04
Date: 22-Sep-2023 65
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 7-1: Study Treatments for CA2097DX
Product 
Description/ Class and 
Dosage FormPotency IP/Non -
IMP Blinded or Open 
LabelPackaging / 
AppearanceStorage Conditions
(per label)
BMS -936558-01 
(Nivolumab) Solution 
for Injectiona100mg (10mg/mL) IMPOpen Labelb Vial (multiple vials per 
carton)Store at 2o‚Äì 8oC.
Protect from light and 
freezing.
0.9% Sodium Chloride
for InjectionN/A IMPOpen -Labelb Various (local
commercial product)As per package insert
5% Dextrose for 
InjectionN/A IMPOpen -Labelb Various (local
commercial product)As per package insert
Docetaxel 80mg IMP Open Label Vial in various 
packaging 
configurationsRefer to sto rage 
conditio ns on container 
label.
Prednisone 5mg Non-IMP Open Label Tablets in various 
packaging 
configurations.Refer to sto rage 
conditio ns on container 
label.
aMay be labeled as ‚ÄúBMS -936558-01‚Äù or ‚ÄúNivolumab .
bThe term ‚Äúopen label‚Äù refers to the m edication as it i s upon receipt at the pharmacy. Not applicable per Protocol Amendment 04: Unblinded pharmacy staff 
at the sites will prepare blinded Nivolumab -placebo.
Protocol Amendment No.: 04
Date: 22-Sep-2023 66
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
7.1 Treatments Administered
Per Protocol Amendment 04 , due to lack of rPFS benefit at the final analysis and OS benefit 
at the first interim analysis for nivolumab added to docetaxel plus prednisone compared to 
placebo added to docetaxel plus prednisone, on 26-Jul -2023, a BMS EOC decided to 
terminate the study. The decision to terminate the study was not based on any safety 
concerns or issues. Study teams and investigators were unblinded to study treatment 
assignment on 03-A ug-2023 and, therefore, no participant receiving study treatment will 
receive placebo.
The select ion and timing of  dose for each parti cipant, bas ed on all ocati on to an arm , is presented 
inTable 7.1-1. Durati on of  treatm ent per arm  is discussed in the sections below the table.
The select ion and timing of dose for each participant is as fo llows:
Table 7.1-
1: Selection and Timing of Dose
Per Protocol Amendment 0 4, investigators and study teams were unblinded to study treatment assignment ; 
therefore , no participant receiving study treatment will receive placebo.
Study TreatmentUnit dose 
strength(s)/Dosage 
level(s)Dosage formulation
Frequency of AdministrationRoute of 
Administration
Arm A
Nivolumaba 360mg Every 3 weeks Intravenous
Prednisone 5mg Twice daily (BID ) Oral
Docetaxel 75mg/m2Every 3 weeks through cycle 10 Intravenous
Arm B
Prednisone 5mg Twice daily (BID ) Oral
Docetaxel 75mg/m2Every 3 weeks through cycle 10 Intravenous
Not applicable per Protocol 
Amendment 04: PlaceboNot applicable Every 3 weeks Intravenous
aNivolumab or placebo will be administered as combination therapy with docetaxel and prednisone for maximum 
10 cycles, followed by nivolumab monotherapy (480 mg Q4W) or placebo until progression, unacceptable toxicity 
or withdrawal of Consent.
Nivo lumab:
There will be no dose escalat ions or reduction s of nivolumab allowed. For Q3W and Q4W dosing 
cycles, allparticipants may be dosed within a ÔÇ±3day window. For the Q3W dosing cycle, 
participants may be dosed no less than 18 days after the prior dose. Premedicat ions are not 
recommended for the first do se of nivo lumab.
Doses of nivolumab may be interrupted, delayed, or discont inued depending on how well the 
participant tol erates the treatment. Dosing visits are not skipped, only delayed.
Protocol Amendment No.: 04
Date: 22-Sep-2023 67
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
For nivo lumab, refer to the current version of the Investigator Bro chure and/or Pharmacy Manual 
for com plete storage, handling, dispensing, and infusion informat ion.
Nivo lumab infusio ns are compatible with polyvinyl chloride (PVC) or polyo lefin containers and 
infusio n sets, and glass bottles. 
7.1.1 Nivolumab or Placebo C ombine d with Docetaxel 
Per Protocol Amendment 04, due to lack of rPFS benefit at the final analysis and OS benefit 
at the first interim analysis for nivolumab added to docetaxel plus prednisone compared to 
placebo added to docetaxel plus prednisone, on 26-Jul -2023, a BMS EOC decided to 
terminate the study. The decision to terminate the study was not based on any safety 
concerns or issues. Full study teams and investigators and study teams were unblinded to 
study treatment assignment on 03-A ug- 2023 ;therefore, no participant receiving study 
treatment will receive placebo.
Parti cipants will receive nivo lumab or placebo IV at a flat dose of 360 mg as a 30 -minute infusio n 
in combination with docetaxel  IV at 75 mg/m2as a 1-hour infusio n Q3W and prednisone 
(orpredn isolone) 5 mg orally twi ce daily continuously. Oral dexamethasone 8 mg (or equivalent 
dose of another corticosteroid) to be administered at 12 hours, 3 hours ,and 1 hour before the 
docetaxel infusio n. Other schedules and routes of administrati on are al so acceptable according to 
local standards
After the nivolumab or placebo infusio n, there is a 3 0-minute delay  before the start of the docetaxe l 
infusio n to monitor the participant for signs of possible infusio n react ions and differentiate any 
such reacti on from one related to the subsequent docetaxel infusio n. Dosing of docetaxel  and 
prednisone (or predniso lone) will continue for a maximum o f 10 cy cles every  3 weeks (¬± 3 days), 
until progressi on, unacceptable toxicity, withdrawal  of consent, or the study ends, whichever 
occurs first.
Dosing calculat ions of docetaxel should be based on the body weight assessed at baseline. It is not 
necessary  to re-calculate subsequent doses if the participant weight is within 10% of the weight 
used to calculate the previous dos e. All doses should be rounded up or to the nearest milligram per 
institutional standard.
Parti cipants shoul d begin study  treatm ent wi thin 3 cal endar day s ofstart of randomizat ion
.
7.1.2 Nivolumab or Placebo Dosing
Per Protocol Amendment 04, due to lack of rPFS benefit at the final analysis and OS benefit 
at the first interim analysis for nivolumab added to docetaxel plus prednisone compared to 
placebo added to docetaxel plus prednisone, on 26-Jul -2023, a BMS EOC decided to 
terminate the study. The decision to terminate the study was not based on any safety 
concerns or issues. Full study teams and investigators were unblinded to study treatment 
assignment on 03 -Aug-2023; therefore, no participant receiving study treatment will receive 
placebo.
Protocol Amendment No.: 04
Date: 22-Sep-2023 68
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS-936558 nivolumab
After the completion of maximum 10 cycles of combination treatment, nivolumab dosing will 
change to 480 mg. Nivolumab 480 mg or placebo IV will continue to be given alone as a 30-minute 
infusion as maintenance therapy Q4W ( s3 days). The treatment with nivolumab or placebo will 
be given until progression, unacceptable toxicity, completion of 24 months of treatment, 
withdrawal of consent, or the study ends, whichever occurs first.
There will be no dose escalations or reductions of nivolumabor placeboallowed. For Q4W dosing 
cycles, all participants may be dosed within a ¬±3 day window. 
Doses of nivolumabor placebo may be interrup ted, delayed, or discontinued depending on how 
well the participant tolerates the treatment. Dosing visits are not skipped, only delayed.
For nivolumab, refer to the current version of the Investigator Brochure and/or Pharmacy Manual 
for complete storage, handling, dispensing, and infusion information.
Nivolumab infusions are compatible with polyvinyl chloride (PVC) or polyolefin containers and 
infusion sets, and glass bottles.
Premedication:
Premedications are not recommended for the first dose of nivolumab or placebo.
For docetaxel, given the concurrent use of pr ednisone, the recommende d premedication regimen 
is oral dexamethasone 8 mg (or equivalent dose of another corticosteroid) to be administeredat 
12hours, 3 hours, and 1 hour before the docetaxel infusion, however other corticosteroids and/or 
schedules and routes of administration are also acceptable according to local standards. Antiemetic 
premedication will be administered according to local standards. 
If one of the study drugs is discontinued, the other study drug may be continued for the remainder 
of the cycles. 
Participants should be carefully monitored for infusion reactions during nivolumab and docetaxel 
administration. If an acute infusion reaction is noted, participants should be managed according to Section7.4.6 and Section 7.4.7.
7.2 B linding 
Not applicable per Protocol Amendment 04. Due to lack of rPFS and OS benefit from 
nivolumab added to docetaxel plus prednisone compared to placebo added to docetaxel plus prednisone, on 26-Jul-2023 a BMS EOC decided to terminate the study. The decision to 
terminate the study was not based on any s afety concerns or issues. Full study teams and 
investigators were unblinded to study treatment assignment on 03-Aug-2023.
Blinding of treatment assignment is critical to the integrity of this clinical study. However, in the 
event of a medical emergency or pregnancy in an individual participant in which knowledge of the 
investigational product is critical to the parti cipant's management, the blind for that participant 
may be broken by the investigator. The participant‚Äôs safety takes priority over any other considerations in determining if a treatment assignment should be unblinded.
Protocol Amendment No.: 04
Date: 22-Sep-2023 69
6.0 Approved 930142083 5.0 v Approved 1.0 v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Before breaking the blind of an individual participant's treatm ent, the invest igator should 
determine that the unblinded informat ion is necessary , ie, that it will alter the participant's 
immediate m anagement. In many  cases, parti cularly  when the em ergency  is clearly not rel ated to 
the investigational product, the problem may be properly managed by assuming that the participant 
is receiving act ive product. It is highly desirable that the decision to unblind treatment assignment 
be discussed wi th the Medical Monitor, but the investigator always has ul timate authori ty for the 
decisio n to unblind. The actual  TASK of unblinding can be delegated by the invest igator to a 
designee assigned the task on the Delegat ion of Authority. The Principal Invest igator o r appointed 
designee shoul d only call in for emergency unblinding AFTER the decisio n to unblind the 
participant has been documented .
For this study , the method of unblinding for emergency purposes is through the IRT. For 
inform ation on how to unblind for e mergency, please consult the IRT manual.
In cases of accidental  unblinding, contact the Medical Moni tor and ensure every  attem pt is made 
to preserve the blind. Any request to unblind a participant for non -emergency purposes shoul d be 
discussed with the Medical Moni tor.Scient ist in the Bioanaly tical Science departm ent of BMS 
(and/or a designee in the external bioanalyt ical laboratory ) will be unblinded to th e rando mized 
treatm ent assignments in order to minimize unnecessary  bioanaly tical analysis of samples . Any 
resul ts shared by the Bioana lytical Science group with the s ponsor‚Äôs study  team  will be blinded to 
ensure integrity of the study .The independent central  review is blinded to the study  therap y 
administrated as well.
7.3 Method of Treatment Assignment
Allparticipants will be centrally randomized using an Interacti ve Response Techno logy (IRT). 
Before the study  is initiated, each user will receive log in informat ion and directions on how to 
access the IRT.
Study  treatm ent will be dispensed at the study visi ts as listed in Section2(Schedule o f Act ivities).
Within each panel, participants will be rando mized in a 1:1 ratio to receive either Docetaxel  + 
Nivo lumab arm (Arm A) or Docetaxel + Placebo arm (Arm B) according to a computer -generated 
rando mizat ion scheme prepared by a Rando mization Coordi nator within the Drug Supply 
Management Department of BMS Research and Development. Randomization will be stratified 
by the fo llowing factors:
ÔÇ∑1 prior Novel Ant iandrogen Therapy ( NAT) for mCRPC vs 1 prior NAT for nmCRPC/mCSPC 
vs 2 prior NAT
ÔÇ∑Visceral  disease (Y vs N)
Visceral  disease status will be assessed by invest igator based on the tum or assessment perform ed 
during screening. Visceral disease is defined as the presence of metastati c disease in the liver, lung, 
adrenal, peritoneum, brain or other internal organs. Bone,lymph node metastases and prostate 
lesions(or bladder/rectum if from  direct invasio n from prostate) are not considered viscera l 
disease .
Protocol Amendment No.: 04
Date: 22-Sep-2023 70
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Enrolled participant s, including those not dosed, will  be assigned sequent ial participant numbers 
starting with . Sequential numbering may restart at 
 for each part icipating site as the dist inct patient ident ification number (PID ) will ult imately 
be comprised of the site number and participant number . Those enrolled 
participants meet ing inclusio n and exclusio n criteria will be eligible to be randomized. 
Randomization numbers will be assigned prior to dosing.
7.4 Dosag e Modification
Per Protocol Amendment 04, full study teams and investigators were unblinded to study 
treatment assignment on 03-A ug-2023; therefore, no participant receiving study treatment 
will receive placebo.
Table 7.4-1shows AE criteria to delay, resum e, or discont inue nivolumab/ placebo. Table 7.4-2
shows AE criteria to delay, reduce, resume, or discontinue docetaxel.
Protocol Amendment No.: 04
Date: 22-Sep-2023 71
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 7.4-1: Adverse Event Criteria to Delay, Resume, or Discontinue Nivolumab/ Placebo
Per Protocol Amendment 04, full study teams and investigators were unblinded to study treatment assignment ; therefore , no participant receiving 
study treatment will receive placebo.
Drug -
Related Adverse Event 
(AE) per NCI CTCAE v.5.0Severity Action Taken Clarifications, Exceptions, and Resume Criteria
Gastrointestinal
Colitis o r diarrheaGrade 2 Delay dose Dosing may resume when AE resolves to baseline. 
Grade 3 Delay dose Dosing may resume when AE resolves to baseline. If Grade 
3 diarrhea or colitis recurs while on nivolumab, 
permanently discontinue. 
Grade 4 Permanently discontinue N/A
Renal
Serum creatinine increasedGrade 2 or 3 Delay dose Dosing may resume when AE resolves to Grade ‚â§ 1 or 
baseline value.
Grade 4 Permanently discontinue N/A
Pulmonary
Pneumo nitisGrade 2 Delay dose Dosing may resume after pneumonitis has resolved to 
‚â§Grade1
Grade 3 or 4 Permanently discontinue N/A
Hepatic
Aspartate aminotransferase 
(AST), alanine aminotransferase 
(ALT), o r total bilirubin (T.bili) 
increasedAST or ALT > 3x and ‚â§ 5x 
upper limit of normal (ULN) 
or T.bili > 1.5 x and ‚â§ 3 x 
ULN, regardless of baseline 
valueDelay dose Dosing may resume when laboratory values return to 
baseline.
AST or ALT > 5 x ULN or 
T.bili > 3 x ULN, regardless 
of baseline valuePermanently discontinue In most cases of AST or ALT > 5 x ULN, study treatment 
will be permanently discontinued. If the investigator 
determines a possible favorable benefit/risk ratio that 
warrants continuation of study treatment, a discussion 
between the investigator and the Medical Monitor/designee 
Protocol Amendment No.: 04
Date: 22-Sep-2023 72
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 7.4-1: Adverse Event Criteria to Delay, Resume, or Discontinue Nivolumab/ Placebo
Per Protocol Amendment 04, full study teams and investigators were unblinded to study treatment assignment ; therefore , no participant receiving 
study treatment will receive placebo.
Drug -
Related Adverse Event 
(AE) per NCI CTCAE v.5.0Severity Action Taken Clarifications, Exceptions, and Resume Criteria
must occur and approval must be obtained from the Medical 
Monitor prior to resuming therapy.
Concurrent AST or ALT > 3 x 
ULN and T.bili > 2 x ULN, 
regardless of baseline valuePermanently discontinue N/A
Endocrinopathy
Adrenal insufficiencyGrade 2 adrenal insufficiency Delay dose Dosing may resume after adequately controlled with 
hormone replacement.
Grade 3 or 4 adrenal 
insufficiency or adrenal crisisDelay dose or 
permanently discontinueMandatory discussion with and approval from the Medical 
Monitor needed prior to resuming therapy. If adrenal 
insufficiency resolves or is adequately controlled with 
physiologic ho rmone replacement, participant may not 
require discontinuation of study drug.
HyperglycemiaHyperglycemia requiring 
initiatio n or change in daily  
management (Grade 2 or 3)Delay dose Dosing may resume if hyperglycemia resolves to Grade ‚â§ 1 
or baseline value, or is adequately controlled with glucose -
controlling agents.
Grade 4 Delay dose or 
permanently discontinueMandatory discussion with and approval from the Medical 
Monitor needed prior to resuming therapy. If 
hyperglycemia resolves, or is adequately controlled with 
glucose -controlling agents, participant may not require 
discontinuation of study drug.
Hypophysitis or hypopituitarism Symptomatic Grade 1 -3 that is 
also associated with 
corresponding abnormal lab 
and/o r pituitary  scanDelay dose Dosing may resume if endocrinopathy resolves to be 
asymptomatic, o r is adequately controlled with only 
physiologic ho rmone replacement.
Grade 4 Delay dose or 
permanently discontinueMandatory discussion with and approval from the Medical 
Monitor needed prior to resuming therapy. If 
Protocol Amendment No.: 04
Date: 22-Sep-2023 73
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 7.4-1: Adverse Event Criteria to Delay, Resume, or Discontinue Nivolumab/ Placebo
Per Protocol Amendment 04, full study teams and investigators were unblinded to study treatment assignment ; therefore , no participant receiving 
study treatment will receive placebo.
Drug -
Related Adverse Event 
(AE) per NCI CTCAE v.5.0Severity Action Taken Clarifications, Exceptions, and Resume Criteria
endocrinopathy resolves or is adequately controlled with 
physiologic ho rmone replacement, participant may not 
require discontinuation of study drug.
Hyperthy roidism or 
hypothyroidismGrade 2 or 3 Delay dose Dosing may resume if endocrinopathy resolves to be 
asymptomatic, o r is adequately controlled with only 
physiologic ho rmone replacement or other medical 
management.
Grade 4 Delay dose or 
permanently discontinueMandatory discussion with and approval from the Medical 
Monitor needed prior to resuming therapy. If 
endocrinopathy resolves or is adequately controlled with 
physiologic ho rmone replacement or other medical 
management, participant may not require discontinuation of 
study drug.
Skin
RashGrade 2 rash covering >30% 
body surface area or Grade 3 
rash Delay dose Dosing may resume when rash reduces to ‚â§ 10% body 
surface area. 
Suspected Stevens -Johnso n 
syndrome (SJS), toxic 
epidermal necrolysis (TEN), 
or drug reaction with 
eosinophilia and systemic 
symptoms (DRESS)Delay dose Dosing may resume if SJS, TEN, or DRESS is ruled out 
and rash reduces to is ‚â§10% body surface area.
Grade 4 rash or confirmed 
SJS, TEN, or DRESSPermanently discontinue N/A
Neurological
Guillain -Barr √©Syndrome (GBS) Any Grade Permanently discontinue N/A
Protocol Amendment No.: 04
Date: 22-Sep-2023 74
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 7.4-1: Adverse Event Criteria to Delay, Resume, or Discontinue Nivolumab/ Placebo
Per Protocol Amendment 04, full study teams and investigators were unblinded to study treatment assignment ; therefore , no participant receiving 
study treatment will receive placebo.
Drug -
Related Adverse Event 
(AE) per NCI CTCAE v.5.0Severity Action Taken Clarifications, Exceptions, and Resume Criteria
Myasthenia gravis (MG) Any Grade Permanently discontinue N/A
Encephalitis Any Grade encephalitis Delay dose After workup for differential diagnosis (ie, infection, tumor -
related), if encephalitis is not drug related, then dosing may 
resume when AE resolves. 
Any Grade drug- related 
encephalitis Permanently discontinue N/A
MyelitisAny Grade my elitis Delay dose After workup for differential diagnosis (ie, infection, tumor -
related), if myelitis is not drug related, then dosing may 
resume when AE resolves. 
Any Grade drug- related 
myelitisPermanently discontinue N/A
Neurological (other than GBS, 
MG, encephalitis, or myelitis)Grade 2 Delay dose Dosing may resume when AE resolves to baseline. 
Grade 3 or 4 Permanently discontinue N/A
Myocarditis
MyocarditisSymptoms induced from mild 
to moderate activity or 
exertio nDelay dose Dosing may resume after myocarditis has resolved.
Severe or life -threatening, 
with sy mptoms at rest or with 
minimal activity or exertion, 
and/o r where intervention 
indicated.Permanently discontinue N/A
Other Clinical AE
Pancreatitis: Grade 3 with symptoms Delay dose Note: Grade 3 increased amylase or lipase without signs or 
symptoms of pancreatitis does not require dose delay. 
Dosing may resume when patient becomes asymptomatic.
Protocol Amendment No.: 04
Date: 22-Sep-2023 75
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 7.4-1: Adverse Event Criteria to Delay, Resume, or Discontinue Nivolumab/ Placebo
Per Protocol Amendment 04, full study teams and investigators were unblinded to study treatment assignment ; therefore , no participant receiving 
study treatment will receive placebo.
Drug -
Related Adverse Event 
(AE) per NCI CTCAE v.5.0Severity Action Taken Clarifications, Exceptions, and Resume Criteria
Amylase or lipase increased Grade 4 Permanently discontinue N/A
UveitisGrade 2 uveitis Delay dose Dosing may resume if uveitis responds to topical therapy 
(eye drops) and after uveitis resolves to Grade ‚â§ 1 or 
baseline. If patient requires oral steroids for uveitis, then 
permanently discontinue study drug. 
Grade 3 or 4 uveitis Permanently discontinue N/A
Other drug-related AE (not listed 
above)Grade 2 non -skin AE, except 
fatigueDelay dose Dosing may resume when AE resolves to Grade ‚â§ 1 or 
baseline value.
Grade 3 AE -First occurrence 
lasting ‚â§ 7 daysDelay dose Dosing may resume when AE resolves to Grade ‚â§ 1 or 
baseline value.
Grade 3 AE -First occurrence 
lasting > 7 daysPermanently discontinue N/A
Recurrence of Grade 3 AE of 
any duratio nPermanently discontinue N/A
Grade 4 or Life -threatening 
adverse reactionPermanently discontinue N/A
Other Laboratory Abnormalities 
Other drug-related laboratory 
abnormality (not listed above)Grade 3 Delay dose Exceptions:
No delay  required for : Grade 3 lymphopenia. 
Permanent discontinuation for: Grade 3 thrombocytopenia 
> 7 days or associated with bleeding. 
Grade 4 Permanently discontinue Exceptions: The following events do not require 
discontinuation of study drug: 
ÔÇ∑Grade 4 neutropenia ‚â§ 7 days
Protocol Amendment No.: 04
Date: 22-Sep-2023 76
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 7.4-1: Adverse Event Criteria to Delay, Resume, or Discontinue Nivolumab/ Placebo
Per Protocol Amendment 04, full study teams and investigators were unblinded to study treatment assignment ; therefore , no participant receiving 
study treatment will receive placebo.
Drug -
Related Adverse Event 
(AE) per NCI CTCAE v.5.0Severity Action Taken Clarifications, Exceptions, and Resume Criteria
ÔÇ∑Grade 4 lymphopeni aor leukopenia
Grade 4 isolated electrolyte imbalances/abnormalities that 
are not associated with clinical sequelae and are responding 
to supplementation/appropriate management within 72 
hours of their onset.
Infusion Reactions (manifested by fever, chills, rigors, headache, rash, pruritus, arthralgia, hypotension, hypertension, bronchospasm, or other 
allergic -like reactions.)
Hypersensitivity reaction or 
infusion reactionGrade 3 or 4 Permanently discontinue Refer to Section 7.4.6 on Treatment of Related Infusion 
Reactions. 
Protocol Amendment No.: 04
Date: 22-Sep-2023 77
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 7.4-2: Adverse Event Criteria to Delay, Resume, Reduce or Discontinue Docetaxel
Drug -Related Adverse Event 
(AE) per NCI CTCAE v.5.0Severity Action Taken Clarifications, Exceptions, and Resume Criteria
Hematological
NeutropeniaGrade 2Delay dose /reduce dosea Ifnot recovered on the day of administration, delay next 
infusion until neutrophil counts ‚â• 1.5 x 109/ L.
ÔÇ∑1st episode: no dose reduction is required.
ÔÇ∑2nd episode: consider dose reduction by 1 dose levela.
Granulocyte colon y-stimulating factor (G -CSF) may be 
administered at the discretion of the investigator and 
following local guidelines.
Grade 3 or Grade 4Delay dose /reduce doseaor 
permanently discontinue Delay next infusion until neutrophil counts ‚â•1.5 x 109/ L.
No dose reduction if isolated and duration ¬£ 7 days. 
If duration > than 7 days or not recovered on D21:
ÔÇ∑1st episode: consider prophylactic G-CSF in 
subsequent cycles.
ÔÇ∑2nd episode or 1st episode despite prophylactic G -CSF: 
Reduce dose by 1 dose levela.
ÔÇ∑3rd episode or 2nd episode despite prophylactic G-
CSF:  permanently discontin ue.
Febrile neutropenia or
neutropenic infectionGrade 3 or Grade 4Delay dose/ reduce doseaor 
permanently discontinueDelay next infusion until neutrophil counts ‚â•1.5 x 109/ L. 
ÔÇ∑1st episode: reduce the do seaand consider prophylactic 
G-CSF in subsequent cycles.
ÔÇ∑2nd episode: permanently  discontinue.
ThrombocytopeniaGrade 2 Delay dose Dosing may resume when AE resolves to Grade ‚â§1 or 
baseline. 
Protocol Amendment No.: 04
Date: 22-Sep-2023 78
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 7.4-2: Adverse Event Criteria to Delay, Resume, Reduce or Discontinue Docetaxel
Drug -Related Adverse Event 
(AE) per NCI CTCAE v.5.0Severity Action Taken Clarifications, Exceptions, and Resume Criteria
No dose reduction required.
Grade 3 or Grade 4Delay dose/ reduce doseaor 
permanently discontinueDosing may resume when AE resolves to Grade ‚â§1 or 
baseline.
If Grade 3 without delay, no dose reduction required.
If Grade 4, or Grade 3 with delay.
ÔÇ∑1st episode: reduce dose by 1 dose levela.
ÔÇ∑2nd episode: per manently discontinue.
Permanent discontinuation for : Grade 3 thrombocytopenia 
> 7 days or associated with bleeding.
Gastrointestinal
DiarrheaGrade 2 Delay dose Dosing may resume when AE resolves to baseline.
Grade 3Delay dose/reduce doseaor 
permanently discontinue1st episode: reduce dose by 1 dose levela. 
2nd episode: permanently discontinue. 
Grade 4 Permanently discontinue N/A
Colitis o r enterocolitisGrade 2 Delay dose Dosing may resume when AE resolves to baseline.
Grade 3 Permanently discontinue Rare cases of gastrointestinal events, gastrointestinal 
perforation, ischaemic colitis, colitis, neutropenic 
enterocolitis, ileus, and intestinal obstruction have been 
reported with docetaxel.
Participants with obvious signs of enterocolitis or 
peritoneal irritation should be referred urgently to the 
appropriate specialist (ie, gastroenterologist) for 
assessment, and full details of the participant‚Äôs exposure to 
docetaxel should be provided.Grade 4 Permanently discontinue
Oral mucositis Grade 2 Delay dose Dosing may resume when AE resolves to baseline. 
Protocol Amendment No.: 04
Date: 22-Sep-2023 79
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 7.4-2: Adverse Event Criteria to Delay, Resume, Reduce or Discontinue Docetaxel
Drug -Related Adverse Event 
(AE) per NCI CTCAE v.5.0Severity Action Taken Clarifications, Exceptions, and Resume Criteria
Grade 3 or Grade 4Delay dos e/reduce doseaor 
permanently discontinueDosing may resume when AE resolves to Grade ‚â§1 or 
baseline. 
ÔÇ∑1st episode : reduce dose by 1 dose levela. 
ÔÇ∑2nd episode : permanently discontinue. 
Skin
RashGrade 2 rash covering <30% 
body surface area Delay dose Dosing may resume when AE resolves to Grade ‚â§ 1 or 
baseline.
Dosing may resume when rash reduces to ‚â§ 10% body 
surface area 
Grade 2 rash covering >30% 
body surface area or Grade 3 
rashDelay dose/reduce doseaor 
permanently discontinueDosing may resume when AE resolves to Grade ‚â§1 or 
baseline.
ÔÇ∑1st episode: reduce dose by 1 dose levela. 
ÔÇ∑2nd episode: permanently discontinue. 
Grade 4 Permanently discontinue N/A
Renal
Creatinine increaseGrade 2 or Grade 3Delay dose/ reduce dosea Dosing may resume when AE resolves to Grade ‚â§1 or 
baseline.
Dose reduction may be considered for Grade 3 events at 
the discretion of the investigator and following local 
guidelines.
Grade 4 Permanently discontinue N/A
Neurological
Neurological toxicityGrade 2Reduce doseaReduce dose by 1 dose levela.
Grade 3 or Grade 4 Permanently discontinue N/A
Protocol Amendment No.: 04
Date: 22-Sep-2023 80
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 7.4-2: Adverse Event Criteria to Delay, Resume, Reduce or Discontinue Docetaxel
Drug -Related Adverse Event 
(AE) per NCI CTCAE v.5.0Severity Action Taken Clarifications, Exceptions, and Resume Criteria
Hepatic
Aspartate aminotransferase 
(AST), alanine 
aminotransferase (ALT), or 
total bilirubin (T.bili) 
increased with or without 
alkaline phosphatase increaseAST or ALT > 3 x and ‚â§5 x 
upper limit of normal (ULN) or 
T.bili > 1.5x and ‚â§3 x ULN, 
regardless of baseline value
or 
T.bili > ULN and/or AST/ALT 
>1.5x ULN associated with 
alkaline phosphatase > 2.5 x 
ULNDelay dose/ reduce dosea Dose reduction may be considered at the discretion of the 
investigator and fo llowing local guidelinesa. 
Dosing may resume when laboratory values return to 
baseline. 
AST or ALT > 5 x ULN or 
T.bili > 3 x ULN, regardless of 
baseline value or 
T.bili > ULN and/or ALT and 
AST > 3.5 x ULN associated 
with alkaline ph osphatase > 6 x 
ULNPermanently discontinue N/A
Concurrent AST or ALT > 3 x 
ULN and T.bili > 2 x ULN, 
regardless of baseline valuePermanently discontinue N/A
Infusion Reactions (manifested by fever, chil ls, rigors, headache, rash, pruritus, arthralgia, hypotension, hypertension, bronchospasm, or other 
allergic -like reactions.)
Hypersensitivity reaction or 
infusion reactionGrade 3 or 4 Permanently discontinue Refer to Section 7.4.7 : Docetaxel -related Hypersensitivity 
Reactions . 
Other Clinical AE
Cystoid macular oedema 
(CMO)  diagnosed by 
ophthalmologic examination Any Grade Permanently discontinue 
docetaxelCMO has been reported in participants treated with 
docetaxel. Participants with impaired vision should 
undergo a prompt and complete ophthalmologic 
examination. In case CMO is diagnosed, docetaxel 
Protocol Amendment No.: 04
Date: 22-Sep-2023 81
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Table 7.4-2: Adverse Event Criteria to Delay, Resume, Reduce or Discontinue Docetaxel
Drug -Related Adverse Event 
(AE) per NCI CTCAE v.5.0Severity Action Taken Clarifications, Exceptions, and Resume Criteria
treatment should be discontinued and appropriate 
treatment initiated.
Other drug-related AE (not 
listed above)Grade 2 non -skin AE, except 
fatigueDelay dose Dosing may resume when AE resolves to Grade ‚â§ 1 or 
baseline value.
Grade 3 AE Delay dose /reduce doseaor 
permanently discontinue Dosing may resume when AE resolves to Grade ‚â§ 1 or 
baseline value.
ÔÇ∑1st episode: dose reduction may be considered at the 
discretio n of the investigatora. 
ÔÇ∑2nd episode: permanently discontinue.
Grade 4 or life -threatening 
adverse reaction Permanently discontinue N/A
Other Laboratory Abnormalities
Other drug-related laboratory 
abnormality (not listed 
above)Grade 3Delay dose or reduce dosea  Dose reduction may be considered at the discretion of the 
investigator and following local guidelinesa. 
Exceptions:
No delay  required for : Grade 3 lymphopenia.
Grade 4 Permanently discontinue Exceptions: The following events do not require 
discontinuation of study drug: 
ÔÇ∑Grade 4 lymphopenia or leukopenia.
ÔÇ∑Grade 4 isolated electrolyte imbalances/abnormalities 
that are not associated with clinical sequelae and are 
respondin g to supplementation/ appropr iate 
management within 72 hours of their onset.
Participants receiving docetaxel may receive growth factors (including G -CSF and erythropoietin) at the discretion of the investigator and following local 
guidelines.
aPlease refer to section 7.4.2 for instructions on docetaxel dose reduction.
Protocol Amendment No.: 04
Date: 22-Sep-2023 82
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
7.4.1 Nivolumab or Placebo
There will be no dose modificat ions permitted for nivo lumab or placebo
7.4.2 Docetaxel Dose Reduction
Dose reductions o f docetaxel may be required and will be performed according to Table 7.4.2 -1.
Table 7.4.2 -1: Dose Reductions for Docetaxel
Dose Level Docetaxel
Starting dose 75 mg/m¬≤
First dose reduction 60 mg/m¬≤
Second dose reduction Discontinue docetaxel
Docetaxel dose can be reduced when necessary as described in Table 7.4.2 -1. The dose which has 
been reduced for toxi city must not be re -escalated. Up to a m aximum  of 1 dose reducti on will be 
allowed per participant . If a second dose reducti on is requi red 
per the modificat ions above, the 
patient shoul d discont inue study  treatm ent.
Prednisone (or prednisolone) 
Prednisone or prednisol one doses shoul d not be delayed or m odified or stopped (unl ess there is a 
contraindicat ion to continue, the decisio n will be left to the investigator‚Äôs discret ion).
If prednisone or predni solone is stopped, the participant will continue docetaxel  treatm ent in the 
absence ofmajor toxicity, disease progressi on or any other discont inuat ion criteria as defined in 
Section
8.
7.4.3 Dose Delay Criteria
Dose del ay cri teria apply for all drug -related AEs regardl ess of  whether the event is attributed to 
nivolumab /placebo or docetaxel or both. Delay administrati on of both nivolumab /placebo and 
docetaxel if any of the delay criteria in Table 7.4-
1and Table 7.4-2are met. Dela y 
nivolumab /placebo and docetaxel  dosing for any adverse event, laboratory  abnormalit y, or 
intercurrent illness which, in the judgment of the investigator, warrants delaying the dose of stud y 
medicat ion. Delay administrati on of all drugs if SARS -CoV -2 infect ion either confirmed or 
suspected. 
For participants who require delay  of nivolumab/placebo and docetaxel, re-evaluate weekly, or 
more frequent ly, if clinically  indicated and resume dosing when criteria to resum e treatm ent are 
met(see Section 7.4.4 ). Continue tumor assessments per protocol even if dosing is delayed.
If treatm ent is delayed > 8 weeks (Q3W cycle) or > 10 weeks (Q4W cycle), nivolumab/placebo
treatm ent must be permanently discont inued, except as specified in Section 8 . Prior to re -initiating 
treatm ent in a participant with a dosing delay last ing > 8 weeks (Q3W cycle) or > 10 weeks (Q4W 
cycle), the Medi cal Moni tor (or designee ) must be consul ted.
Protocol Amendment No.: 04
Date: 22-Sep-2023 83
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
7.4.4 Criteria to Resume Study Treatment
Parti cipants may resume dosing when resuming criteria for BOTH nivolumab and docetaxel are 
met if they have completed AE management (ie,corticosteroi d taper) or are on ‚â§ 10 mg prednisone 
or equivalent, and meet the requirements per Table 7.4-1and Table 7.4-2. That is, nivolumab or 
placebo and docetaxel must be administered together until complet ion of Cycle 10 or until  one or 
both agents are discont inued. The only except ion is immune -related toxicities that require 
prolonged nivolumab delay (ie, toxicities treated with a prolonged corticosteroi d taper). In such 
cases, dosing with docetaxel  may resume prior to nivolumab, when the criteria to resum e dosing 
for docetaxel have been met. Nivo lumab or placebo dosing may be resumed later, after complet ion 
of the corticosteroi d taper and when criteria to resume nivolumab or placebo dosing have been 
met. It is allowed to administer either nivo lumab/placebo or docetaxel if the other is discont inued 
because of toxicity if, in the opinio n of the treating investigator, it is in the best interest of the 
participant .
Prior to re -initiating treatment in a participant with a dosing delay last ing > 8 weeks (Q3W cycle) 
or > 10 weeks (Q4W cycle), the Medical Monitor (or designee ) must be consulted. Continue tumor 
assessments per protocol ev en if dosing is delayed. Continue periodic study  visits to assess safet y 
and laboratory  studi es asclinically indicated during such dosing delays. 
Parti cipants wit
h SARS -CoV -2 infect ion (either confirmed or suspected) may resume treatm ent 
after all of thefollowing criteria are met: 1) at least 10 days (20 days for severe/crit ical illness) 
have passed since symptom s first appe ared or posit ive test result (eg,RT-PCR or viral antigen) ;
2) resol ution of  acute symptom s (including at least 24 hours have passed since last fever wi thout 
fever -reducing medicat ions);3) evaluat ion by the i nvestigator with confirmat ion that there are no 
sequelae that would place the participant at a higher risk of receiving invest igational treatm ent;
and 4) consul tation with the Medi cal Monitor. For suspected cases, treatm ent m ay also resum e if 
SARS -CoV -2 infect ion is ruled -out and other cri teria to resum e treatm ent are m et.
7.4.5 Management Algorithms for Nivolumab 
Immuno-oncol ogy (IO) agents are associ ated with AEs that can diffe r in severi ty and durat ion 
from AEs caused by other therapeuti c classes. Nivo lumab is considered an IO agent ,and the 
management algorithms in Appendix 6 provide guidance on assessing and managing the fo llowing 
groups of AEs :
ÔÇ∑Gastrointestinal
ÔÇ∑Renal
ÔÇ∑Pulmo nary
ÔÇ∑Hepati c
ÔÇ∑Endocrinopathy
ÔÇ∑Skin
ÔÇ∑Neurol ogical
ÔÇ∑Myocardi tis
Protocol Amendment No.: 04
Date: 22-Sep-2023 84
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
7.4.6 Treatment of Related Infusion Reactions
Since nivolumab contains only human immunoglobulin protein sequences, it is unlikely to be 
immunogenic and induce infusio n or hy persensi tivity react ions. Howev er, if such a reacti on were 
to occur, it might manifest with fever, chills, rigors, headache, rash, pruri tus, arthralgias, 
hypotension, hypertensio n, bronchospasm, or other allergic -like react ions. Report all Grade 3 or 4 
infusio n reactions as SAEs (if the y meet the criteri a) wi thin 24 hours of onset . 
Treatment recommendations are provided below based on National Cancer Institute Commo n 
Termino logy Criteria for Adverse Events (NCI CTCAE) versio n 5. Grading definit ions and may 
be modified based on local tre atment standards and guidelines, as appropriate:
For Grade 1 symptoms (mild reacti on; infusio n interruption not indicated; intervent ion not 
indicated):
ÔÇ∑Remain at bedside and monitor participant until recovery  from symptom s. The following
prophylact ic prem edicat ions are recommended for future infusio ns: diphenhydramine 
50 mg 
(or equivalent) and/or acetaminophen/paracetamol 325 to 1000 m g at l east 30 minutes before 
additional nivo lumab administrations.
For Grade 2 symptoms: (Therapy  or infusio n interruption indicated but responds prom ptly to
symptom atic treatm ent (eg, antihistamines, nonsteroidal anti-inflammatory  drugs [NSAIDS ], 
narcoti cs, IV fluids); prophylact ic medicat ions indicated for ‚â§ 24 hrs ):
ÔÇ∑Stop the study  drug infusio n, begin an IV infusio n of norm al saline, and treat the participant 
with diphenhydramine 50 mg IV (or equivalent) and/or acetaminophen/paracetamo l 325 to 
1000 mg; remain at bedside and monitor participant until resolution of symptom s. 
Corti costeroi d and/or bronchodilator therapy  mayalso be administered as appropriate. If the 
infusio n is interrupted, then restart the infusio n at 50% of the original infusio n rate when 
symptoms resolve; if no further complicat ions ensue after 30 minutes, the rate may be 
increased to 100% of the origina l infusio n rate. Monitor participant closely. If symptoms recur, 
then no further study  medicat ion will be administered at that visit.
ÔÇ∑For future infusio ns, the following prophylacti c prem edicat ions are recommended:
diphenhydramine 50 mg (or equivalent) and/or acetaminophen/paracetamo l 325 to 1000 mg 
administered at least 30 minutes before nivolumab infusions. If necessary , corti costeroi ds (up 
to 25 m g of hydrocorti sone or equivalent) may be used.
For Grade 3 or 4 symptoms : (severe reacti on, Grade 3: Prol onged (eg , not rapi dly responsive to 
symptom atic medicat ion and/or brief interruption of infusion); recurrence of symptoms fo llowing 
initial improvement; hospi talizati on indicated for clinical sequelae. Grade 4: Life-threatening 
consequences; urgent interven tion indicated):
ÔÇ∑Immediately discont inue infusio n of study drug. Begin an IV infusio n of normal  saline and 
treat the participant as follows: Recommend bronchodilators: epinephrine 0.2 to 1 mg of a 
1:1000 solution for subcutaneous administration or 0.1 to 0.25 mg of a  1:10,000 solution 
injected slowly for IV administrati on; and/or diphenhydramine 50 mg IV with 
methylpredniso lone 100 mg IV (or equivalent), as needed. Monitor participant until the 
Protocol Amendment No.: 04
Date: 22-Sep-2023 85
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
investi gator judges that the symptom s will not recur. Study  drug will be permanent ly 
discontinued. Follow institutional guidelines for the treatment of anaphylaxis. Remain at 
bedside and mo nitor parti cipant until  symptoms resolve .
In case of late-occurring hypersensit ivity symptoms (eg, appearance oflocalized or generalized 
pruri tus within 1 week after treatm ent), symptomat ic treatment may be given (eg, oral 
antihistamine or corticosteroids) .
7.4.7 Docetaxel -related Hypersensitivity Reactions
Patients shoul d be observed closely for hypersensit ivity react ions especially  during the first and 
second infusio ns. Hypersensit ivity reacti ons may occur within a few minutes following the 
initiation of the infusion of docetaxel , thus facilities for the treatm ent of hypotension and 
bronchospasm shoul d be available. If hypersensit ivity reacti ons occur, minor symptom s such as 
flushing or l ocalized cutaneous reacti ons do not requi re interrupti on of  therapy. However, severe 
reacti ons ( ‚â• Grade 3), such as severe hypotension, bronchospasm or generalized rash/ery thema 
requi re immediate discont inuat ion of docetaxel  and appropri ate therapy . Patients who have 
developed severe hypersensit ivity react ions should not be re-challenged with docetaxel . Pati ents 
who have previ ously experienced a hypersensit ivity reaction to paclitaxel may be at risk to develop 
hypersensit ivity react ion to docetaxel, including more severe hypersensit ivity react ion. These 
patients shoul d be cl osely m onitored during ini tiation of docetaxel therapy.
7.5 Preparation/Handling/Storage/Accountability
The invest igational product shoul dbe stored in a secure area according to local regulat ions. It is 
the responsibilit y of the investigator to ensure that invest igational product is only dispensed to 
study  Parti cipants. The invest igational product must be dispensed only fro m official study sites by 
authori zed personnel according to local regulat ions.
The product storage manager shoul d ensure that th e study  treatm entis stored in accordance with 
the environmental condi tions (temperature, light, and humidit y) as determined by BMS. If 
concerns regarding the qualit y or appearance of the study  treatm entarise, the study treatm ent
shoul d not be di spensed and contact BMS immediately.
Study  treatm entnot supplied by BMS will be stored in accordance with the package insert.
Invest igational product doc umentation (whether supplied by BMS or not) must be maintained that 
includes all processes requi red to ensure drug is accurately administered. This includes 
docum entati on of drug storage, administration and, as applicable, storage temperatures, 
reconstitut ion, and use of required processes ( eg, requi red diluents, administration sets).
For nivo lumab, refer to the current version of the Investigator Brochure and/or Pharmacy Manual 
for com plete storage, handling, dispensing and infusion informat ion.
For doceta xel and prednisone, refer to the current prescribing informat ion for the complete storage, 
handling, dispensing and administration information.
Protocol Amendment No.: 04
Date: 22-Sep-2023 86
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
Further guidance and informat ion for final dispositi on of unused study  treatm ent are provided in 
Appendix 2 and Study  Reference Manual.
7.5.1 Retained Samples for Bioavailability/Bioequivalence/ Biocomparability
Not applicable
7.6 Treatment Compliance
Treatment compliance will be monitored by drug accountabilit y as well as the participant‚Äôs 
medical rec ord and eCRF.
7.7 Concomitant Therapy
Drug -drug interacti ons (DDI) between nivolumab and co-administered medications are unlikely. 
See the recent nivo lumab IB for information concerning DDI studies conducted with nivo lumab.
7.7.1 Prohibited and/or Restricted Treatments
7.7.1.1 All Participants
For both treatm ent arm s, the following medicat ions are prohibited during the study (unless utilized 
to treat a drug -related AE):
ÔÇ∑Immunosuppressive agents and immunosuppressive doses of systemic corticosteroids (e xcept 
as stated in Sect ion 7.7.2 ) are prohibited during the treatment with nivo lumab
ÔÇ∑Any concurrent non-protocol -specified anti-neoplastic therapy  (ie, chem otherapy , horm onal 
therapy other than ADT, immunotherapy, extensive, non -palliat ive radiat ion therapy, standard 
or investigational agents for treatment of mCRPC)
ÔÇ∑Any non -palliat ive radiat ion therapy (unless specified per protocol). Limited radiat ion therap y 
administered with palliative intent (ie,for pain,  bleeding, spinal cord compressio n, brain 
metastasis, new or impending patho logic fracture, superior vena-cava syndro me, or 
obstructi on) is permi tted  
ÔÇ∑Any complementary  medicat ions (eg,herbal supplements or traditional Chines e medicines) 
intended to treat the disease under study . Such medicat ions are permitted if they are used as 
supportive care .
ÔÇ∑Any live/attenuated vaccine (eg,varicella, zoster, yellow fever, rotavirus, oral polio and 
measles, mumps, rubella [MMR ]) during t reatment and unt il 100 days post last dose .
ÔÇ∑Initiation or dose adjust ment of approved bone targeting agents is prohibited within 28 days 
prior to start of study  treatm ent. Init iation of these agents is allowed during study treatment, if 
clinically indicated, and should not result in study  treatm ent discont inuat ion.
7.7.1.2 Nivolumab Combined with Docetaxel
Strong CYP3A4 inhibitors and inducers shoul d be avoided during the treatment with docetaxel . 
Please refer to Appendix 7 for a list of commo n strong CYP3A4 inhibitors and inducers.
7.7.1.3 Imagin g Restriction and Precautions
It is the local imaging facility‚Äôs responsibilit y to determine, based on partici pant attributes 
(eg,allergy history , diabetic history , and renal status), the appropriate imaging modality and 
Protocol Amendment No.: 04
Date: 22-Sep-2023 87
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
contrast regimen per imaging study . Imaging contraindicat ions and contrast risks are to be 
considered in this assessment. Participants with renal insufficiency are to be assessed as to whether 
or not they should receive contrast and if so, which contrast a gent and dose is appropriate. Specific 
to MRI, participants with severe renal insufficiency (ie, estimated glomerular filtrat ion rate (eGFR) 
< 30 mL/min/1.73 m2) are at increased risk of nephrogenic systemic fibrosis, therefore MRI 
contrast is contraindica ted. In addition, participants may be excluded from MRI if they have 
tattoos, metallic implants, pacemakers, etc. This will be outlined in the image acquisit ion manual.
Gent le hydrat ion before and after IV contrast should follow local standard of care. Theultimate 
decisio n to perform MRI in an individual partici pant in this study  rests with the site radiologist, 
the invest igator, and standards set by  the l ocal Ethics Committee.
7.7.2 Permitted Therapy
Parti cipants are permitted the use of topical, ocular, intra-articular, intranasal, and inhalat ional 
corticosteroi ds (with minimal systemic absorpti on). Adrenal replacement steroi d doses > 10 mg 
daily  predniso ne are permitted. A brief (less than 3weeks) course of corticosteroi ds for 
prophylaxis (eg, contrast dye al lergy ) or for treatm ent of non-autoimmune condit ions (eg, delayed -
type hypersensit ivity reacti on caused by a contact allergen) is permitted.
7.7.3 Palliative Local Therapy 
Palliat ive local therapy, including palliat ive radiotherapy  and palliat ive surgical resec tion, to 
symptom atic tumor lesions is permi tted. Parti cipants requi ring palliat ive local therapy shoul d be 
evaluated (by CT/MRI and bone scan if clinically  indicated) for objective evidence of disease 
progression prior to the init iation of such therapy, pa rticularly if the most recent tumor assessment 
was more than 4 weeks prior to th e planned start of local therapy. If progression per PCWG3 is 
ident ified prior to the init iation of palliat ive local therapy, then participants must either discont inue 
study  treatm ent or they must meet criteria to continue treatm ent beyo nd progression (Secti on7.7.4 )
in order to resume study  treatm ent af ter the com pletion of  palliat ive local therapy.
In cases where palliat ive radiotherapy is required, nivo lumab dosing should be withheld for at least 
1 week before, during, and 1 week after radiotherapy. Participants sh ould be closely mo nitored for 
any potential  toxicity during and after receiving radiotherapy , and AEs shoul d resolved to 
Grade ÔÇ£1 prior to resuming nivo lumab.
For docetaxel local standard of care guidelines should be fo llowed. 
7.7.4 Treatment Beyond Progressio n 
Not applicable per Protocol Amendment 04.
Parti cipants will be permitted to conti nue treatment beyo nd initial PCWG3 -defined PD, as 
assessed by the invest igator ,up to a maximum of 24 months from date of first dose , as long as the 
following criteria are considered:
ÔÇ∑Invest igator -assessed clinical benefit
ÔÇ∑Tolerance of study  drug
ÔÇ∑Stabl e performance status
Protocol Amendment No.: 04
Date: 22-Sep-2023 88
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
ÔÇ∑Treatment beyond progressi on will not delay an imminent intervent ion to prevent serious 
complicat ions of disease progressi on (eg, CNS m etastases)
ÔÇ∑Participant provi des wri tten informed consent prior to receiving addit ional treatm ent wi th the 
study  drug regimen. All other elements of the main consent including descript ion of reasonably 
foreseeable risks or disco mforts, or other alternative treatment op tions will st ill apply .
7.7.5 Re-assessment Following Initial Assessment of Progression
Not applicable per Protocol Amendment 04.Radiographic tumor assessments by BICR 
following PCWG3 criteria will no longer apply. All participants receiving study treatment 
will have radiographic tumor assessments based on the clinical judgment of the treating 
investigator and following local imaging tumor assessment guidelines for mCRPC. 
Submission of tumor imaging assessments for central review will no longer apply.
Radiographic assessment/scan(s) shoul d continue in accordance with Section 2(Schedule of 
Activities)for the durati on of the treatment beyond progressi on and shoul d be submi tted to the 
central  imaging vendor. This assessment will allow determinat ion of whether there has been a 
decrease in the tumor size or continued PD. The assessment of clinical benefit should be balanced 
by clinical jud gment as to whether the participant is clinically deteriorating and unlikely to receive 
any benefit from cont inued treatment with nivo lumab.
For the participants who continue study therapy beyo nd progression, further progression is defined
as fo llows: 
Further disease progression of soft tissue is defined as an addit ional 10% increase in tumor burden 
with a minimum  5 mm absol ute increase from  time of  initial PD. Thi s includes an increase in the 
sum of diameters of all target lesio ns and/ or the diameters of new measurable lesio nscompared to 
the time o f initial PD.
New l esions are considered m easurable at the time of init ial progression if the lo ngest di ameter is 
at least 10 mm (except for pathological lymph nodes ,which must have a short axis of at least
15mm). Any new lesio n considered non -measurable at the time of init ial progressio n may beco me 
measurable and therefore included in the tumor burden if the longest diameter increases to at least 
10 mm  (except for pathol ogical lymph nodes ,which must have a sh ort axis of at least 15 mm). In 
situations where the relative increase in total tumor burden by 10% is solely due toinclusio n of 
new lesions ,which become measurable, these new lesio ns m ust dem onstrate an absolute increase 
of at least 5 mm.
Further bone d isease progressi on is defined as addi tional two or m ore new bone lesio ns noted on
bone scans co mpared to the time of PCWG3 -defined progression of bone disease.
Study  treatm ent should be discont inued perm anent ly upon docum entati on of any further 
progression as described above .Confirmed PSA progression alone is not necessarily a n indicat ion 
to stop treatment.
Protocol Amendment No.: 04
Date: 22-Sep-2023 89
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
7.8 Treatment After the End of the Study
Per Protocol Amendment 04, due to lack of rPFS benefit at the final analysis and OS benefit 
at the first interim analysis for nivolumab added to docetaxel plus prednisone compared to 
placebo added to docetaxel plus prednisone, on 26-Jul -2023, a BMS EOC decided to 
terminate the study. The decision to terminate the study was not based on any safety 
concerns or issues. Based on these results, BMS recommends discontinuation of nivolumab 
in all participants receiving this study treatment. In the event that the investigator deems a 
participant is deriving clinical benefit from nivolumab therapy and, together with the 
counse led participant, wishes to continue nivolumab, this may be allowed following 
discussion with the Medical Monitor to ensure a clinical rationale exists that justifies 
continuation of nivolumab treatment. 
Study  treatm ent will be provided via an extensio n ofthe study, a rollo ver study requiring approval 
by responsible health authori ty and ethics committee or through another mechanism at the 
discreti on of  BMS.
BMS reserves the right to terminate access to BMS supplied study treatm ent if any of the fo llowing 
occur: a) the study  is terminated due to safety concerns; b) devel opment is terminated for other 
reasons, including but not limit ed to lack of efficacy and/or not meeting the study objectives; c) the 
participant can obtain medication from a government spons ored or private healt h program. In all 
cases BMS will fo llow l ocal regulat ions.
8 DISCONTINUATION CRITERIA
8.1 Discontinuation from Study Treatmen t
Parti cipants MUST discont inue invest igational product (and non-invest igational product at the 
discreti on of  the in vestigator) for any o f the following reasons:
ÔÇ∑Parti cipant‚Äôs request to stop study treatm ent.Participants who request to discontinue study 
treatm ent will remain in the study  and must continue to be followed for proto col-specified 
follow-up procedures. The only excepti on to this is when a participant specifically wit hdraws 
consent for any further contact with him/her or persons previously authorized by participant to 
provi de thi s informat ion
ÔÇ∑Any clinical adverse event (AE), laboratory  abnormalit y or intercur rent illness which, in the 
opinio n of the invest igator, indicates that continued participat ion in the study is not in the best 
interest of the participant
ÔÇ∑Terminat ion of the study by Bristol -Myers Squibb (BMS) for reasons including but not limited 
to the f ollowing: safet y concerns, terminat ion of drug development, l ack of  efficacy, and lack
of meeting study  object ives/endpo ints.
ÔÇ∑Loss of ability to freely  provide consent through imprisonment or involuntarily incarceration 
for treatm ent of either a psychiatri c or physical (eg, infect ious disease) illness . (Note: Under 
specific circumstances and only in countries where local regulat ions permit , a participant who 
has been imprisoned may be permitted to continue as a participant. Strict condit ions apply and 
BMS approval  is requi red.)
Protocol Amendment No.: 04
Date: 22-Sep-2023 90
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
ÔÇ∑Parti cipant meets criteria for radiographic progressio n per PCWG3 criteria (as defined in 
Appendix 5) unless criteria for treatm ent beyo nd progression have been met (see 
Secti on7.7.4 ).PSA progression alone is not an indicat ion to discont inue study  treatm ent (see 
Secti on9.1.2 ).
Refer to Section 2(Schedule of Activities)for data to be collected at the time of treatment 
discontinuat ion and fo llow-up and for any  further evaluat ions that can be completed .
All participant s who discont inue study  treatm entshoul d comply with protoc ol-specified follow-
up procedures as outlined in Secti on 2 (Schedule of Activities). The only except ion to this 
requi rement is when a participant withdraws consent for all study  procedures including post-
treatm ent study  follow-up or l oses the abili ty to consent freely ( ie, is imprisoned or invol untarily 
incarcerated for the treatment of either a psychiatric or phy sical illness).
If study  treatm entis discontinued prior to the participant ‚Äôs co mpletion of the study , the reason for 
the discont inuat ion must be docum ented in the participant ‚Äôs medical records and entered on the 
appropriate case report f orm (CRF) page.
8.1.1 Discontinuation of Specific Study Treatments
The assessment for discont inuat ion of nivolumab and docetaxel  should be made separately for 
each study  drug. Although there is overlap among the discont inuat ion criteria, if discontinuat ion 
criteria are met for one study  treatm ent but not the other, it may be acceptable to continue t reatm ent 
with the study  treatm ent that is not felt to be related to the toxici ty. If the invest igator considers 
the toxi city to be related to both study  treatm ents or is unable to determine which study  treatm ent 
is the cause of toxicity, then both study  treatments shoul d be discont inued, and the 
recommendat ions for management of toxicit y related to both study treatments should be prompt ly 
initiated.
Nivo lumab and/or docetaxel treatment must be permanent ly discont inued per criteria in Table 7.4-
1and Table 7.4-2.
Discontinue nivolumab and/ordocetaxel for any adverse event, laboratory  abnorm ality, or 
intercurrent illness which, in the judgment of the investigator, presents a substant ial clinical risk 
tothe parti cipant wi th cont inued nivolumab and/or docetaxel dosing. 
Any event that leads to delay in dosing last ing > 8 weeks (Q3W cycle) or > 10 weeks (Q4W cycle), 
from the previous dose requires discont inuat ion of study drug, with the fo llowing except ions:
ÔÇ∑Dosing delays to allow for prolonged steroid tapers to manage drug -related adverse events are 
allowed. 
ÔÇ∑Dosing delays lasting > 8 weeks (Q3W c ycle) or > 10 weeks (Q4W cycle) from the previ ous 
dose that occur for non
-drug-related reasons may be allowed if approved by the Medical 
Moni tor (or designee ).
Protocol Amendment No.: 04
Date: 22-Sep-2023 91
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
8.1.2 Post Study Treatment -Study Follow -up
Not applicable per Protocol Amendment 04. Only participants who received study provided 
nivolumab and areup to100 days after theirlast nivolumab infusion will have post-study 
treatment safety follow -up. After completion of the 100-day safety follow -up requirement 
and resolution or stabilization of AEs, nivolumab -treated participants will be discontinued 
from the study. All other participants currently on safety or survival follow -up with 
resolution or stabilization of AEs will be discontinued from the study. 
In this study , overall survival is a key endpo int of the study . Post study  follow
-up is of critical 
importance and is essential to preserving participant safet yand the integrity of the study . 
Parti cipants who discont inue study  treatment must continue to be followed (in this study  or a 
rollover study )for collect ion of outcom e and/or survival follow-up data as required and in line 
with Secti on 5until death or the conclusio n of the study .
BMS may request th at survival data be collected forall treated participants outsi de the protocol -
defined window (as detailed in the Schedule of Activit ies in Section 2). At the time of this request, 
each participant will be contacted to determine his or her survi val status ,unless the participant has 
withdrawn consent for all contact or is lost tofollow
-up.
8.2 Discontinuation from the Study
Not applicable per Protocol Amendment 04. Only participants continuing study -provided 
nivolumab and areup to100 days after theirlast nivolumab infusion will have post-study 
treatment safety follow -up. After completion of the 100-day safety follow -up requirement 
and resolution or stabilization of AEs, nivolumab -treated participants will be discontinued 
from the study. All other participants currently on safety or survival follow -up with 
resolution or stabilization of AEs will be discontinued from the study. 
Parti cipants who request to discont inue study  treatment will remain in the study and must conti nue 
to be followed for protocol -specified follow
-up procedures. The only  except ion to thi s is when a 
participant specifically withdraws consent for any further contact with him/her or persons 
previously authorized by participant to provi de this informat ion. 
ÔÇ∑Parti cipants shoul d notify  the investigator of the decisio n to withdraw consent from future 
follow-up in writing, whenever possible.
ÔÇ∑The withdrawal  of consent should be explained in detail in the medical records by the 
investigator, as to whether the withdrawal is from further treatm ent wi th study  treatm entonly 
or also from study  procedures and/or post treatment study  follow-up, and entered on the 
appropriate CRF page.
ÔÇ∑In the event that vital status (whether the participant is alive or dead) is being measured, 
publicly  available informat ion shoul d be used to determine vital status only as appropri ately 
directed in accordance with local law.
ÔÇ∑If the participant withdraws consent for disclosure of future informat ion, the sponsor may 
retain and cont inue to use any data collected befor e such a withdrawal o f consent.
Protocol Amendment No.: 04
Date: 22-Sep-2023 92
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
8.3 Lost to Follow -Up
Not applicable per Protocol Amendment 04. 
ÔÇ∑All reasonable efforts must be made to locate participant s to determine and report their ongoing 
status. This includes fo llow-up wi th persons authorized by  the participant .
ÔÇ∑Lost to f ollow -up is defined by the inabilit y to reach the participant after a minimum of three 
docum ented phone calls, faxes, or emails as well as lack of response by participant to one 
registered m ail letter. All attempts should be documented in the participant‚Äôs medical records.
ÔÇ∑If it is determined that the participant has died, the site will use permissible local methods to 
obtain date and cause of death.
ÔÇ∑If invest igator‚Äôs use o f third-party  representative to assist in the fo llow-up porti on of the study 
has been included in the partici pant‚Äôs informed consent, then the investigator may use a 
sponsor retained third-party  representative to assist site staff with obtaining participant‚Äôs 
contact information or other public vital status data necessary to complete the follow-up 
porti on of  the study . 
ÔÇ∑The si te staff  and representative will consul t publicly available sources, such as public healt h 
registries and databases, in order to obta in updated contact information.
ÔÇ∑If after all attempts, the participant remains lost to fo llow-up, then the last known alive date as 
determined by the invest igator should be reported and documented in the participant‚Äôs medical 
records.
9 STUDY ASSESSMENTS AND PROCEDURES
ÔÇ∑Per Protocol Amendment 04:
ÔÄ≠Participants continuing study -provided nivolumab and deriving treatment benefit 
per investigator assessment, as well asparticipants up to100 days after the last 
infusion of nivolumab, will continue study participati on. All other participants will 
be discontinued from the study.
ÔÄ≠Safety clinical and laboratory assessments will apply only to participants continuing 
study -provided nivolumab, and participants up to 100 days after the irlast nivolumab 
infusion.
ÔÄ≠Radiographi c tumor assessments will be performed based on the clinical judgment of 
the treating investigator and following local imaging tumor assessment guidelines for 
mCRPC. The same applies for PSA collection.
ÔÇ∑Study  procedures and timing are summarized in Secti on2(Schedule of Activities).
ÔÇ∑Protocol  waivers or exempt ions are not allowed .
ÔÇ∑All immediate safet y concerns must bediscussed with thesponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
treatm ent.
ÔÇ∑Adherence to the study  design requi rements, incl uding those specified inSecti on2(Schedule 
of Activities), is essent ial and required for study  conduct.
ÔÇ∑All screening evaluat ions must be completed and reviewed to confirm that potential 
participants m eet all eligibilit y criteria before randomizat ion. The invest igator will maintain a 
Protocol Amendment No.: 04
Date: 22-Sep-2023 93
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
screening log to record details of all participants screened and to confi rm eligibili ty or record 
reasons for scr eening failure, as applicable.
ÔÇ∑Procedures conducted as part of the participant‚Äôs routine clinical management (eg, blood count) 
and obtained before signing of inform ed consent may be utilized for screening or baseline 
purposes provided the procedure meets the protocol -defined criteria and has been performed 
within the t imeframe defined i n the S chedule of Activit ies.
ÔÇ∑Perform  additional measures, including non-study  required laboratory  tests, as clinically 
indicated or to comply with local regulations. Laboratory  toxicities (eg, suspected drug-
induced liver enzyme evaluat ions) will be monitored during the follow-up phase via on-
site/local labs until all study drug-related toxi cities resolve, return to baseline, or are deemed 
irreversible.
ÔÇ∑Evaluate participant immediately to rule out cardiac or pulmonary toxicit y if participant shows 
cardiac or pulmo nary-related signs (hypoxia, abnorm al heart rate,or changes from baseline) 
or symptoms (eg ,dyspnea, cough, chest pain, fat igue, palpitat ions).
ÔÇ∑Some of the assessments referred to in this section may not be captured as data in the eCRF. 
They  are intended to be used as safet y monitoring by the treating physician. Addit ional testing 
or assessments m ay be perform ed as clinically  necessary or where requi red by inst itutional or 
local regulati ons.
9.1 Efficacy Assessments
9.1.1 Imaging Assessment for the Stu dy
Not applicable per Protocol Amendment 04:Radiographic tumor assessments by BICR 
following PCWG3 criteria will no longer apply. Moving forward from Protocol Amendment 
04, all participants receiving study treatment will have radiographic tumor assessments 
based on the clinical judgment of the treating investigator and following local imaging tumor 
assessment guidelines for mCRPC. Submission of tumor imaging assessments for central 
review will no longer apply.   
Images will be submitted to a central imaging vendor for BICR during the study. Prior to scanning 
first participant, sites shoul d be qualified and understand the image acquisit ion guidelines and 
submissio n process as outlined in the CA2097DX Imaging Manual provided by the central 
imaging.
Screening and on study  images shoul d be acquired as outlined in Secti on2(Schedule of Activit ies).
Tumor assessments at other timepoints may be performed if clinically  indicated and shoul d be 
submitted to the central imaging vendor as soon as possible. Unscheduled bone scans, CT/MRI 
shoul d be submi tted to central imaging vendor. X-rays that clearly demonstrate interval 
progression of disease, for example most commo nly as unequivocal  lesions that are unmistakably 
new since the prior CT/MRI, should be submitted to central imaging vendor. Otherwise, they do 
not need to b e submitted centrally .
Protocol Amendment No.: 04
Date: 22-Sep-2023 94
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
9.1.1.1 Methods of Measurement
Bone lesio ns, including those wi th soft tissue component, will be assessed using t echnetium -99m 
(Tc-99m) based radionuclide bone scans. 
Contrast -enhanced CT of the, chest, abdom en, pelvis, and all other known and/or suspected si tes 
of disease shoul d be perform ed for tumor assessme nts. Bone lesions, including those with or 
without a soft tissue component, will be assessed by radionuclide bone scans and not by CT or 
MRI. Images shoul d be acquired with slice thick ness of 5 mm or less with no intervening gap 
(conti guous). Every  attempt shoul d be made to image each participant using an ident ical 
acquisit ion protocol on the same scanner for all imaging timepo ints. Tum or measurements shoul d 
be made by the same invest igator or radi ologist for each assessment, whenever possible. Change 
in tumor measurements and tumor response to guide ongoing study  treatment decisions will be 
assessed by  the invest igator using the PCWG3 criteria.
If a participant has a contraindicat ion for CT intravenous contrast, then a non-contrast CT of  the 
chest and a contrast -enhanced MRI of the abdomen, pelvis, and other known/suspected sites of 
disease shoul d be obtained. 
If a participant has a co ntraindicat ion for both MR and CT intravenous contra sts, then a no ncontrast 
CT of  the chest and a non -contrast MRI of the abdom en, pelvis, and other known/suspected si tes 
of disease shoul d be obtained. 
If a participant has a contraindicat ion for MRI (eg, incompatible pacemaker) in addition to 
contraindicat ion to CT intravenous contrast, then a non -contrast CT of the chest, abdomen, pelvis, 
and other known/suspected sites of disease is acceptable.
MRI of brain (without and with contrast) should be acquired as outlined in Section 2(Schedule of 
Activities). CT of the Brain (without and with contrast) can be performed if MRI is 
contraindicated.
9.1.1.2 Imaging and Clinical Assessment
Not applicable per Protocol Amendment 04 :Radiographic tumor assessments will no longer 
apply. Moving forward from protocol Amendment 04, all participants receiving study 
treatment will have radiographic tumor assessments based on the clinical judgment of the 
treating investigator and following local imaging tumor assessment guidelines for mCRPC. 
Submission of tumor imaging assessments for central review will no longer apply.
Tumor assessments shoul d continue even if dosing is delayed or di scont inued. Changes in tumor 
measurements and tumor responses will be assessed by the same investigator or designee using 
PCWG3 criteria. Assessments of PR and CR must be confirmed at least 4 weeks (28 days) after 
initial response. A Best Overall  Response (BOR) of SD requi res a minimum o f 56days on study 
from date of first dose to the date of the first imaging assessment .
9.1.2 BICR Confirmatio n of Progression 
Not applicable per Protocol Amendment 04. Moving forward from Protocol Amendment 04, 
all participants receiving study treatment will have radiographic tumor assessments by 
Protocol Amendment No.: 04
Date: 22-Sep-2023 95
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
BICR following PCWG3 criteria based on the clinical judgment of th e treating investigator 
and following local imaging tumor assessment guidelines for mCRPC. Submission of tumor 
imaging assessments for central review will no longer apply.
Sites shoul d submit all scans to the central imaging vendor on a rolling basis, throughout the 
durati on of the study. BICR of scans will occur on a rolling basis, blinded to treatm ent arm, clinica l 
data, and invest igator assessment of submi tted scans. When progressi on per PCWG3 criteria is 
assessed by the invest igator, the site will infor m the central  imaging vendor, in order for BICR 
assessment of progression to be performed. The BICR will be completed and the results provided 
to the site as specified in the imaging vendor documents, provided there are no pending imaging 
queri es to the site. All details on the timelines and associated process requirements will be outlined 
in the Imaging Manual.
Parti cipants whose progression is not confirmed by the BICR will be requi red to continue tumor 
assessments (if clinically feasible) according to the protocol -specified schedule, or sooner if 
clinically indicated. Also, if participants discont inue treatm ent without radiographic progression, 
tumor assessments will continue according to the protocol -specified schedule, as noted in 
Secti on2(Schedule of Activities) until progressi on has been confirmed by BICR. Incase 
subsequent therapy  has begun, imaging must continue unt il radiographic progressi on per PCWG3 
is confirmed by  BICR.
All study  treatm ent deci sions will  be based on the investigator‚Äôs assessment of tum or images and 
not on the BICR assessment.
Disease Progression Criteria
Radiographic Progression in soft tissue lesio ns (Target lesio ns, Non-target [non-bone] lesio ns) and 
bone lesio ns is described in Table 9.1.2 -1. See Appendix 6for more inform ation.
Protocol Amendment No.: 04
Date: 22-Sep-2023 96
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
Table 9.1.2 -1: Definition of Radiographic Progression
Parameter Progression Date of Progression
Soft tissue lesions 
(target, no n-target 
lesions with CT or 
MRI)Progression of soft tissue lesions (target, non -target, new 
lesions with CT or MRI)Date of first unequivocal 
progression of soft tissue 
lesion (target, non -target, or 
new lesions) as per PCWG3a
Bone lesions on 
radio nuclide bone 
scan per PCWG3At least 2 new lesions on the first post-treatment bone 
scan, with at least 2 additional lesions on the next scan 
(performed at least 6 weeks later) as compared to the first 
post-treatment bone scan.Date of first post -treatment 
scan
For scans after the first post -treatment scan, at least 2 
new lesions relative to the first post treatment scan AND 
confirmed on a subsequent scan (performed at least 6 
weeks later)Date of progression is the 
date of the scan that first 
documents at least 2 new 
lesions relative to the first 
post-treatment scan
aRECIST v1.1 criteria are modified for assessing soft tissue lesions per PCWG3. See Appendix 5 .
Disease progression by PSA (PSA Progression): For participants with an initial PSA decline
from baseline, the date of PSA progressi on is the date that an increase of 25% or more and an 
absolute increase of 2 ng/mL or more from the nadir are docum ented and confirmed by a second 
consecut ive PSA value at least 3 weeks later . For parti cipants with no PSA decline fro m baseline, 
the date of  PSA progressi on is the date that an increase of 25% or m ore and an absol ute increase 
of 2 ng/mL or m ore from baseline are documented at or bey ond Week 13.
PSA progression alo ne is not an indicat ion to stop treatm ent. Rather, participants must discont inue 
study  treatm ent upon radiographic progressi on cri teria per PCWG3 for measurable disease and/or 
bone disease (Table 9.1.2 -1above). Participantswho discont inue treatm ent without PSA 
progression or radiographic progressi on will continue to have PSA at FU1, FU2,and every 12 
weeks thereafter (or sooner if needed to confirm PSA progressi on or if clinically  indicated. PSA 
collect ion will continue until PSA progression, radiographic progression or end of study treatment, 
whichever occurs last.
9.1.3 Patient -Reported Outcomes
Not applicable per Pro tocol Amendment 04. 
The evaluat ion of patient-reported outcom es is an increasingly important aspect of clinical efficac y 
in onco logy trials. Such data provide an understanding of the impact of treatment from the 
participant‚Äôs perspect ive and offer insight s into patient experience that may not be captured 
through phy sician reporting. Addi tionally, generic heal th-related quali ty of life measures provide 
data needed for calculat ing utilit y values to inform healt h economic models.
Parti cipants will be asked tocomplete the Brief Pain Inventory  -Short Form (BPI -SF), The 
Funct ional Assessment Of Cancer Therapy  -Prostate Cancer (FACT -P), and the 5-level versio n 
of the EuroQol  Group‚Äôs EQ-5D (EQ
-5D- 5L) in the partici pant‚Äôs preferred language when 
available.  The assessments will be given before any clinical activities are performed during on-
Protocol Amendment No.: 04
Date: 22-Sep-2023 97
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
treatm ent dosing visit s and at safet y follow-up visit s. Addit ionally , the EQ -5D- 5L and the Prostate 
Cancer Subscale (PCS) from the FACT -P will be administered at survival follow-up visits by 
telephone. A standardized guide can be used the EQ-5D- 5L by telephone. A similar guide does 
not exist for the PCS. Participants will be provided with a hard copy  of the PCS to take hom e and 
use as a visual aid during telephone interviews. See Secti on 2(Schedule of Activit ies) for more 
inform ation on timing of assessments. If exceptional circumstances precl ude the continued 
administration of measures using planned modaliti es, alternate admi nistrati on methods may be 
requi red .
9.1.4 The Brief Pain Inventory - Short Form
Not applicable per Protocol Amendment 04. 
The BPI -SF103measures both pain severit y and funct ional interference caused by pain through the 
use of a numerical rating scale. Participant s rate the severit y of their pain at its ‚Äúworst,‚Äù ‚Äúleast,‚Äù 
and ‚Äúaverage‚Äù in the last 24 hours using an 11-point numerical rating scale with anchors of ‚Äúno 
pain‚Äù and ‚Äúpain as bad as you can imagine.‚Äù They are also asked to rate their pain at the time they 
complete the BPI -SF. Using an 11 point numerical rating scale with anchors of ‚Äúdoes not interfere‚Äù 
and ‚Äúcompletely interferes,‚Äù the BPI-SF similarly assesses to what extent pain interferes with 
mood, walking, general activity, work, relations with others, sleep, and enjoyment of life. The 
BPI-SF also asks participants to mark the location of  their pain on a body drawing and includes 
additional quest ions regarding pain treatment and the extent of pain relief. The original instrument 
on which the BPI-SF is based, The Wisconsin Brief Pain Quest ionnaire, was developed and 
validated in oncology patients with the fo llowing four tumor types: breast, prostate, colorectal, and 
gyneco logical.104The BPI-SF has been validated in cancer patients in several countri es with 
psycho metrically validated translat ions in over 25 countries .
9.1.5 The Functional Assessment of Cancer Therapy 
-Prostate Cancer 
(FACT -P)
Not applicable per Protocol Amendment 04. 
The FACT -P is a multidimensio nal, self-report instrument specifically designed for use with 
prostate cancer patients.105The FACT -P includes the 27-item FACT -General (FACT -G), a generic 
cancer -related core, to assess physical well-being (PWB; seven items), social/family  well-being 
(SWB; seven items), emotional well-being (EWB; six items), and functional well-being (FWB; 
seven items). In addition, the FACT -P includes a 12-item disease- specific Prostate Cancer 
Subscale that assesses prostate -related symptoms. Each of the 39 items is rated on a 0 (Not at all) 
to 4 (Very  much) Likert -type scale, then co mbined to produce subscale scores for each domain, a 
Trial Outcom e Index (TOI) based on the Physical and Functi onal well-being scales and the PCS 
as well as a total score which ranges fro m 0 to 156. Higher scores represent better QoL. The FACT -
P uses a recall period of the past 7 day s.
9.1.6 The 5 -Level EQ -5D
Not applicable per Protocol Amendment 04. 
Protocol Amendment No.: 04
Date: 22-Sep-2023 98
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
The EQ-5D- 5L is a standardized instrument used to measure self-reports of general healt h 
status.106The instrum ent has two c omponents, a descript ive system , and a visual analogue scale 
(VAS). The descript ive system  consists of 5dimensions: mobility, self-care, usual activities, 
pain/disco mfort, and anxiety /depressi on. Each dimensi on has five levels, re flecting no probl ems, 
slight problems, moderate problems, severe problems, and extreme probl ems. A dimensio n for 
which there are no problems is said to be at level 1, while a dimensio n for which there are extreme 
probl ems is said to be at level 5. Thus, th e vectors 11111 and 55555 represent the best healt h state 
and the worst health state, respectively. Altogether, the instrument describes 3,125 different healt h 
states. Em pirically -derived weights can be applied to an individual‚Äôs responses to the EQ-5D- 5L 
descript ive system  to generate a utility index measuring the value to society of his or her current 
healt h.107
The EQ -5D- 5L VAS allows parti cipants to rate th eir own current heal th on a 0to100 point scale 
ranging from ‚Äúthe worst health you can imagine‚Äù to the ‚Äúbest healt h you can imagine,‚Äù 
respectively .
The EQ -5D- 5L uses a recall period of ‚Äútoday .‚Äù
9.2 Adverse Events
Per Protocol Amendment 04, AE assessments will only be applicable to participants 
continuing study -provided nivolumab, and participants up to 100 days after their last 
infusion of nivolumab. After completion of the 100-day safety follow -up requirement and 
resolution or stabilization of AEs, nivolumab -treated participants will be discontinued from 
the study. All other participants will be discontinued from the study.
The definit ions of  an AE or seri ous adverse event (SAE) are classified according to NCI CTCAE 
versio n 5 and can be found in 
Appendix 3.
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally  authori zed representative). 
The invest igator and any designees are responsible for detecting, docum enting, and reporting 
events that meet the definit ion of an AE or SAE and remain responsible for following up AEs that 
are serio us, considered related to the study treatment or the study, or that caused the participant to 
discontinue before complet ing the study. 
Immune
-mediated adverse events are AEs consistent with an immune -mediated mechanism or 
immune -mediated component for which non-inflammatory  etiologies (eg, infect ion or tumor 
progression) have been ruled out. IMAEs can include events with an alternate etio logy which were 
exacerbated by the induction of autoimmunit y. Inform ation supporting the assessment will be 
collected on the parti cipant‚Äôs case report form.
Contacts for SAE reporting specified in Appendix 3
9.2.1 Time Period and Frequency for Collecting AE and SAE Information
Secti ons 5.6.1 and 5.6.2 in the Investigator Brochure (IB) represent the Reference Safet y 
Inform ation todetermine expectedness of serious adverse events for expedited reporting. 
Protocol Amendment No.: 04
Date: 22-Sep-2023 99
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
All SAEs must be collected from the time of signing the consent, including those thought to be 
associ ated with protocol -specified procedures and within 100 days of discont inuat ion of dosing.
For participants assigned to treatm ent and never treated with study drug, SAEs should be co llected 
for 30 days fro m the date of treatment assignment.
The investigator must report any SAE that occurs af ter these time periods and that is believed to 
be related to study  drug or protocol -specified procedure, (eg, a follow-up skin biopsy ), Medical 
occurrences that begin before the start of study treatm ent but after obtaining informed consent will 
be recorded on the appropri ate secti on of  the CRF module.
ÔÇ∑All SAEs wi ll be recorded and reported to sponsor or designee within 24 hours , as indicated in 
Appendix 3.
ÔÇ∑The invest igator will submit any updated SAE data to the sponsor or designee within 24 hours
ofupdated informat ion being available.
All nonserious AEs (not only those deemed to be treatm ent-related) shoul d be collected 
continuously during the treatm ent period and for a minimum of 100 days fo llowing discont inuat ion 
of study  treatm ent.
All SAEs, and all AEs (SAEs and non serious AEs) asso ciated with confirmed or suspected SARS -
CoV -2 infect ion must be co llected fro m the date of the participant‚Äôs written consent unt il 100 days 
following discont inuat ion of dosing.
Invest igators 
are not obligated to actively seek AEs or SAEs in former study  participants. 
However, if the invest igator learns of any SAE, including a death, at any time after a participant 
has been discharged fro m the study, and he/she considers the event reasonably related to the study 
treatm ent or study  parti cipat ion, the invest igator must prompt ly notify the sponsor.
The method of evaluat ing, and assessing causality  of AEs and SAEs and the procedures for 
completing and reporting/ transmi tting SAE reports are provided in Appendix 3.
9.2.2 Method of Detecting AEs and SAEs
Adverse events can be spontaneously reported or elicited during open -ended quest ioning, 
examinat ion, or evaluation of a participant . Care shoul d be taken not to introduce bias when 
collect ing AE and/or SAEs. Inqui ry about specific AEs sh ould be guided by clinical judgment in 
the context of known adverse events, when appropriate for the program or protocol.
Every  adverse event must be assessed by the investigator wit
h regard to whether it is considered 
immune -mediated. For events which are potenti ally immune -mediated, additional informat ion will 
be co llected on the participant‚Äôs case report form.
9.2.3 Follow -up of AEs and SAEs
ÔÇ∑Nonserious AEs shoul d be followed to resol ution or stabilizat ion, or reported as SAEs if t hey 
beco me serious (see Appendix 3).
ÔÇ∑Follow
-up isalso requi red for nonserious AEs that cause interruption or discont inuation of 
study  treatm ent and for those present at the end of study  treatm ent as appropri ate.
Protocol Amendment No.: 04
Date: 22-Sep-2023 100
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
ÔÇ∑All ident ified nonseri ous AEs must be recorded and described on the nonserious AE page of 
the CRF (paper or electronic). Com pletion of supplemental  CRFs may be requested for AEs 
and/or laboratory  abnorm alities that are reported/ident ified during the course of the study .
After the init ial AE/SAE report, the investigator is required to proactively follow each parti cipant 
at subsequent visits/contacts. All SAEs, nonserious AEs of special interest (as defined in 
Secti on9.1.3 Adverse Events) ,and AEs (SAEs and non serious AEs) associated with confirmed or 
suspected SARS -CoV -2 infect ionwill be followed until resol ution;until the condi tion stabilizes;
until the eve nt is otherwise explained; the event is deemed irreversible ;until the participant is lost 
to follow-up (as defined in Section8.3);or,for suspected cases, until SARS-CoV -2 infection is 
ruled out.
Further informat ion on fo llow-up procedures i s given in Appendix 3.
9.2.4 Regulatory Reporting Requirements for SAEs
ÔÇ∑Prom pt notificat ion by the invest igator to the sponsor of SAEs is essent ia
l so that legal 
obligat ions and ethical responsibilit ies towards the safet y of participants and the safet y of a 
product under clinical investigation are met.
ÔÇ∑An invest igator who receives an invest igator safety report describing SAEs or other specific 
safet y inform ation (eg, summar y or listing of SAEs) from the sponsor will file it along with 
the Invest igator Brochure and will notify  the IRB/IEC, if appropri ate according to local 
requi rements.
Sponsor or designee will be reporting adverse events to regulatory  authorities and ethics 
committees according to local applicable laws including European Directive 2001/20/EC and FDA 
Code of Federal Regulat ions 21 CFR Parts 312 and 320. A SUSAR (Suspected, Unexpected 
Serious Adverse Reacti on) is a subset of SAEs and will  be reported to the appropri ate regul atory 
authori ties and invest igators fo llowing l ocal and global  guidelines and requi rements.
9.2.5 Pregnancy
Per Protocol Amendment 04,only applicable to female partner sof male participant s
continuing study -provided nivolumab, and female partner sof male participants up to100 
days after the irlast infusion of nivolumab. 
Any pregnancy that occurs in a female partner of a male study  participant should bereported to 
sponsor or designee. In order for sponsor or designee to collect any pregnancy  surveillance 
inform ation from the female partner, the female partner must sign an informed consent form for 
disclosure of this informat ion. Inform ation on this pregnancy will be collected on the Pregnancy 
Surveillance Form.
In cases where a study  drug can be present in seminal fluid, at exposures sufficient to potenti ally 
cause fetal toxicit y, and if any sexual act ivity (eg, vaginal, anal, oral) has occurred between a male 
participant and a pregnant WOCBP partner(s), the informa tion shoul d 
be reported to the sponsor 
or designee, even if the male participant has undergone a succ
essful vasectomy . In order for 
sponsor or designee to collect any pregnancy surveillance informat ion fro m the female partner, the 
Protocol Amendment No.: 04
Date: 22-Sep-2023 101
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
female partner(s) must sign an informe d consent form for disclosure of this informat ion. 
Inform ation on the pregnancy  will be collected on the Pregnancy  Surveillance Form .
9.2.6 Laboratory Test Result Abnormalities
Per Protocol Amendment 04, only applicable to participants continuing study -provided 
nivolumab, and participants up to 100 days after theirlast infusion of nivolumab, as required 
in Table 2-2.
The following labora tory test resul t abnorm alities shoul d be captured on the nonseri ous AE CRF 
page or SAE Report Form  electronic ,as appropri ate. Paper f orms are only intended as a back-up 
option when the el ectronic system is not functioning.
ÔÇ∑Any laboratory  test resul t that is clinically significant or meets the definit ion of an SAE 
ÔÇ∑Any laboratory  test resul t abnormalit y that required the participant to have study  treatm ent
discontinued or interrupted
ÔÇ∑Any laboratory  test resul t abnormalit y that required the participant to receive specific 
corrective therapy
It is expected that wherever possible, the clinical rather than laboratory term would be used by the 
reporting invest igator ( eg, anemia versus low hemoglobin value).
9.2.7 Potential Drug Induced Liver Injury (DILI)
Per Protocol Amendment 04, only applicable to participants continuing study -provided 
nivolumab, and participants up to 100 days after the irlast infusion of nivolumab.
Wherever possible, timely confi rmation of initial liver-related laboratory  abnormalit ies shoul d 
occu r prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meet ing 
the defined criteria, must be reported as SAEs (see Secti on 9.2.1 and Appendix 3 for reporting 
details) .
Potenti al drug induced liver injury  is defined as:
1)AT (ALT or AST) elevation > 3 Xupper limit of normal (ULN)
AND
2)Total  bilirubin > 2 XULN, without initial findings of cholestasis (elevated serum  alkaline 
phosphatase),
AND
3)No other immediately apparent possible causes of AT elevat ion and hyperbilirubinemia, 
including, but not limi ted to, vi ral hepatitis, pre-exist ing chronic or acute liver disease, or the 
administration of other drug(s) know n to be hepatotoxic.
9.2.8 Other Safety Considerations
Per Protocol Amendment 04, only applicable to participants continuing study -provided 
nivolumab, and participants up to 100 days after the irlast infusion of nivolumab.
Protocol Amendment No.: 04
Date: 22-Sep-2023 102
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
Any significant worsening noted during interim or final physical examinat ions, electrocardiogram, 
x-ray filming, any other potenti al safet y assessment required or not required by protocol  should 
also be recorded as a nonserious or serious AE, as appropriate, and reported accordingly.
9.3 Overdose
Per Protocol Amendment 04, only applicable to participants continuing study -provided 
nivolumab, and participants up to 100 days after the irlast infusion of nivolumab.
An overdose is defined as the accidental or intent ional administration of any dose of a product that 
is considered both excessive and medically important. Overdoses that meet the regulatory 
definit ion of SAE will be reported as an SAE (refer to Appendix 3).
All instances of accidental  overdose and/or dosing errors should be reported on the Dosage 
Administrati on Record eCRF.
There are a few reports of docetaxel overdose. There is no known ant idote for docetaxel overdose.
In case of overdose, the participant should be kept in a specialized unit and vital funct ions closely 
monitored. In cases of overdose, exacerbation of AEs may be expected. The primary anticipated 
complicat ions of overdose would consist of bone marrow suppression, peripheral neurotoxi city 
and mucosit is. Participants shoul d receive therapeuti c G-CSF as soon as possible after disco very 
of overdose. Other appropriate symptomat ic measures should be taken, as needed.
9.4 Safety
Per Protocol Amendment 04, only applicable to participants continuing study -provided 
nivolumab, and participants up to 100 days after the irlast infusion of nivolum ab.
Planned time po ints for all safet y assessments are listed in Secti on 2(Schedule of Act ivities).
9.4.1 Physical Examinations
Refer toSchedule of Activities(Secti on 2).
9.4.2 Vital signs
Refer to Schedule of Act ivities(Secti on 
2).
9.4.3 Electrocardiograms
Refer to Schedule of Act ivities(
Secti on 2).
9.4.4 Clinical Safety Laboratory Assessments
Per Protocol Amendment 04, laboratory tests will include local safety laboratory tests only 
and will exclude tests such as PSA,  and pharma cokinetics. In addition, the 
requirement for local safety laboratory tests will ONLY be applicable to participants 
continuing study -provided nivolumab and participants up to 100 days after their last 
nivolumab infusion. All other participants will be disco ntinued from the study and switched 
to local standard of care for metastatic castration
-resistant prostate cancer outside of the 
study.
Protocol Amendment No.: 04
Date: 22-Sep-2023 103
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
Invest igators must document their review of each laboratory  safety  report.
Hematology
Hem oglobin
Hem atocri t
Total  leukocy te count, including different ial
Platelet coun t
Chemistry
Aspartate aminotransferase (AST)
Alanine aminotransferase (ALT)
Total  bilirubin
Alkaline phosphatase
Lactate dehy drogenase (LDH)**
Creatinine**
Blood Urea Ni trogen (BUN) or Serum  Urea
Fastingglucose**
TSH, Free T3 (fT3), Free T4 (fT4)** 
(screening)
TSH wi th reflexive fT3*** and fT4 if TSH is 
abnorm al on treatm entAlbumin* 
Sodium
Potassi um
Chloride
Calcium
Phosphorus**
Magnesium**
Creatinine clearance (CLcr) -screening only 
(Cockcroft -Gault method)
Serology
Serum  for hepati tis C antibody , hepat itis B surface antigen, HIV -1 and -2 antibody (screening 
only) Note: Testing for HIV must be performed at sites where mandated locally (see Appendix 
9).
Other Analyses
Prostate Specific Ant igen (PSA) (PSA should be performed by  the same lab throughout the 
treatm ent peri od to avoi d vari ations in results between cycles)
Testosterone (at screening only)
*Screening only.
**Assess as indicated in Table 2-1and Table 2-2. Assess at Safety FU2 only if toxicities are 
present.
***Total  T3 m ay be obtained when free T3 is not available. 
9.4.5 Imaging Safety Assessment
Any incidental findings of potenti al clinical relevance that are not direct ly associated wit
h the 
objectives of the protocol  should be evaluated and handled by the Study  Investigator as per 
standard m edical/clinical judgment. 
9.5 Pharmacokinetic s
 
 
Protocol Amendment No.: 04
Date: 22-Sep-2023 104
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
 All on treatm ent PK time points 
are intended to align with days on which study treatment is administered. If it is known that a dose 
is go ing to be delayed, then the predose sample should be collected just prior to the delayed dose. 
However, if a predose sample is collected but the dose is subsequent ly delayed, an additional 
predose sample should not be collected. 
Serum  concentration analyses for nivo lumab will be performed by validated bioanalyt ical method. 
Further details of sam ple collection, processing, and shipment will be provi ded in the laboratory 
procedures manual. Bioanaly tical sample s designated for assessments (eg,immunogenicit y, PK, 
) from the same collection time point may be used interchangeab ly for analyses, if 
requi red (eg, insufficient volume for complete assess ment, to follow
-up on suspected 
immunogenicit y related AE, etc.).
Addit ionally , residual bioanalyt ical samples will be archived and may be used for potentia l 
exploratory  bioanalysis (including but not limited to: analysis of drug-ADA immune complexes, 
metabo lite analyses, etc.) and or for addit ional method purposes (including ,but not limited to, 
cross -validation, ADA/PK select ivity, cut point, etc.).
Table 9.5-1: Pharmacokinetic Sampling Schedule for all A rms
S
tudy Day of Sample Collectiona
Combination Phase (max 10 cycles) :
1Cycle = 3 weeks
Monotherapy Phase: (1 Cycle = 4 weeks)EventTime Relative to 
Nivolumab/Placebo 
Dose
Hour: MinNivolumab 
PK Serum 
SampleNivolumab 
IMG Serum 
Sample
Cycle 1 Day  1Predoseb00:00 X X
EOIc00:30 X
Cycle 2Day 1 Predoseb 00:00 X X
Cycle 4Day 1 Predoseb 00:00 X X
Cycle 6Day 1 Predoseb 00:00 X X
Cycle 10 Day  1dPredoseb00:00 X X
EOIc00:30 X
Every 4 Cycles (D1) starting at first cycle 
of Monotherapy Phase Day 1until 2 years
(e.g. C11, C15, C19, C23)Predoseb00:00 X X
Follow Up Period
Follow Up 30 Day s
Note: from the last dose of nivolumab 
during treatment periodX X
Follow Up 100 Day s
Note: from the last dose of nivolumab 
during treatment periodX X
Protocol Amendment No.: 04
Date: 22-Sep-2023 105
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
aIf a participant discontinues study drug treatment during the treatment/sampling period, they will move to sampling 
at the follow -up visits . See notes .
bPredose samples should be c ollected just before the administration of the drug (preferably within 30 minutes prior 
to the start of infusion ). If it is known that a dose is going to be delayed, then the predose sample should be collected 
just prior to the delayed dose. However, if a predose sample is collected but the dose is subsequently  delayed, an
additional predose sample should not be collected.
cSince the end of infu sion pharmacokinetic (EOI-PK) sample is drawn with the intent of accurately  estimating the 
maximum concentration (Cmax) of the drug, draw the EOI-PK sample when allofthe study drug has been infused. 
If the site infuses drug without a flush, then collect the EOI -PK sample within approximately 5 minutes after end 
of infusion. If a flush is administered to clear the IV lines of the drug and to ensure delivery of the enti re drug dose, 
then draw the EOI -PK sample within approximately 5 minutes after end of the flush. Do not draw EOI-PK samples 
from the same IV access through which that the drug was administered .
dIf combination therapy ends before 10 cycles, switch directly to the monotherapy phase sampling schedule starting 
at Cycle 11 .
9.6 Pharmacodynamics
9.7 Pharmacogenomic s
Not applicable
Protocol Amendment No.: 04
Date: 22-Sep-2023 106
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
Protocol Amendment No.: 04
Date: 22-Sep-2023 107
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
Protocol Amendment No.: 04
Date: 22-Sep-2023 108
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
Protocol Amendment No.: 04
Date: 22-Sep-2023 109
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
 
 
 
 
 
 
 
 
 
 
 
 
9.8.2 Additional Research Collection
 
This protocol will include residual sample storage for addit ional research.
This protocol  will include both sample collect ion and residual sample storage for addit ional 
research (AR).
For All US sites:
Addit ional research participat ion is requi red for all invest igational sites in the US.
If the IRB and invest igative site agree to the mandatory  additional research retenti on and/or 
collect ion, then the study participant must agree to the mandatory addit ional research collection as 
a requireme nt for parti cipat ion in the study .
For non -US Sites :
Addit ional research is optional for al l study  participants, except where retenti on is prohibited by 
local laws or regul ations, ethics committees, or institutional requirements. 
This additional research is intended to expand the transl ational R&D capabilit y at Bristol -Myers 
Squibb, and will support as yet undefined research aims that will advance our understanding of 
disease and options for treatm ent. It may also be used to support health authori ty reques ts for 
Protocol Amendment No.: 04
Date: 22-Sep-2023 110
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
analysis, and advancement of pharm acodiagnosti c development to better target drugs to the ri ght 
patients. Thi s may also include  aimed at exploring disease  
progression and response to treatment etc. 
Sample Colle ction and Storage :
All requests for access to sam ples or data f or addi tional research will be vetted thro ugh a diverse 
committee of the s ponsor‚Äôs senior leaders in R&D to ensure the research supports appropriate and 
well-defined scient ific research act ivities. 
 
 
Samples kept for future research will be stored at the BMS Bioreposi tory in  USA or an 
independent, BMS -approved storage vendor.
The manager of  these samples will  ensure they  are properly  used throughout thei r usable life and 
will destroy  the samples at the end of the scheduled storage period, no longer than fifteen (15) 
years after the end of the study  or the maximum allowed by  applicable l aw.
Transfers of samples by research sponsor to third parties will be subject to the recipient‚Äôs 
agreem ent to establish similar storage procedures.
Samples will be stored in a coded fashion, and no researcher will have access to the key . The key 
is securely  held by  the invest igator at the clinical site, so there is no direct abilit y for a researcher 
to connect a sample to a specific individual.
Further details of sample collection and processing will be provi ded to th e site in the procedure 
manual .
9.8.3 Immunogenicity Assessments 
 
Protocol Amendment No.: 04
Date: 22-Sep-2023 111
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
Blood sam ples for immun ogenici ty analysis will be collected according to th e schedule given in
Secti on 9.5(Pharmacokinet ics and Immunogenici ty).Samples collected will be evaluated for 
development of Anti-Drug Antibody  (ADA) by a validated electrochemiluminescent (ECL) 
immunoassay. Samples may als o be analyzed for neutralizing ant ibodies and PK samples may be 
used for ADA analysis in the event of insufficient volume, to complete immunogenicit y 
assessment, or to follow up on suspected immunogenicit y-related AEs. 
 
 
 
 
9.9 Health care Resource Utilization and Health Economics
Not applicable per Protocol Amendment 04. 
Healthcare resource utilizat ion data, associ ated with medical encounters, will be collected in the 
CRF by the invest igator and study -site personnel  for all participants throughout the study . 
Protocol -mandated procedures, tests, and encounters are excluded. 
The data collected may be used to conduct exploratory  economic analyses and will include:
ÔÇ∑Number and durati on of medical  care encounters, including surgeri es, and other selected 
procedures (inpatient and outpatient)
ÔÇ∑Durati on of hospitalizat ion (total days length of stay, including durati on by wards; eg, intensive 
care unit)
ÔÇ∑Number and character of diagnostic and therapeutic tests and procedures
ÔÇ∑Outpati ent m edical encounters and treatments (including physician or emergency room visits, 
tests and procedures, and medicat ions)].
10 STATISTICAL CONSIDERATIONS
10.1 Sample Size Determination 
The primary  object ives of this study are to compare rPFS and OS between treatment groups in all 
rando mized participants. The primary endpo ints, rPFS and OS comprise the primary endpo int 
family and will be compared at the 0.01 level and 0.04 level respect ively, ensuring family -wise 
control  of the Type I error rate. These endpo ints will be tested separately and if significant, the 
alpha allocated to each endpoint will be recycled to the other endpoint. For example, if rPFS is 
Protocol Amendment No.: 04
Date: 22-Sep-2023 112
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
significant at the 0.01 level, then 0.01 will be transferred to the OS analysis for testing at 0.05 
level. Sample size est imation is conducted using EAST 6.4 and further verified in Solara .
Approximately  984 participants will be randomized in a 1:1 ratio to Arm A and Arm B. Sample 
size i s calculated assuming exponential distribut ion for time -to-event endpoints. See Table 10.1-1
for a summary  of the sam ple size assumpt ions.
Sample size just ification for rPFS endpoint
The number of events was estimated assuming an exponent ial distribut ion of rPFS for the
Docetaxel arm (Arm  B) and a piecewise exponent ial distribut ion with a 2monthsdel ayed 
treatm ent effect for the Nivolumab + Docetaxel arm (Arm  A).Approximately  530 rPFS events , 
observed amo ng the 984randomized participants, provides 90% power to detect an average hazard 
ratio(HR) of 0. 67with a type 1 error of  0.01(two-sided). The average HR of 0. 67resul ted from 
an assumed targeted hazard ratio of 1
 for the initial 2months from rando mizat ion and a targeted 
hazard ratio of 0.58 for the time beyo nd 2-months fromrandomization . 
Sample size just ification for OS endpoint
The number of events was est imated assuming an exponent ial distribut ion of OSfor the Docetaxel 
arm (Arm B) and a piecewise exponent ial distributi on with a 3-month s delayed treatm ent effect  
for the Nivo lumab + Docetaxel arm (Arm A). Approximately 690 OS events, observed amo ng the 
984 rando mized partici pants, provi des 92% power to detect an average hazard ratio of 0. 76with a 
type 1 error of 0.04(two-sided). The average hazard ratio of 0.76resulted from an assumed 
targeted hazard rati o of 1 for the initial 3months from  randomizat ion and a targeted hazard rati o 
of 0.72for the time beyo nd 3-months from rando mizat ion. 
For all rando mized participants, two interim OS analyses are planned. The two interim OS analyses 
are planned at approximately 47% and 80% of the total events observed at final analysis, 
respectively . The first interim analysis will occur at the time of rPFS analysis .The stopping 
boundaries at the interim and final analyses will be bas ed on the actual number of OS events at the 
time of the analysis using Lan -DeMets alpha-spending funct ion with O‚ÄôBr ien-Fleming boundaries , 
taking into account any alpha that was passed fro m the rPFS analysis (if applicable). Details o f the 
interim analysis will be included in 
Section 10.3.6 (Interim Analysis).
Assuming an average enrollment rate of2,20, 45,and 70participants randomized per month
during month
s 1to 7, 8to15, 1 6to 21,and 22to 29, respectively ,with a 29-month accrual period, 
it will take approximately 51months from the date of rando mizat ion of the first participant to 
observe the required number of events for OS analyses in all randomized popul ation. The number 
of events needed for the analyses will be monitored by the unblinded independent statistician 
supporting the IDMC. 
Table 10.1-
1: Sample Size Determination
Endpoint rPFS
Hypothesized median survival time (month) Arm A= 9 : Arm B = 6
Protocol Amendment No.: 04
Date: 22-Sep-2023 113
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
Table 10.1-1: Sample Size Determination
Endpoint rPFS
Target Hazard RatioHR=1 for t < 2m ; Hazard Ratio =0.58 for t ‚â•2months
Average Hazard Ratio =0.67
Critical Hazard Ratio 0.80
2-Sided Alpha 0.01
Sample Size 984
Accrual Duration 29months
Power 90%
Expected Number of Events 530eventsa
Expected Timing of rPFS Final Analysis (from 
randomization of first participant)31months
Endpoint OS
Hypothesized median survival time (month) Arm A= 19.7 : Arm B = 15
Target Hazard Rat ioHR=1 for t < 3m; HR=0. 72for t‚â•3 months
Average Hazard Ratio =0.76
Critical Hazard Ratio
   The 1st IA 0.70
   The 2nd IAb0.82
Final Analysis 0.85
2-Sided Alpha 0.040 (full allocation )
   The 1st IA 0.0014
   The 2nd IAb0.018
   Final Analysisb0.034(nominal)
Sample Size 984
Accrual Duration 29months
Power 92%
Expected Number of Events for 
   The 1st IA 326events
   The 2nd IAb552events
   Final Analysisb690events
Expected Timing of OS Analysis (from randomization 
of firstparticipant) 
   The 1st IA 31months
Protocol Amendment No.: 04
Date: 22-Sep-2023 114
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
Table 10.1-1: Sample Size Determination
Endpoint rPFS
   The 2nd IAb42months
   Final Analysisb51months
Abbreviations: HR = hazard ra tio;IA = Interim Analysis ; OS = overall survival .
arPFS analysis is performed after enrollment completes and observing 530 events in all randomized subjects .
bPer Protocol Amendment 0 4, the second IA for OS and final analysis for OS will not be performed, and the 
firs
t IA will be considered as the final analysis. At the time of study closeout, an updated descriptive OS 
analysis will be provided to report all death events.
10.2 Populations for Analyses
Table 10.2-1: Populations for Analyses
Population Description
Enrolled All participants who signed an informed consent and were registered into 
the IRT.
Randomized All participants who were randomized to either treatment arm in the 
study. Primary efficacy analysis, demography, protocol deviations, and 
baseline characteristics wi ll be performed on this population.
All TreatedAll treated participants who receive any dose of study drug. Participants 
are grouped within the all treated population according to the treatment 
they actually  receive. This is the analysis set for all safe ty analy ses and 
study drug administration.
All Response Evaluable PopulationAll randomized participants who have measurable disease at baseline as 
assessed by investigator per PCWG3.
PKAll treated participants with available serum concentration data for 
nivolumab.
ImmunogenicityAll treated participants with baseline and at least 1 pre -infusion 
immunogenicity assessment.
10.3 Statistical Analyses
Not applicable per Protocol Amendment 0 4.
The statistical analysis plan (SAP) will be devel oped and finalized before database lock and will 
describe the select ion of participants to be included in the analyses, and procedures for accounting 
for missing, unused, and spuri ous data. Bel ow is a summary  of planned statisti cal analyses of the 
primary  and secondary endpoints .
Protocol Amendment No.: 04
Date: 22-Sep-2023 115
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
A descript ion of the participant populat ion will be included in a statistical output report, including 
subgroups of age and race.
10.3.1 Efficacy Analyses
Not applicable per Protocol Amendment 04.
Statistical analyses for efficacy are shown in Table 10.3.1-1 .
Table 10.3.1 -1: Efficacy Statistical Analyses
Endpoint Statistical Analysis Methods
Primary
rPFS is defined as thetime fromrandomization
initiatio ntothefirstdate ofdocumented radiographic
progr essions perPCWG3 ordeath duetoanycause,
whichever occurs first. The rPFS will be censored at 
the last tumor assessment up to the start of subsequent 
systemic cancer therapy. It will also be censored at the 
date of last tumor assessment prior to the missed tumor 
assessment sfor participants w ho had progr essive 
disease ( PD)or death immediately after more than one 
consecutive missed tumor assessment s.
Thefollowing radiographic progr essive diseases will 
be collected and documented as assessed by BICR .
ÔÇ∑Soft tissue disease progr ession perPCWG3.
Date offirst unequivocal progr ession ofsoft
tissue lesion will be recorded per BICR 
assessment .
ÔÇ∑Bone disease progr ession perPCWG3. Date
ofbone progr ession will berecorded per 
BICR assessments .rPFS in allrandomized participants will be compared 
using a stratified 2 -sided log rank test with 
alpha=0.01 .The log -rank test p -value will be reported.
The hazard ratio and the corresponding 2-sided 99% 
CI will be estimated in a stratified Cox proportional 
hazard model using the randomiz ed arm as a single 
covariate.
The rPFS function for each treatment arm will be 
estimated using the KM product limit method and wi ll 
be displayed graphically. A 2 -
sided 95% CI for median 
rPFS in each arm will be estimated via the log -log 
transformation meth od(primary comparison where 0.01 
alpha will be spent). In addition, descriptive estimates 
for 6 months and 12 -months rPFS rates will be 
presented along with their associated 95% CIs.
OS is thetime from rando mization initiation tothedate
ofdeath fromanycause.The OS for all randomized participants will be 
compared using a stratified 2 -sided log rank test with 
adjusted alpha at each interim analysis and final 
analy sis (alpha will be recycled from r PFS to OS if 
rPFS test is significant) . The log -rank t est p-value will 
be reported. The hazar d ratio and the corresponding 2 -
sided (1 -adjusted alpha)*100% CI will be estimated in 
a stratified Cox proportional hazard model using the 
randomized arm as a single covariate.
The OS function for each treatment arm w ill be 
estimated using the KM product limit method and will 
be displayed graphically. A 2-sided 95% CI for median 
OS in each arm will be estimated via the log -log 
transformation method (primary comparison where up 
to 0.04 alpha will be spent). In addition, descriptive
estimate sfor 12-
months and 24 -months OS rate will be 
presented along with their associated 95% CIs. 
Protocol Amendment No.: 04
Date: 22-Sep-2023 116
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
Table 10.3.1 -1: Efficacy Statistical Analyses
Endpoint Statistical Analysis Methods
Secondary
Objective response rate (ORR) per PCWG3 assessed 
by BICR ORRs per PCWG3 andcorresponding 2-sided exact
95% CIs willbecalculated using theClopper -Pearson
method forall R esponse Evaluable participants by 
treatment arm.
PSA response rate (PSA -RR) PSA-RRs per PCWG3 andcorresponding 2-sided
exact 95% CIs willbecalculated using theClopper -
Pearson method forall randomized participants with 
PSA values at baseline and at least one post baseline 
assessment by treatment arm.
Time to response (TTR) and duration of response 
(DOR) per PCWG3 assessed by BICRSummary statistics of time toobjective response
(TTR) willbeprovided forall randomized
participants with aBOR ofCRorPR by each
treatment arm.
Duration of response (DOR) will be summarized for 
participants with a BOR of PR or CR per BICR using 
the Kaplan -Meier methodolog y. Median values, along 
with 2 -sided 95% CIs will also be calculated.
Time to PSA progression Kaplan -Meier plots of time to PSA progression willbe
presented forallrandomized participants by treatment 
arm. The estimates ofthemedian andcorresponding
log-log transformed 2-sided 95% CIswillbe
calculated. Therates atmonths 6and 12 and 
corresponding 95% CIs will be estimated via the 
Kaplan -
Meier methodology.
10.3.2 Safety Analyses
Statistical analyses for efficacy are shown in Table 10.3.2-1
Table 10.3.2 -
1: Safety Statistical Analyses
Secondary Statistical Analysis Methods
Incidence of AE, SAE, AE leading to 
discontinuation, immune- related AEs, 
deaths, and laboratory abnormalitiesDescriptive statistics of safety will be presented using NCI CTCAE 
v5.0 by treatment arm. All on -study AEs, treatment -related AEs, 
SAEs, and treatment -related SAEs will be tabulated using worst 
grade per NCI CTCAE v5.0 criteria by system organ class and 
preferred term. On -study laboratory parameters including 
hematology, chemistry, liver function, and renal function will be 
summarized using worst grade NCI CTCAE v5.0 criteria.
10.3.3 Pharmacokinetic Analyse s
Not applicable per Protocol Amendment 04.
The nivolumab concentrati on data obtained in this study  may be combined with data from other 
studi es in the clinical development program to develop population PK models.
Protocol Amendment No.: 04
Date: 22-Sep-2023 117
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
These models may be used to evaluate the effects of intrinsic and extrinsic covari ates on the PK 
of nivo lumab and to determine measures of individual exposure (such as steady state peak, trough 
and time averaged concentrati on). Model determined exposures may be used for exposure -
response analyses of selected efficacy  and safet y endpoints. If the analyses are conducted, the 
resul ts of popul ation PK and exposure response analyses will be reported separately.
10.3.4 Immunogenicity Analyses
Not applicable per Protocol Amendment 04.
Methodol ogy for analysis of immunogenicit y will be described in the statist ical analysis plan.
10.3.5 Outcomes Research Analyses
Not applicable per Protocol Amendment 04.
Analyses of BPI-SF, FACT -P, and EQ-5D-5L data will be performed by treatm ent arm in all 
treated participants who have a n assessment at baseline (Day 1, assessment prior to administration 
of drug on day o f first dose) Change fro m baseline analyses also require at least 1 other assessment 
post-baseline
. Quest ionnaire complet ion rate, defined as the proportion of quest ionnair es actually 
received out of the expected number, will be calculated and summarized at each assessment point.
Further details will be provided in the Statist ical Analysis Plan.
Thresho lds for change scores judged to be important to patients are summarized i n Table 10.3.5 -1
Table 10.3.5 -1: Thresholds Values for Change Scores Judged to be Important to 
Patients
Instruments and Domains Thresholds reported in the 
literatureMain analyses thresholds
BPI-SF1102 2
FACT -P
Total Score111 6-10 8
Total Outcome Index (TOI)112 5-9 7
Prostate Cancer Scale (PCS)112 2-3 3
Emotio nal Well Being Score113 2-3 3
Functional Well Being Score114 2-3 3
Physical Well Being Score114 2-3 3
Social Well Being Score114 2-3 3
EQ-5D-5L VAS110 7 7
Protocol Amendment No.: 04
Date: 22-Sep-2023 118
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
10.3.5.1 BPI-SF
Time to Pain Progression
The participant ‚Äôs assessment of pain wit h BPI-SF Item  #3 (pain symptoms at thei r worst over the 
last 24hours) will form the basis forthe analysis of median time to pain progressi on.112Pain 
progression will be considered to have occurred ,114if an increase in the worst pain intensit y of ÔÇ≥2 
points is observed fro m baseline and maintained over 2 consecut ive time periods. Parti cipants who 
die without a reported pain progression will be considered to have progressed on the date of their 
death. Those who neither progress nordie will be censored at the time of their last BPI-SF 
assessment prior to subsequent therapy ,while those who neither die nor have any BPI-SF 
assessments after randomizat ion will be censored on the date of rando mizat ion.Time to pain 
progression for all rando mized participants will be summarized and plotted using the Kaplan -
Meier methodol ogy. Median values, along with two-sided 95% CIs will also be calculated. The 
rate of pain progression at select timepoints and corresponding 95% CIs will also be est imate d.
Change in Pain Intensity
The mean value of least pain (Item #4), average pain (Item #5), and current pain (Item #6), along 
with Item #3, will also be analyzed as a composite assessment of change in pain intensity.110
Summary  statistics at each assessment point will be provided for each treatment group. The mean 
change from baseline will also be reported at each post -baseline assessment point.
10.3.5.2 FACT -P
Time t o Deterioration in Cancer -Related Symptoms and Quality of Life
The analysis of FACT -P will be performed for the total  score and all subscales .Parti cipants who 
die without a reported deterioration will be considered to have deteri orated on the date of their 
death. Those who neither deteriorate nor die will be censored at the time of their last FACT -P 
assessment, while those who neither die nor have any FACT -P assessments after randomizat ion 
will be censored on the date of rando mizat ion.
Change in Cancer -Related Symptoms and Quality of Life
For FACT -P total scores and all subscales, summary  statistics at each assessment point will be 
provi ded for each treatm ent group. The mean change from baseline will also be reported at each 
post-baseline assessme nt point.
10.3.5.3 EQ-5D-5L
Summary  statistics for healt h status and health utility using EQ-5D- 5L data at each assessment 
point will be provided for each treatm ent group. The mean change from baseline will also be 
reported at each post -baseline assessment point.
10.3.6 Other Analyses
Methodol ogy f or analysis o f other exploratory objectives  will be described 
in the statist ical analysis plan.
Protocol Amendment No.: 04
Date: 22-Sep-2023 119
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
10.3.7 Interim Analyses 
The Stati stical Analysis Plan will further describe the planned interim analyses.
10.3.7.1 Interim Analysis for OS
For the rando mized popul ation, two interim OS analyses and one final analysis isplanned using 
an alpha of 0.04 if rPFS is not si gnificant and 0.05 if rPFS is significant (0.01 al pha passed). The 
two interim  OS analyses are planned at appro ximately 47% and 80% of  the total  events observed 
at final analysis, respectively. The stopping boundari es at the interim and final analyses will be 
based on the actual number of OS events at the time of the analysis using Lan-DeMets alpha
-
spending function with O‚ÄôBrien -Fleming boundari es, taking into account any alpha that was 
passed fro m the rPFS analysis (if applicable) . If the interim analyses are performed exactly at 326
and 552events, respectively, and the rPFS was not si gnificant, the study  coul d be stopped for OS 
superi ority if the p -values are ÔÇ£0.0014and 0.01 8, respect ively . The no minal significance level for 
the final look of OS in all rando mized participants after 690events would then be 0.034.
An independent statist ician external to BMS will perform interim analysis.
Per Protocol Amendment 04 and the decision to terminate the study early, the second interim 
analysis for OS and final analysis for OS will no longer be performed, and the first interim 
analysis will be considered as final. Atthe time of study closeout, an updated descriptive OS 
analysis will be provided to report all death events .
Protocol Amendment No.: 04
Date: 22-Sep-2023 120
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
11 REFERENCES
1Martin AM, Nirschl  TR, Nirschl  CJ, et al. Pauci ty of PD-L1 expression in prostate cancer: 
Innate and adaptive immune resistance. Prostate Cancer and Prostati c Diseases .
2015;18(4):325 -
332.
2Topalian SL, Hodi  FS, Brahmer JR, et al . Safety, activi ty, and immune correlates of ant i-PD-
1 antibody  in cancer. N Engl J Med. 2012;366:2443-54.
3Dong H, Strom e SE, Sal omaoDR, et al . Tum or-associ ated B7 -H1 prom otes T -cell apoptosis: 
a potenti al mechanism  of immune evasion . Nat Med. 2002;8:793 -800.
4Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-
cell proliferat ion and interleukin-10 secret ion. Nat Med. 1999; 5:1365 -69.
5Pardoll D ,Drake C. Imm unotherapy  earns its spot in the ranks of cancer therapy . J Exp Med .
2012;209:201 -9.
6Gannon PO, Poisson AO, Delvo ye N, et al. Characterizat ion of the intra- prostati c immune cell 
infiltrat ionin androgen -deprived prostate cancer patients. J Immuno l Methods .2009;348:9 -
17.
7Mercader M, Bodner BK, Moser MT, et al. T  c ell infiltrat ion of the prostate induced by 
androgen withdrawal  in patients with prostate cancer. Proc Natl Acad Sci USA. 
2001;9 8:14565-70.
8Aragon -Ching JB, Willia ms KM, Gulley JL. Impact of androgen -deprivat ion therapy  on the 
immune system : implicat ions for combinat ion therapy  of prostate cancer. Front Biosci. 
2007;12:71.
9Drake CG. Prostate cancer as a model for tumour immun otherapy . Nature Rev Immuno l. 
2010;10:580 -93.
10Massard et al. Keynote -365 cohort b: Pembro lizumab (pembro) plus docetaxel and predniso ne 
in abiraterone (abi) or enzalutamide (enza) -pretreated patients (pts) with metastatic castrate 
resistant prostate cancer (mCRPC).Journal of Clinical Onco logy 37, no. 7_suppl (March 1 
2019)
11Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 
2015;65:87 -108.
12Bray  F, Ferlay  J, Soerj omataram  I,et al, Global Cancer Statistics. GLOBOCAN Estimates of 
Incidence and Mortalit y Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin .2018, 
68:394 -424.
13Siegel RL, Miller KD, Jemal A. Cancer Statist ics
,2018, CA Cancer J Clin .2018, 68:7 -30.
Protocol Amendment No.: 04
Date: 22-Sep-2023 121
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
14Ferlay J, Colombert M, Soerjo mataram  I,et al. Cancer incidence and mortalit y patterns in 
Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer (2018 , 103) 
356-87.
15Tannock IF, de Wit R, Berry  WR, et al. Docetaxel plus predniso ne or mitoxantrone plus 
prednisone for adv anced prostate cancer. N Engl J Med. 2004;351:1502
-12.
16Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel  andestram ustine compared with 
mitoxantrone and predniso ne for advanced refractory  prostate cancer. N Engl J Med. 
2004;351:1513-20.
17De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or m itoxantrone for 
metastati c castration -resistant prostate cancer progressing after docetaxel treatm ent: a 
rando mised open -label trial. Lancet. 2010;376: 1147 ‚Äì1154.
18Oudard S, Fizazi K, Sengel ov L, et al. Cabazitaxel versus docetaxel  as first-line therapy for 
patients with metastati c castrati on- resistant prostate cancer: A rando mized phase III trial-
FIRSTANA. J Clin Onco l. 2017;35(28):3189
-3197.
19Small EJ, Schellhammer PF, Higano CS, et al. Placebo -controlled phase III trial of
immuno logic therapy wit h Sipuleucel -T (APC8015) in subjects with metastati c,asymptomatic 
hormone refractory  prostate cancer. J Clin Onco l 2006 ;24:3089-3094.
20Scher HI, Fizazi K, Saad F, et al. AFFIRM investigators increased survival wit h enzalutamide 
in prostate cancer after chemotherapy . N Engl  J Med. 2012;367:1187 ‚Äì97.
21de Bono JS, Logothetis CJ, Molina A, et al. COU -AA-
301 i nvest igators abiraterone and
increased survival in metastatic prostate cancer. N Engl J Me d. 2011;364:1995‚Äì2005.
22Ryan CJ, Smi th MR, Fizazi  K, et al . Abi raterone acetate pl us prednisone versus placebo pl us 
prednisone in chem otherapy -naive men with metastati c castrati on-resistant prostate cancer 
(COU -AA-302): final overall  survival  analysis ofa rando mised, doubl e-blind, placebo 
controlled phase 3 study . Lancet Oncol . 2015;16:152 ‚Äì160.
23Beer TM, Armstrong AJ, Rathkopf DE, et al. PREVAIL enzalutamide in metastatic prost ate 
cancer before chemotherapy. N Engl J Med. 2014; 424‚Äì433.
24Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium -
223 and survival in metastati c 
prostate cancer. N Engl J Med. 2013;369:213-223.
25Sweeney CJ, Chen YH, Carducci M, et al. Chemohorm onal therapy in metastati c horm one
-
sensit ive prostate cancer. N Engl J Med. 2015;373(8):737 -746.
26Fizazi K, Tran N, Fein L, et al. Abiraterone plus predniso ne in metastati c, castrati on- sensitive 
prostate cancer. N Engl J Med. 2017;377:352-360.
27James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated 
with 
hormone therapy. N Engl J Med. 2017;377:338-351.
Protocol Amendment No.: 04
Date: 22-Sep-2023 122
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
28Armstrong A, Smulewi tz RZ, Petrylak DP, et al: Phase 3 study o f androgen deprivat ion therap y 
with enzalutamide or pl acebo in metastati c horm one-sensi tive prostate cancer: The ARCHES 
trial. 2019 Geni tourinary  Cancers Symposi um. Abstract 687. Presented February  14, 2019 .
29Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastati c, castrati on-
resistant prostate cancer. N Engl J Med 2018; 378:2465 - 74.
30Smith MR, Saad, F, Chowdhury S, et al. Apalutamide treatment and metastasis -free survival 
in prostate cancer. N Engl J Med 2018;378:1408 -18.
31Fizazi K, Shore N, Tammela TN, et al. Darol utamide in nonmetastati c, castrati on-resistant 
prostate c ancer. N Engl J Med 2 019; 380:1235 -
46.
32Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastati c prostate
cancer. N Engl J Med. 2015;373:1697 -
708.
33Abida W, Bryce AH, Vogel zang NJ, et al. Preliminary results from TRITON -2: A phase 2 
study of rucaparib in patients with metastati c castrati on-resistant p rostate cancer (mCRPC) 
associ ated with homol ogous recombination repair (HRR) gene alterations. ESMO 2018 . 
793PD.
34Mateo J, Porta N, McGovern UB, et al. TOPARP -B: A phase II randomized trial of the 
poly(ADP) -ribose polymerase (PARP) inhibitor olaparib for metastatic castrati on resistant 
prostate cancers (mCRPC) with DNA damage repair (DDR) alterations. J Clin Onco l 2019 , 37
suppl : abstr 5005.
35Pardoll D. Does the immune system  see tumors as foreign or self? Annu Rev Immunol. 
2003;21:807 -
39.
36Zitvogel L, Tesniere A, Kroem er G. Cancer despite immunosurveillance: immunoselect ion 
and immunosubversio n. Nat Rev Immuno l. 2006;6(10):715 -
27.
37Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoedit ing: from immunosurveillance to 
tumor escape. Nat Immuno l. 2002;3(11):991 -8.
38Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immuno l. 
2005;23:515 -
48.
39Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD -1 immunoinhibitory  receptor by a 
novel B7 family  member leads to negative regulati on of lymphocy te activat ion. J Exp Med 
2000;192(7):1027 -
34.
40Sharpe AH, Wherry  EJ, Ahmed R, et al. The function of programmed cell death 1 and its 
ligands in regulat ing autoimmunit y and infect ion. Nat Immuno l. 2007;8(3):239
-45.
41Wolchok JD, Hoos A, O‚ÄôDay S, et al. Guidelines for the evaluat ion of immune therapy act ivity 
in solid tumors: immune -related response criteria. Clin Cancer Res. 2009;15(23):7412 -20.
Protocol Amendment No.: 04
Date: 22-Sep-2023 123
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
42TAXOTERE (docetaxel) prescribing informat ion. Sano fi-Avent is U.S. RSI-SmPC -EMA, 
Revisio n 47. April 2020. 
43Berthol d DR, Pond GR, Soban F, et al. Docetaxel plus predniso ne or mitoxantrone plus 
prednisone for advancedprostate cancer: updated survival in th e TAX 327 study. J Clin Onco l. 
2008;26:242 -5.
44De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or m itoxantrone for 
metastati ccastrati on-resistant prostate cancer progressing after docetaxel  treatm ent: a
rando mised open -label trial. Lancet.2010 ;376:1147 -54.
45Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium -223 and survival in metastati c 
prostate cancer. N .Engl. JMed. 2013;369, 213-23.
46Ryan CJ, Smi th MR, Fizazi  K, et al . Abi raterone acetate pl us prednisone versus place bo pl us 
prednisone inchem otherapy -na√Øve men with metastati c castration -resistant prostate 
cancer(COU -AA-302): final overall survival analysis of a randomised, double -blind, placebo -
controlled phase 3 study . Lancet Oncol . 
2015; 16:152 -60.
47Beer TM, Armstr
ong AJ, Rathkopf DE, et al. PREVAIL enzalutamide in metastatic prostate 
cancer before chemotherapy. N. Engl. J.Med. 2014;37: 1‚Äì10.
48OPDIVO¬Æ (nivo lumab). Bristol  Myers Squibb. Prescribing Informati on. January  2021. 
https://www.accessdata.fda.gov/drugsatfda _docs/label/2021/125554s090lbl.pdf
49Summary  of Product Characterist ics ‚ÄìOpdivo (nivolumab). Bristol Myers Squibb. 
12/14/2020. https://www.ema.europa.eu/en/documents/product -informat ion/opdivo -epar-
product -information_en.pdf
50Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in pat ients 
with metastatic castration -resistant prostate cancer that had progressed after docetaxel 
chemotherapy (CA184 -043): a multicentre, randomised, doubl e-blind, phase 3 trial. Lancet 
Onco l. 2014;15(7):700 -12.
51Beer TM, Kwon ED, Drake CG et al. Rando mized, doubl e -blind, Phase III trial of ipilimumab 
versus placebo in asymptom atic or minimally symptom atic patients with 
metastatic 
chemotherapy -na√Øve castrati on-resistant pros tate cancer. J Clin Onco l. 2017 ,35(1):40 -47.
52Yu EY, Massard C, Retz M,et al. Pembrolizumab (pembro) plus olaparib in docetaxel -
pretreated patients (pts) with metastatic castrate -resistant prostate cancer (mCRPC): Cohort A 
of the phase 1b/2 KEYNOTE -365 study. J Clin Oncol 37, 2019 (suppl; abstr 5027) ;170-170.
53Fong PCC, Retz M, Drakaki  A, et al. Pembro lizumab (pembro) plus enzal utamide (enza) in 
abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer 
(mCRPC): Coho rt C of the phase 1b/2 KEYNOTE -365 study . J Clin Onco l 37;no. 7_suppl 
(March 1 2019):171-171.
Protocol Amendment No.: 04
Date: 22-Sep-2023 124
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
54Rizvi N, Hellmann M, Brahmer J, et al. Nivo lumab in combination with platinum -based
doubl et chemotherapy for first-line treatm ent of advanced non‚Äì small -cell lung cancer. Clin 
Onco l. 2016; 34:2969 -79.
55Massard C, Retz M, Hammerer F, et al. KEYNOTE -365 Cohort B: Pembro lizumab plus 
docetaxel and prednisone in abiraterone -or enzalutamide -pretreated patients with metastati c 
castrate -resistant prostate cancer. Presented at the American Society of Clinical Onco logy 
Genitourinary  Cancers Symposi um (ASCO -GU); February  14-16, 2019; San Francisco, 
California.
56Mezynski J, Pezaro C, Bianchini D, et al. Ant itumour activit y of docetaxel fo llowing treatment 
with the CYP17A1 inhibitor abiraterone: 
clinical evidence for cross -resistance? Ann Onco l 
2012;23:2943 -7.
57Sharma P, Pachynski RK, Naray an V, et al : Initial results from a phase II study  of nivo lumab 
plus ipilimumab for the treatm ent of metastatic castrati on-resistant prostate cancer (CheckMate 
650). 2019 Genitourinary  Cancers Symposium. Abstract 142. Presented February  14, 2019 .
58Ebelt K, Babaryka G, Figel AM, et al. Dominance of CD4+ lymphocy tic infiltrates with 
disturbed effector cell characterist ics in the tumor microenvironment of prostate carcino ma. 
Prostate. 2008;68:1-10.
59May KF Jr, Gulley JL, Drake CG, et al.Prostate cancer immunotherapy . Clin Cance r Res. 
2011 Aug 15;17(16):5233- 8. doi : 10.1158/1078 -0432.CCR -10-3402. Epub 2011 Jun 23.
60Shafer -Weaver KA, Anderson MJ, Stagliano K, et al. Cutting Edge: Tum or-specific CD8+ T 
cells infiltrat ing prostati c tumors are induced to beco me suppressor cells. J Immuno l. 
2009;183:4848
‚Äì52.
61Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor 
and peripheral blood of prostate cancer subjects. J Immuno l. 2006;177:7398‚Äì405.
62Kiniwa Y, Miyahara Y, Wang HY, et al. CD8+ Foxp3 +regula tory T  c ells mediate 
immunosuppressio n in prostate cancer. Clin Cancer Res. 2007;13:6947 ‚Äì58. 
63Ness N, Andersen S, Khanehkenari MR, et al. The prognosti c role of immune checkpo int 
markers programmed cell death protein 1 (PD -1) and programmed death ligand 1 (PD -L1) in 
a large, m ulticenter prostate cancer cohort. Oncotarget. 2017;8:26789
-26801.
64Kwon ED, Drake CG, Scher Hi, et al. Ipilimumab versus placebo after radiotherapy in pat ients 
with metastatic castration -resistant prostate cancer that had progres sed after docetaxel 
chemotherapy (CA184 -043): a multicentre, randomised, doubl e-blind, phase 3 trial. Lancet 
Onco l. 2014;15(7):700 -12
65Beer TM, Kwon ED, Drake CG et al. Rando mized, double -blind, Phase III trial o f ipilimumab 
versus placebo in asymptom atic or minimally symptom atic patients with metastatic 
chemotherapy -naive castration -resistant prostate cancer. J Clin Onco l. 2017;35(1):40
-47.
Protocol Amendment No.: 04
Date: 22-Sep-2023 125
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
66Graff JN, Alumkal JJ, Thompson RF ,et al. Pembrolizumab (Pembro) plus enzalutamide (Enz) 
in metastati c castrati on resistant prostate cancer (mCRPC): Extended follow up. J Clin Onco l 
36;no. 15_suppl (May 20 2018) 5047 - 5047.
67Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel -T immunothera py for castration -resistant 
prostate cancer. N Engl J Med. 2010;363:411 -22.
68Small EJ, Schellhammer PF, Higano CS, et al. Placebo -controlled Phase III trial of 
immuno logic therapy wit h Sipuleucel -T (APC8015) in subjects with metastatic, asymptomatic 
horm one refractory  prostate cancer. J Clin Onco l 2006; 24:3089 -94.
69Topalian SL, Hodi FS, Brahmer JR, et al. Safet y, activit y, and immune correlates o f anti-PD-
1 antibody  in cancer. N Engl  J Med 2012; 366(26):2443 -54. 
70Kim JW, Shaffer DR, Massard C,et al. A phase Ia study of safety and clinical activity of 
atezolizumab (atezo) in patients(pts) with metastatic castration -resistant prostate cancer 
(mCRPC) J Clin Onco l 36, no. 6_suppl (February  2018) ;187-187.
71Antonarakis ES, Goh JC, Gross -Goupil M
,et al. Pembrolizumab for metastati c castrati on-
resistant prostate cancer (mCRPC) previ ously  treated with docetaxel : Updated analysis of 
KEYNOTE -199. J Clin Oncol 37 ;no. 7_suppl  (March 1 2019) :216- 216.
72Kotsaki s, A.; Sarra, E.; Peraki, M.; Koukourakis, M.; Apostolaki, S.; Sougl akos, J.; 
Mavrom anomakis, E.;Vl achonikolis, J.; Georgoulias, V. Docetaxel -induced lymphopenia in 
patients wi th solid tum ors:A prospective phenoty pic analysis. Cancer 2000 ,
89: 1380-6.
73Kodum
udi, KN,Woan, K; Gilvary , DL, Sahaki an, E.; Wei, S.; Djeu, J.Y. A nove l 
chemo immuno modulatingproperty  of docetaxel : Suppression of myeloid-derived suppressor 
cells in tumor bearers. Clin. Cancer Res 2010;6: 4583 - 94.
74Li, J.Y.; Duan, X.F.; Wang, L.P.; Xu, Y.J.; Huang, L.; Zhang, T.F.; Liu, J.Y.; Li, F.; Zhang, 
Z.; Yue, D.L.; et al. 
Selective depleti on of regulatory  t cell subsets by docetaxel  treatm ent in 
patients wi th nonsmall  cell lung cancer. J. Immunol Res 2014 ;2014:286170.
75Garnett, CT; Schlo m, J; Hodge, JW.Combinat ion of docetaxel and recombinant vaccine 
enhances t
-cell responses and antitumor activit y: Effects of docetaxel  on immune 
enhancement. Clin Cancer Res 2008 ;14, 3536 -44.
76Yarchoan, M;Johnson, BAIII,  Lutz, ER; Laheru, DA; Jaffee, EM Targeting neoanti gens to 
augm ent ant itumour immuni ty. Nat Rev Cancer 2017 ;17: 209‚Äì22.
77Chan OTM, Yang L. The immuno logical effects of taxanes. Cancer Immunol Immunother. 
2000;49:181 -
5.
78Carson, WE III, Shapi ro, CL; Crespin, TR; Thornton, LM; Andersen, BL .Cellular immunit y 
in breast cancer patients complet ing taxane treatment. Clin Cancer Res 2004; 10 :3401-9.
Protocol Amendment No.: 04
Date: 22-Sep-2023 126
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
79Rizvi N, Hellmann M, Brahmer J, et al. Nivo lumab in combination with platinum -based 
doubl et chemotherapy for first-line treatment of advanced non‚Äì small -cell lung cancer. Clin 
Onco l. 2016 ;34:2969-79.
80Azad AA, Leibowitz -Amit  R, Eigl BJ, et al. A retrospective, canadian multi-center study 
examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in 
metastati c castrati on-resistant prostate cancer. Prostate 2014;74:1544‚Äì50.
81Mezynski J, Pezaro C, Bianchini D, et al. Ant itumour activit y of docetaxel fo llowing treatment 
with the CYP17A1 inhibitor abiraterone: clinical evidence for cross -resistance? Ann Onco l 
2012;23:2943 ‚Äì7.
82Oudard S, Fizazi K, Sengel ov L, et al. Cabazitaxel versus docetaxel  as first-line therapy for 
patients with metastati c castrati on-resistant prostate cancer: A rando mized phase III trial-
FIRSTANA. J Clin Onco l. 2017;35(28):3189-9.7
83Paz-Ares L, Ciuleanu TE, Cobo M, et al. First -line nivo lumab plus ipilimumab co mbined with 
two cycles of chemotherapy in pat ients with non -small -cell lung cancer (CheckMate 9LA): an 
internat ional, randomised, open -label, phase 3 trial [published correcti on appear s in Lancet 
Onco l. 2021 Mar;22(3):e92]. Lancet Oncol. 2021;22:198-211.
84Doki  Y, Ajani JA, Kato K, et al. Nivolumab Combinat ion Therapy in Advanced Esophageal 
Squam ous-Cell Carcino ma. N Engl J Med. 2022;386(5):449 -462.
85Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chem otherapy  versus 
chemotherapy alone for advanced gastri c, gastro -oesophageal junct ion, and oesophageal 
adenocarcino ma (CheckMate 649): a rando mised, open -label, phase 3 trial. Lancet. 
2021;398(10294):27-40.
86Fizazi K, Drake CG, Beer TM, et al. Final Analysis of the Ipilimumab Versus Placebo 
Following Radiotherapy Phase III Trial in Postdocetaxel  Metastati c Castrati on-resistant 
Prostate Cancer Identifies an Excess o f Long -term Survivors. Eur Urol. 2020;78(6):822-830.
87Brahmer J, Reckamp KL, Baas P, et al. Nivo lumab versus docetaxel  in advanced squamous -
cell non ‚Äìsmall -cell lung cancer. N Engl  J Med 2015;373:123 - 35.
88Borghaei H, Luis Paz-Ares L, Horn L, et al.Nivo lumab versus docetaxel in advanced 
nonsquam ous non‚Äì
small-cell lung c ancer . N Engl  J Med 2015; 373:1627-39.
89Hellmann, MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line 
treatm ent for advanced non -small -cell lung cancer (CheckMate 012): results of an open -label, 
phase 1, mult icohort s tudy. Lancet Oncol  2017; 18(1):31 - 41.
90Larkin J, Chiario n-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or 
monotherapy  in untreated melano ma. N Engl J Med. 2015;373:23 -34.
91Motzer RJ, Escudi er B, McDermott DF, et al. Nivo lumab versus evero limus in advanced renal -
cell carcino ma. N Engl J Med. 2015;373(19):1803 -
13.
Protocol Amendment No.: 04
Date: 22-Sep-2023 127
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
92Schadendorf D , Wo lchok JD, Hodi  FS,et al.Efficacy  and qualit y of life outcom es in pat ients 
with advanced melano ma (MEL) who discont inued treatm ent with nivolumab (NIVO) plus 
ipilimumab (IPI) due to toxicit y in a phase III trial (CheckMate 067). 2016 Annual Meeting o f 
the European Associ ation of Derm ato-Oncology; August 31-September 3, 2016; Vienna, 
Austria.
93Schadendorf D,Hodi FS, Robert C,et al. Pooled analysis oflong-term survival  data from 
Phase II and Phase III trials of ipilimumab in unresectable or metastatic melano ma. J Clin 
Onco l 2015;33:1889 - 94.
94Brahmer J, Horn L, Jackman D et al. Five- year follow-up from the CA209 -003 study  of 
nivolumab in previ ously treated advanced non-small cell lung cancer: clinical characterist ics 
of long-term survivors. Oral presentati on presented at: Amer ican Associ ation for Cancer 
Research (AACR) Annual Meet ing; April 1 -5, 2017; Washington, DC, USA.
95Felip E, Getti nger SN, Burgio MA et al. Three -year follow
-up from Checkmate 017/057: 
Nivo lumab versus docetaxel in patients with previously treated advanced non-small  lung 
cancer (NSCLC). Poster discussio n presentation at the European Societ y of Medical Onco logy 
Annual Meet ing. September 8- 12, 2017;Madrid, Spain. Poster 1301PD.
96Herbst RS, Garon E, Kim DW et al. KEYNOTE -010: Durable clinical benefit in pati ents wi th 
previously treated, PD-L1-expressing NSCLC who completed pembro lizumab. Poster 
presentation at the World Conference on Lung Cancer ;December 4 -7,2016;Vienna, Austria.
97Robert C , Long GV, Schachter J et al. Long -term outcom es in pati ents wi th ipilimumab -naive 
advanced melanoma in the phase 3 KEYNOTE -006 study  who completed pembrolizumab 
treatm ent.J Clin Onco l 2017;35( 15_suppl ):9504- 9504 .
98Spigel DR, McLeod M, Hussein MA et al. Randomized results of continuous vs 1 -year fixed -
durati on in patients wit
h advanced non-small cell lung cancer. Oral presentati on at the 
European Societ y of Medical  Oncol ogy Annual  Meeting; Sep 8 -12, 2017 ;Madrid, Spain .
99Shen YC, Chi ang PH, Luo HL, et al. Determine of the optimal  number of  cycles of docetaxel 
in the treatm ent of metastati c castrati on-resistant prostate cancer. Kaohsiung J Med Sci. 
2016;32(9):458 -
63.
100Pond GR, Armstrong AJ, Wood BA, et al. Evaluat ing the value of number of cycles of 
docetaxel and predniso ne in men with metastatic castration -resistant prostate cancer. Eur Urol. 
201261:363-9.
101Nivo lumab (Opdivo) US Prescribing Information. Bristol -Myers Squibb Company; Revised
January  2018.
102Medicines.org.uk. OPDIVO 10 mg/mL Concentrate for Solution for Infusio n -Summary of
Product Characterist ics -(eMC). Bristol-Myers Squibb Pharmaceut icals, Ltd; Updated July 
2019.Available from: URL: https://www.medicines.org.uk/emc/ product /6888/smpc . Accessed 
July 1 , 2019.
Protocol Amendment No.: 04
Date: 22-Sep-2023 128
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Pro tocol CA2097DX
BMS -936558 nivolumab
103Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory . Ann Acad 
Med Singapore 1994;23(2):129 -38.
104Cleeland CS. The measurement of pain from metastati c bone disease: capturing the patient's 
experience. Clin Cancer Res 2006;12(20 Pt 2):6236s -42s.
105Esper P, Mo F, Chodak G
,et al. Measuring quali ty of life in men with prostate cancer using 
the funct ional assessment of cancer therapy -prostate instrument. Urology . 1997;50:920-8
106Herdm an M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. 
Development and preliminary testing of the new five-level versio n of EQ-5D (EQ-5D- 5L). 
Qual  Life Res 2011 ,20(10):1727 -36.
107Van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Ll oyd A, Scal one 
L, Kind P, Pi ckard AS.Interim scoring for the EQ -5D- 5L: mapping the EQ -5D- 5L to EQ-5D-
3L value sets. Value  Health. 2012,15(5):708- 15.
 
 
 
110Pickard AS, Neary  MP, Cella D.Estimation of minimally  important differences in EQ-5D 
utilit y and VAS scores in cancer. Health and qualit y of life outcom es2007; 5(1):70
111Cella D, Nicho lMB, Eton D, et al. Estimat ing c linically meaningful changes for the functional
assessment of canc er therapy --prostate: Results from a clinical trial o f patients with metastatic 
hormone
-refractory  prostate cancer. Value Healt h. 2009:12(1):124 -9. 
112Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: 
IMMPACT recommendat ions. Pain 2005, 113: 9 -19.
113Cella D, Hahn E, Dineen K. Meaningful change in cancer -specific quali ty of life scores: 
Differences between improvement and worsening. Qual Life Res. 2002;11 :207-21. 
114Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes 
in chroni c pain intensity measured on an 11-point numerical pain rating scale. Pain 
2001; 94(2):149 - 58.
Protocol Amendment No.: 04
Date: 22-Sep-2023 129
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
12 APPENDICES
Protocol Amendment No.: 04
Date: 22-Sep-2023 130
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
APPENDIX 1 ABBREVIATIONS AND TR ADEMARKS
Term Definition
ADA anti-drug ant ibody
ADT androgen deprivat ion therapy
AE adverse event
AJCC American Jo int Committee on Cancer
ALT alanine aminotransferase
AST aspartate aminotransferase
AT aminotransaminases
AUC area under the concentration -time curve
BID, bi d bis in die, twice daily
BICR Blinded Independent Central Review
BMS Bristol-Myers Squibb
BP blood pressure
BPI-SF brief pain inventory  short form
BUN blood urea nitrogen
C Celsius
CBC complete bl ood count
CFR Code of Federal Regulat ions 
Protocol Amendment No.: 04
Date: 22-Sep-2023 131
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Term Definition
CI confidence interval
CLcr creatinine clearance
cm centimeter
Cmax, CMAX maximum observed concentration
CMO cystoi d macular oedem a
CNS central  nervous system
COVID -19 coronavirus disease 2019
CRC Clinical Research Center
CRF Case Report Form, paper or electronic
CTAg Clinical Trial Agreement
CTC circulat ing tumor cells
CYP cytochrom e p-450
dL deciliter
DMC Data m onitoring committee
DRESS drug reaction with eosinophilia and systemic symptoms
ECG electrocardi ogram
eCRF Electronic Case Report Form
EDC Electronic Data Capture
eg exempli gratia (for example)
EOC Execut ive Oversight Committee
EOI-PK end of infusio n pharmacokinet ic
Protocol Amendment No.: 04
Date: 22-Sep-2023 132
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Term Definition
FACT -P Funct ional Assessment of Cancer Therapy -Prostate
FACT -P-PCS Funct ional Assessment of Cancer Therapy -Prostate Prostate Cancer 
Subscale
FDA Food and Drug Administration
FSH follicle stimulat ing horm one
g gram
GBS Guillain -Barr√© syndro me
GCP Good Clinical Pract ice
G-CSF granulocy te col ony-stimulat ing factor
h hour
HBsAg hepat itis B surface antigen
HBV hepat itis B virus
HCV hepat itis C virus
HIV Hum an Immunodeficiency Virus
HR heart rate
IA Interim Analysis
ICH International Conference on Harmonisation 
ie id est (that is)
IEC Independent Ethics Committee
IgG immunogl obulin G
IHC immunohistochemistry
Protocol Amendment No.: 04
Date: 22-Sep-2023 133
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Term Definition
IMP investigat ional medicinal products
IND Invest igational New Drug Exempt ion
IO immuno -oncol ogy
IRB Institutional Review Board
IRT Interactive Response Techno logy
IV intravenous
kg kilogram
L liter
LDH lactate dehy drogenase
MDSC myelo id-derived suppressor cell
mg milligram
MG myasthenia gravis
min minute
mCRPC metastati c castrati on-resistant prostate cancer
mCSPC metastati c castrati on-sensit ive prostate cancer
mL milliliter
MR medical research
MTD maximum tolerated dose
nmC RPC non- metastatic castration -resistant prostate cancer
ÔÅ≠g microgram
Protocol Amendment No.: 04
Date: 22-Sep-2023 134
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Term Definition
N number of subjects or observations
NAT Novel  antiandrogen therapy
NCI CTCAE National Cancer Inst itute Commo n Termino logy Criteria for Adverse 
Events
ng nanogram
NK natural  killer
OS overall survival
PCWG3 Prostate Cancer Working Group
PD pharmacodynamics
PD-1 programmed death -1
PD-L1 programmed death ligand 1
PK pharmacokinet ics
PO per os (by  mouth route of administration)
PSA Prostate -specific ant igen
rPFS radiographic progressive free survival
SAE serious adverse event
SARS -CoV -2 severe acute respiratory  syndrom e coronavi rus 2 
SD standard deviat ion
SJS Stevens -Johnson syndro me
Protocol Amendment No.: 04
Date: 22-Sep-2023 135
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Term Definition
t temperature
T time
T.bili total bilirubin
TEN toxic epiderm al necrolysis 
ULN upper limit of normal
WBC white blood cell
WOCBP wom en of childbearing potential
WNOCBP wom en notof childbearing potential
x g times gravit y
Protocol Amendment No.: 04
Date: 22-Sep-2023 136
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
APPENDIX 2 STUDY GOVERNANCE CON SIDERATIONS
The term  ‚ÄòParti cipant‚Äô i s used in the protocol to refer to a person who has consented to participate 
in the clinical research study . The term  ‚ÄòSubject‚Äô used in the CRF is intended to refer to a person 
(Parti cipant) who has c onsented to participate in the clinical research study .
REGULATORY AND ETHIC AL CONSIDERATIONS
GOOD CLINICAL PRACTI CE
This study  will be conducted in accordance wit h:
ÔÇ∑Consensus ethical principles derived from internatio nal guidelines including the Declarat ion 
of Helsinki and Council for Internat ional Organizat ions of Medical Sciences (CIOMS) 
International Ethical Guidelines Good Clinical Practice (GCP), 
ÔÇ∑as defined by  the Internat ional Council on Harmo nisati on (ICH)
ÔÇ∑in accordance wit h the ethical principles underlying European Unio n Directive 2001/20/EC
ÔÇ∑United States Code of Federal Regulations, Tit le 21, Part 50 (21CFR50) 
ÔÇ∑applicable local requirements.
The study  will be conducted in com pliance wi th the protocol . The protocol  and any amendments 
and the participant informed consent will receive approval/favorable opinio n by Institutional 
Review Board/Independent Ethics Committee (IRB/IEC), and regulatory  authori ties acco rding to 
applicable local regulat ions pri or to init iation of the study .
All potenti al serious breaches must be reported to the Sponsor or designee immediately. A 
potenti al seri ous breach is defined as a Quali ty Issue (eg, protocol  deviati on, etc) that i s likely to 
affect, to a significant degree one or more of the following:  (1) the physical, safet y or mental 
integrity of one or more subjects/participants; (2) the scient ific value o f the trial (eg, reliabilit y and 
robustness of generated data). Items (1) o r (2) can be associated with eit her GCP Regulat ion(s) or 
Trial protocol (s).
Personnel involved in conducting this study  will be qualified by educat ion, training, and 
experience to perform their respective tasks.
This study  will not use the services of study personnel where sancti ons have been invoked or where 
there has been scient ific misconduct or fraud (eg, loss of medical licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT E THICS COMMITTEE
Before study  initiation, the invest igator must have written and dated approval/favorable opinio n 
from the IRB/IEC for the protocol , consent form, participant recruitment materials 
(eg,advertisements), and any other written information to be provided to subjects/participants. The 
investigator or BMS should al so provi de the IRB/IEC with a copy  of the Investigator Brochure or 
product labeling informat ion to be provided to subjects/participants and any updates. 
Protocol Amendment No.: 04
Date: 22-Sep-2023 137
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
The invest igator, Sponsor or designee should provide the IRB/IEC with reports, updates and other 
infor mation (eg, expedited safet y reports, amendments, and administrative letters) according to 
regul atory  requi rements or i nstitution procedures.
COMPLIANCE WITH THE PROTOCOL AND PROTOCO L REVISIONS
The invest igator should not implement any deviati on or change to the protocol  without prior 
review and docum ented approval /favorabl e opini on of an amendment from the IRB/IEC (and if 
applicable, also by local health authori ty) except where necessary to eliminate an immediate 
hazard(s) to study  subjects/parti cipants. 
If a deviat ion or change to a protocol is implemented to eliminate an immediate hazard(s) prior to 
obtaining relevant approval/favorable opinio n(s) the deviat ion or change will be submitted, as soon 
as possible to:
ÔÇ∑IRB/IEC
ÔÇ∑Regulatory  Authori ty(ies), if app licable by  local regul ations (per nat ional requirements)
Docum entati on of approval /favorabl e opinio n signed by the chairperson or designee of the 
IRB(s)/IEC(s) and if applicable, also by local healt h authorit y must be sent to BMS.
If an amendment substant ially alters the study  design or increases the potential risk to the 
participant: (1) the consent form must be revised and submi tted to th e IRB(s)/IEC(s) for review 
and approval/favorable opinio n; (2) the revised form must be used to obtain consent from 
subjects/parti cipants currently enrolled in the study if they are affected by the amendment; and (3) 
the new form  must be used to obtain consent from new subjects/participants prior to enrollment.
If the revisio n is done via an administrative letter, investi gators m ust inform  their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Invest igators and sub-Invest igators will provi de the Sponsor with sufficient, accurate financia l 
inform ation in accordance with local regulati ons to allow the Sponsor to submit complete and 
accur ate financial certification or disclosure statem ents to the appropriate healt h authori ties. 
Invest igators are responsible for provi ding information on financial interests during the course of 
the study  and f or 1 year after complet ion of the study .
INFORMED CONSENT PROCESS
Invest igators must ensure that subjects/participants are clearly and fully informed about the 
purpose, potential risks, and other crit ical issues regarding clinical studies in which they vo lunteer 
to parti cipate. 
In situations where conse nt cannot be given by subjects/participants, their legally acceptable 
representatives (as per country  guidelines) are clearly and fully inform ed about the purpose, 
potenti al risks, and other critical issues regarding clinical studi es in which the partici pant 
volunteers to participate. 
Protocol Amendment No.: 04
Date: 22-Sep-2023 138
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Sponsor or designee will provide the invest igator with an appropriate (ie, Global or Local) sample 
inform ed consent form which will include all elem ents requi red by ICH, GCP and applicable 
regul atory  requirements. The sample inform ed consent form will adhere to the ethical principles 
that have their origin in the Declaration o f Helsinki.
Invest igators must:
ÔÇ∑Provi de a copy  of the consent form and written information about the study in the language in 
which the part icipant is most proficient prior to clinical study part icipation. The language must 
be non-technical and easily  understood. 
ÔÇ∑Allow time necessary for participant or participant's legally acceptable representative to 
inquire about the details o f the study .
ÔÇ∑Obtain an informed consent signed and personally dated by  the partici pant or the parti cipant's 
legally acceptable representative and by the person who conducted the informed consent 
discussio n. 
ÔÇ∑Obtain the IRB/IEC‚Äôs written approval/favorable opinio n of the written informed consent form 
and any other informat ion to be provided to the subjects/participants, prior to the beginning of 
the study , and afte r any  revisi ons are com pleted for new informat ion.
If inform ed consent is initially given by a partici pant‚Äôs legally acceptable representative or legal 
guardi an, and the participant subsequent ly beco mes capable of making and communicat ing his or 
her infor med consent during the study, consent must additionally be obtained from the participant.
Revise the informed consent whenever important new informat ion beco mes available that is 
relevant to the participant's consent. The invest igator, or a person designat ed by the invest igator, 
shoul d fully inform  the participant or the participant's legally acceptable representative or legal 
guardi an, of all pertinent aspects of the study  and of any new information relevant to the 
participant's willingness to conti nue participat ion in the study . This communication shoul d be 
docum ented. 
The confidenti ality of records that could identify  subjects/parti cipants must be protected, 
respecting the privacy and confident iality rules applicable to regulatory  requirements, the 
subje cts‚Äô/parti cipants‚Äô signed ICF and, in the US, the subjects‚Äô/participants‚Äô signed HIPAA 
Authori zation.
The consent form must also include a statem ent that BMS and regul atory  authori ties have direct 
access to participant records. 
The rights, safet y, and well-being of the study subjects/participants are the most important 
considerations and should prevail over interests of science and societ y.
SOURCE DOCUMENTS
The Investi gator is responsible for ensuring that the source data are accurate, legible, 
contem poran eous, ori ginal  and attributable, whether the data are hand -written on paper or entered 
electroni cally. If source data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electroni cally via computerized systems (and/or any other kind of electronic 
Protocol Amendment No.: 04
Date: 22-Sep-2023 139
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
devices) as part of regulated clinical trial activities, such system s must be compliant with all 
applicable laws and regulati ons governing use of electronic records and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/healt h records (EMRs/EHRs), 
adverse event tracking/reporting, protocol  required assessments, and/or drug accountabilit y 
records).
When paper records from such systems are used in place of electronic format to perform regul ated 
activit ies, such paper records should be certified copies. A certified copy  consists of a copy of 
original  informat ion that has been verified, as indicated by a dated signature, as an exact copy 
having all o f the sam e attri butes and informat ion as the original. 
STUDY TREATMENT RECO RDS
Records for study treatments (whether supplied by BMS, its vendors, or the site) must substant iate 
study  treatment integrity and traceabilit y from  receipt, preparation, administration, and through 
destruction or return. Records must be m ade available for revi ew at the request of BMS/desi gnee 
or a Health Authorit y.
If Then
Supplied by BMS (or its vendors): Records or logs must comply with applicable regulations 
and guidelines and should include:
ÔÇ∑amount received and placed in storage area
ÔÇ∑amount currently  in storage area
ÔÇ∑label ident ificat ion number or batch number
ÔÇ∑amount dispensed to and returned by  each 
participant, including unique participant ident ifiers
ÔÇ∑amount transferred to another area/site for 
dispensing or storage
ÔÇ∑nonstudy  disposi tion (eg, l ost, wasted) 
ÔÇ∑amount destroy ed at study  site, if applicable
ÔÇ∑amount returned to BMS
ÔÇ∑retain samples for 
bioavailabilit y/bioequivalence/bioco mparabilit y, if 
applicable 
ÔÇ∑dates and init ials of person responsible for 
Invest igational Pro duct dispensing/accountabilit y, as 
per the Delegat ion of Authorit y Form .
Sourced by site, and not supplied by 
BMS or its vendors (examples 
include IP sourced from the sites 
stock or commercial supply, or a 
specialt y pharmacy)The invest igator or designee accepts responsibility  for 
docum enting traceabilit y and study  treatment integri ty in 
accordance with requirements applicable under law and 
the SOPs/standards of the sourcing pharmacy.
Protocol Amendment No.: 04
Date: 22-Sep-2023 140
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
BMS or desi gnee will  provide forms to facilitate inventory  control  if the invest igational site does 
not have an established system that meets these requirements.
CASE REPORT FORMS
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observat ions and other data pertinent to the invest igation on each individual treated 
or entered as a control in the invest igation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source documents or the discrepancies must be 
explained. Addit ional clinical informat ion may be collected and analyzed in an effort to enhance 
understanding o f product safet y. CRFs may  be requested for AEs and/or laboratory  abnorm alities 
that are reported or ident ified during the course of the study .
For sites using the Sponsor or designee electronic data capture tool, electroni c CRFs will be 
prepared for all data collect ion fields except for fields specific to SAEs and pregnancy, which will 
be reported on the electroni c SAE form and Pregnancy Surveillance form,respect ively. If 
electroni c SAE form is not available, a paper SAE form can be used. Spaces may be left blank 
only in those circumstances permitted by study -specific CRF completion guidelines provi ded by 
Sponsor or designee. 
The confidenti ality of record s that could identify  subjects/parti cipants must be protected, 
respecting the privacy and confidentialit y rules in accordance with the applicable regulatory 
requi rement(s).
The invest igator will maintain a signature sheet to document signatures and init ials of all persons 
authori zed to m ake entri es and/or corrections on CRFs. 
The co mpleted CRF, SAE/pregnancy CRFs, must be pro mptly reviewed, signed, and dated by the 
investigator or qualified physician who is a subinvesti gator and who is delegated thi s task on the 
Delegati on of  Authori ty Form. Subinvest igators in Japan may not be delegated the CRF approval 
task. For electroni c CRFs, review and approval/signature is completed electroni cally through the 
BMS electroni c data capture tool. The invest igator must retain a copy  of the CRFs including 
records of the changes and corrections.
Each individual electronically signing electroni c CRFs must meet Sponsor or designee training 
requi rements and must only access the BMS electronic data capture tool using the unique user 
account provided by Sponsor or designee. User accounts are not to be shared or reassigned to other 
individuals
MONITORING
Sponsor or designee representatives will review data centrally to ident ify potenti al issues to 
determine a schedule of on -site visits for targeted review o f study  records. 
Representatives of BMS must be allowed to visit all study  site locati ons peri odically to assess the 
data qualit y and study  integrity. They will review study  records and direct ly compare them with 
source documents , discuss the conduct of the study  with the invest igator, and verify that the 
Protocol Amendment No.: 04
Date: 22-Sep-2023 141
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
facilit ies remain acceptable. Certain CRF pages and/or electronic files may serve as the source 
docum ents:
In addi tion, the study  may be evaluated by  Sponsor or desi gnee internal auditors and government 
inspectors who must be allowed access to CRFs, source documents, other study  files, and study 
facilit ies. BMS audit reports will be kept confidential.
The investigator must notify BMS prom ptly of any inspect ions scheduled by regula tory authori ties, 
and prompt ly forward copi es of  inspect ion reports to Sponsor or designee. 
RECORDS RETENTION
The invest igator (or head of the study  site in Japan) must retain all study records and source 
docum ents for the maximum period requi red by appli cable regulat ions and guidelines, or 
institution procedures, or for the period specified by BMS or designee, whichever is longer. The 
investigator (or head of the study site in Japan) must contact BMS prior to destroying any records 
associ ated wi th the stu dy.
BMS or desi gnee will notify the invest igator (or head of the study  site in Japan) when the study 
records are no longer needed.
If the investigator withdraws from the study  (eg, relocation, retirement), the records shall be 
transferred to a m utually  agreed upon desi gnee (eg, another investi gator, study  site, IRB). Noti ce 
of such transfer will be given in writ ing to BMS or designee. 
RETURN OF STUDY TREA TMENT
For thi s study , study  treatm ents (those supplied by  BMS, a vendor or sourced by  the invest igator)
such as partially  used study  treatm ent containers, vials and syringes may  be destroy ed on si te. 
If.. Then
Study  treatments supplied by BMS (including 
its vendorsAny unused study treatments supplied by BMS 
can only be destroyed after being inspected and
reconciled by the responsible Study  Monitor 
unless study  treatm ents containers must be 
immediately  destroy ed as requi red for safet y, 
or to meet local regulat ions (eg, cytotoxi cs or 
biologics).
If study  treatm ents will  be returned, the return 
will be arran ged by the responsible Study 
Moni tor.
Study  treatm ents sourced by site, not supplied 
by BMS (or its vendors) (examples include 
study  treatm ents sourced from the sites stock 
or commercial supply , or a specialt y 
pharmacy)It is the investigator‚Äôs or designe e‚Äôs 
responsibilit y to dispose of all containers 
according to the institutional guidelines and 
procedures.
Protocol Amendment No.: 04
Date: 22-Sep-2023 142
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
It is the invest igator‚Äôs or designee‚Äôs responsibilit y to arrange for disposal, provided that procedures 
for proper disposal have been established according to applicable federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
The fo llowing minimal standards must be met:
ÔÇ∑On-site disposal  pract ices must not expose humans to risks fr om the drug.
ÔÇ∑On-site disposal pract ices and procedures are in agreement with applicable laws and 
regul ations, including any special requirements for controlled or hazardous substances.
ÔÇ∑Written procedures for on-site disposal  are available and followed. The procedures must be 
filed with the site‚Äôs SOPs and a copy  provi ded to BMS upon request.
ÔÇ∑Records are maintained that allow for traceabilit y of each container, including the date 
disposed of, quanti ty disposed, and ident ification of the person disposing the containers. The 
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor 
must be documented.
ÔÇ∑Accountabilit y and disposal  records are complete, up- to-date, and available for the Monitor to 
review throughout the clin ical tri al peri od.
It is the invest igator‚Äôs or designee‚Äôs responsibilit y to arrange for di sposal  of all empt y containers.
If condit ions for destruction cannot be met the responsible Study Monitor will make arrangements 
for return of study treatments provi ded by BMS (or its vendors). Destruction of non-study 
treatm ents sourced by the site, not supplied by BMS, is solely the responsibilit y of the invest igator 
or desi gnee.
CLINICAL STUDY REPOR T
A Signatory  Invest igator must be selected to sign the clinical s tudy report. 
For each CSR related to thi s protocol , the following criteria will be used to select the signatory 
investigator:
ÔÇ∑External Principal Invest igator designated at protocol development
ÔÇ∑Study  Steering Committee chair or their designee
ÔÇ∑Parti cipant 
recruitment (eg, among the top quartile of enrollers)
ÔÇ∑Involvement in trial design
ÔÇ∑Regional representati on (eg, among top quartile of enro llers fro m a specified region or country)
SCIENTIFIC PUBLICATI ONS
The data collected during thi s study  are confident ial and propri etary  to Sponsor or desi gnee. Any 
publicat ions or abstracts arising from this study  must adhere to the publicat ion requi rements set 
forth in the clinical trial agreement (CTAg) governing [Study  site or Invest igator] participat ion in 
the study . These requi rements include, but are not limited to, submitting proposed publicat ions to 
Protocol Amendment No.: 04
Date: 22-Sep-2023 143
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Sponsor or designee at the earliest practicable time prior to submissio n or presentation and 
otherwi se wi thin the time period set forth in the CTAg.
Scientific Publicat ions (such as abstracts, congress podium presentati ons and posters, and 
manuscripts) of the study  resul ts will be a collaborative effort between the study  Sponsor and the 
external authors. No public presentation or publication of any interim results may be made by any 
principal invest igator, sub-invest igator or any other member of the study staff without the prior 
written consent of the Sponsor.  
Authorship of publicat ions at BMS is aligned with the criteria of the International Committee of 
Medical Journa l Editors (ICMJE, www.icmje.org). Authorship select ion is based upon significant 
contributions to the study  (ie, ICMJE criterion #1). Authors must meet all 4 ICMJE criteria for 
authorship:
1)Substant ial intellectual contribut ion to the conception or design o f the work; or the acquisit ion 
of data (ie, evaluable subjects with qualit y dat a), analysis, or interpretation of data for the work 
(eg, problem so lving, advice, evaluat ion, insights and conclusio n); AND
2)Drafting the work or revising it crit ically for impo rtant intellectual content; AND
3)Final approval of the versio n to be published; AND
4)Agreement to be accountable for all aspects of the work in ensuring that questions related to 
the accuracy  or integri ty of any part of  the work are appropriately invest igated and reso lved.
Those who make the mo st significant contribut ions, as defined above, will be considered by BMS 
for authorship of the primary publicat ion. Sub-investigators will generally  not be considered for 
authorship in the primary  publicat ion. Geograp hic representation will also be considered.  
Authors will be listed by  order of  significant contribut ions (highest to l owest), wi th the except ion 
of the last author. Authors in fir st and last position have provided the mo st significant contributions 
to the work. 
For secondary analyses and related publicat ions, author list and author order may vary from 
primary to reflect addi tional contribut ions.
Protocol Amendment No.: 04
Date: 22-Sep-2023 144
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
APPENDIX 3 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENT S: 
DEFINITIONS AND PROC EDURES FO R RECORDING, 
EVALUATING, FOLLOW -UP,AND REPO RTING
ADVERSE EVENTS
Adverse Event Definition:
An Adverse Event (AE) i s defined as any  new untoward m edical  occurrence or worsening of a 
preexist ing medical condit ion in a c linical invest igation partici pant administered study  treatm ent
and that does not n ecessarily have a causal relat ionship wit h this treatm ent. 
An AE can therefore be any unfavorable and unintended sign (such as an abnorm al laboratory 
finding), symptom, or disease temporally associated with the use o f study treatment, whether or 
not cons idered related to the study treatment.
Events Meeting the AE Definition
ÔÇ∑Any abnorm al laboratory  test results (hematol ogy, clinical chemistry , or urinalysis) or 
resul ts from other safet y assessments (eg, ECG, radio logical scans, vital signs 
measurements), including those that worsen from baseline, considered clinically significant 
in the medical and scientific judgment of the investigator. Note that abnormal lab tests or 
other safet y assessments shoul d only be reported as AEs if the final diagnosis is not
available. Once the final diagnosis is known, the reported term  should be updated to be the 
diagnosis .
ÔÇ∑Exacerbat ion of a chronic or intermittent pre -existing condit ion including eit her an increase 
in frequency and/or intensit y of the condit ion.
ÔÇ∑New condit ions detected or diagnosed after study intervent ion administration even though it 
may have been present before the start of the study.
ÔÇ∑Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
ÔÇ∑Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  intervent ion 
or a conco mitant medicat ion. Overdose, as a verbatim term (as reported by the invest igator), 
shoul d not be reported as an AE/SAE unless it is an intent ional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardl ess of sequelae and 
shoul d specify "intent ional overdose" as the verbatim term
Events NOT Meeting the AE Definition
ÔÇ∑Medical or surgical procedure (eg, endoscopy , appendectomy): the condi tion that leads to 
the procedure is the AE.
ÔÇ∑Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospital).
DEFINITION OF SAE
If an event i s not an AE per definit ion above, then it cannot be an SAE even if serious condi tions 
are met.
Protocol Amendment No.: 04
Date: 22-Sep-2023 145
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
SERIOUS ADVERSE EVEN TS
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any 
dose:
Results in death
Is life-threatening (defined as an event in which the participant was at ri sk of  death at the time 
of the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe)
Requi res inpat ient hospitalization or causes prolongation of exist ing hospi talizat ion (see NOTE 
below)
NOTE:
The fo llowing hospi talizati ons are not consi dered SAEs in BMS clinical studies: 
ÔÇ∑a visit to the emergency room  or other hospi tal departm ent < 24 hours, that does not resul t 
in admissio n (unless considered an important medical or life -threatening event)
ÔÇ∑elective surgery, planned prior to signing consent
ÔÇ∑admissio ns as per protocol for a planned medical/surgical procedure
ÔÇ∑routi ne healt h assessment requiring admission for baseline/trending of health status (eg, 
routi ne col onoscopy )
ÔÇ∑medical/surgical admissio n other than to remedy ill healt h and planned prior to entry into 
the study . Appropri ate docum entati on is requi red in these cases
ÔÇ∑admissio n encountered for another life circumstance that carries no bearing on healt h status 
and requi res no medical/surgical interventi on (eg, lack of housing, economic inadequacy, 
caregiver respite, family circumstances, administrative reason)
ÔÇ∑admissio n for administration of anticancer therapy in the absence of any other SAEs (applies 
to oncology  protocol s)
Results in persistent or significant di sabili ty/incapaci ty
Is a congenital ano maly/birth defect
Is an important m edical event (defined as a medical event(s) that m ay not be immediately life-
threatening or resul t in death or hospi talizat ion but, based upon appropriate medical and 
scientific judgment, may jeopardi ze the participant or may require intervent ion [eg, medical, 
surgi cal] to prevent one of the other seri ous outcomes listed in the definit ion above.) Examples 
of such events include, but are not limited to, intensive treatm ent in an emergency  room or at 
home for allergic bronchospasm; blood dyscrasias or convulsio ns that do not resul t in 
hospi talizati on.) Potenti al drug induced liver injury  (DILI) is also considered an important 
medical event. (See Section 9.3.
7for the definit ion of potenti al DILI.) 
Pregnancy and potenti al drug induced liver injury (DILI) must follow the same transmissio n timing 
and processe s to BMS as used for SAEs (see S ection 9. 3.5 for reporting pregnancies).
Protocol Amendment No.: 04
Date: 22-Sep-2023 146
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Any co mponent of a study  endpoint that is considered related to study therapy should be reported 
as SAE (eg, death is an endpo int, if death occurred due to anaphylaxis, anaphylaxis must be 
reported).
EVALUATING AES AND S AES
Assessment of Causality
ÔÇ∑The invest igator i s obligated to assess the relationship between study  intervent ion and each 
occurrence of each AE/SAE.
ÔÇ∑A ‚Äúreasonable possibilit y‚Äù of a relationship conveys that there are facts, evidence, and/or 
argum ents to suggest a causal relationship, rather than a relat ionship cannot be rul ed out.
ÔÇ∑The invest igator will use clinical judgment to determine the relat ionship.
ÔÇ∑Alternat ive causes, such as underlying disease(s), concomitant therapy , and other risk 
factors, as well as the temporal relat ionship of the event to study intervent ion administr ation 
will be considered and invest igated.
ÔÇ∑The invest igator will also consult the Investigator‚Äôs Brochure (IB) and/or Product 
Inform ation, for marketed products, in his/her assessment.
ÔÇ∑For each AE/SAE, the invest igator mustdocument in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
ÔÇ∑There may be situations in which an SAE has occurred and the invest igator has minima l 
inform ation to include in the init ial report to Sponsor. However, it is very  important that the 
investigator always make an assessment of causalit y for every event before the initial 
transmissio n of the SAE data to Sponsor.
ÔÇ∑The invest igator may change his/her opinio n of causalit y in light of follow-up informat ion 
and send a SAE fo llow-up report with the updated causalit y assessment.
ÔÇ∑The causalit y assessment is one of the criteria used when determining regul atory  reporting 
requi rements.
Follow -up of AEs and SAEs
If only limited informat ion is initially available, follow-up reports are requi red. (Note: Foll ow-
up SAE reports must include the same invest igator term(s) init ially reported.) 
If an ongoing SAE changes in its intensit y or relationship to study  treatm entor if new 
inform ation beco mes available, the SAE report must be updated and submitted within 24 hours 
to BMS (or designee) using the same procedure used for transmitt ing the init ial SAE report.
All SAEs must be fo llowed to resol ution or stabilization.
Protocol Amendment No.: 04
Date: 22-Sep-2023 147
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
REPORTING OF SAES TO SPONSOR OR DESIGNEE
ÔÇ∑SAEs, whether related or not related to study  treatment, and pregnancies must be reported 
to BMS (or designee) immediately wit hin 24 hours of awareness of the event.
ÔÇ∑SAEs m ust be recorded on the SAE Report Form.
ÔÄ≠Therequi red m ethod for SAE data reporting is through the eCRF.
ÔÄ≠The paper SAE Report Form  is only intended as a back-up option when the electronic 
data capture (EDC) sy stem  is unavailable/not functi oning for transmissio n of the eCRF 
to BMS (or designee).
ÔÇ®In this case, the paper form is transmitted via email  or confirmed facsimile (fax) 
transmissio n
ÔÇ®When paper forms are used, the original paper forms are to remain on site
ÔÇ∑Pregnancies must be recorded on a paper Pregnancy Surveillance Form and transmitted via 
email or confi rmed facsimile (fax) transmissio n 
SAE Email Address: Refer to Contact Information list.
SAE Facsimile Number: Refer to Contact Information list.
SAE Telephone Contact (required for SAE and pregnancy  reporti ng): Refer to Contact 
Inform ation list
Protocol Amendment No.: 04
Date: 22-Sep-2023 148
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
APPENDIX 4 WOMEN OF CHILDBEARIN G POTENTIAL DEFINITION S AND 
METHODS OF CONTRACEP TION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal unless 
perm anent ly sterile. Perm anent sterilizat ion methods include hysterectomy, bilateral 
salpingectomy , and bilateral  oophorectomy.
Women in the following categories are not considered WOCBP
ÔÇ∑Prem enarchal
ÔÇ∑Prem enopausal  female wi th 1 of the f ollowing:
ÔÄ≠Docum ented hysterectomy
ÔÄ≠Docum ented bilateral  salpingectomy
ÔÄ≠Docum ented bilateral  oophorectomy
Note: Docum entati on can come from the site personnel‚Äôs review of the partici pant‚Äôs medica l 
records, medical examinat ion, or m edical history  interview.
ÔÇ∑Postmenopausal  female
ÔÄ≠A postm enopausal  state is defined as 12 months of amenorrhe a in a wom an over age 
45years in the absence of other biological or physi ological causes. In addition, females 
under the age of 55 years must have a serum  follicle stimulat ing horm one, (FSH) level 
>
40mIU/mL to confirm menopause.
CONTRACEPTION GUIDAN CE FOR MALE PARTICIPANT S WITH PARTNER(S) OF
CHILD BEARING POTENTIAL DURING TREATMENT WIT H DOCETAXEL
Male participants with female partners of childbearing potenti al are eligible to participate if they 
agree to the following during treatm ent with docetaxel and until the end of relevant systemic 
exposure.
ÔÇ∑Inform  any and all partner(s) of their participation in a clinical drug study  and the need to 
comply with contracepti on instructi ons as di rected by  the investi gator.
ÔÇ∑Male participants are requi red to use a condom for study  duration and until end of relevant 
systemic exposure ,defined as 6months after the end of study  treatm entwith docetaxel .
ÔÇ∑Female partners of males participat ing in the study  to consider use of effective methods of 
contraception unt il the end o f relevant systemic exposure, defined as 6months after the end o f 
treatm ent with docetaxel in the male participant.
ÔÇ∑Male participants with a pregnant or breastfeeding partner must agree to remain abst inent fro m 
penile vaginal intercourse or use a male condom during each episode of penile penetrati on 
during the treatment and until 6months after the end of study  treatm entwith docetaxel . 
Protocol Amendment No.: 04
Date: 22-Sep-2023 149
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
ÔÇ∑Refrain from donating sperm  for th e duration of the study  treatment and until 6months after 
the end of study  treatm entwith docetaxel .
COLLECTION OF PREGNA NCY INFORMATION
Guidance for collection of Pregnancy  Inform ation and outcom e of pregnancy on the Pregnancy 
Surveillance Form  is provi ded in Sect ion 9.3.5 and the Appendix for Adverse Events and Serious 
Adverse Events Definit ions and procedures for Evaluat ing, Fo llow
-up and Reporti ng.
Protocol Amendment No.: 04
Date: 22-Sep-2023 150
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
APPENDIX 5 PROSTATE CANCER WORK ING GROUP 3 (PCWG3)
GUIDELINES (WITH MODIFIED RESP ONSE EVALUATION 
CRITERIA IN SOLID TU MORS (RECIST) CRITER IA FOR SOFT 
TISSUE LESION ASSESS MENT)
Not applicable per Protocol Amendment 04.
1 EVALUATION OF LESION S
Bone lesions shoul d be evaluated with Technecium -99m based radionuclide bone scan as per 
PCWG31.
At baseline, soft tissue lesio ns/lymph nodes will be categorized as measurable or non -measurable 
as fo llows. 
1.1 Measurable
Tumor lesio ns: Must be accurately meas ured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:
10mm by CT/MRI scan (scan slice thickness no greater than 5 mm), or ÔÇ≥2x slice thickness if 
greater than 5 mm.
Malignant lymph nodes: To be considered patho logically  enlarged and measurable, a lymph node 
must be ÔÇ≥15 mm in short axis when assessed by CT /MRI scan (scan slice thickness reco mmended 
to be no greater than 5 mm).
Lymph nodes merit special ment ion since they are norm al anatomi cal structures which may be 
visible by imaging even if not involved by tumor. Pathol ogical  nodes which are defined as 
measurable and may be ident ified as target lesions must meet the criterion of a  short axis of
ÔÇ≥15mm by CT /MRI scan. Only  the short axi s of these nodes will contribute to the baseline sum. 
The short axis of the node is the diameter norm ally used by radiologists to judge if a node is 
involved by  solid tum or. Nodal  size is norm ally reported as two dimensions in the plane in which 
the image isobtained (for CT scan this is almost always the axial plane; for MRI the plane of 
acquisit ion may be axial, sagi ttal or coronal ). The smaller of these measures is the short axi s. For 
example, an abdo minal node which is reported as being 20 mm x 30 mm has a short axis o f 20mm 
and qualifies as a malignant, m easurable node. In this example, 20 mm  should be recorded as the 
node measurement. All other pathological nodes (those with short axis ÔÇ≥10 mm but < 15 mm) 
shoul d be considered non-target lesions. Nodes that have a short axis < 10 mm are considered 
non-patho logical and should not be recorded or fo llowed.
Note: Lesi ons on X -Ray are not to be selected as Target or Non -Target Lesions.
1.2 Non-Measurable
All other soft tissue lesions are considered non-measurable , including small  lesions (longest 
diameter < 10mm or pathol ogical lymph nodes with ÔÇ≥10 to < 15 mm short axi s) as well as truly 
non-measurable lesions. Lesio ns considered truly non-measurable include: leptomeningeal 
Protocol Amendment No.: 04
Date: 22-Sep-2023 151
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
disease, inflammatory  breast disease, lymphangiti c involvement of skin or lung, abdo mina l 
masses/abdo minal organomegaly  identified by physical exam  that is not measurable by 
reproducible imaging techniques.
Note: Lesi ons on X -Ray are not to be selected as Target or Non -Target Lesions.
1.3 Special c onsiderations regarding bone lesions
Bone lesio ns will be assessed (as non-target lesions) with Technecium -99m based radionuclide 
bone scans as per PCWG3.
1.4 Baseline Documentation Of ‚ÄòTarget‚Äô And ‚ÄòNon- Target‚Äô Lesions
When more than one measurable lesio n is present at baseline all lesio ns up to a maximum of 
20lesio ns total (and a maximum of 
5lesions per organ system )representative of all involved 
organs should be ident ified as target lesio ns and will be recorded and measured at baseline .
Note: A maximum of 5lesio ns can be selected per organ system . For example, a maximum of 
5lung lesions can be selected . A maximum of 5lymph nodes can be selected at baseline, as the 
lymphat ic system is considered one organ.
Target l esions shoul d be selected on the basis of their size (l esions wi th the longest di ameter), be 
representative of all involved organs, but in additi on shoul d be those that lend themselves to 
reproducible repeated m easurem ents. It m ay be the case that, on occasi on, the largest lesio n does 
not lend itself to reproducible measurement in which circumstance the next largest lesion which 
can be measured reproducibly should be selected.
A sum of the diameters (longest for non-nodal  lesions, short axis for nodal  lesions) for all target 
lesions will be calcul ated and reported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then as noted above, only the short axi s is added into the sum . The baseline 
sum diameters will be used as ref erence to f urther characteri ze any objective tum or regression in 
the measurable dimensio n of the disease.
All other lesions (or sites of disease) including patho logical lymph nodes shoul d be identified as 
non-target lesio ns and shoul d also be recorded at baseline. Pelvic lymph nodes and extrapelvic 
lymph nodes (retroperi toneal, mediastinal, thoracic and other) may be reported separately, per 
PCWG3. Measurements are not required and these lesions shoul d be followed as ‚Äòpresent‚Äô, 
‚Äòabsent‚Äô, or in rare cases ‚Äòunequivocal progression‚Äô (more details to follow). In addition, it is 
possible to record mult iple non -target lesio ns invo lving the same organ as a single item on the case 
record form (eg, ‚Äòm ultiple enlarged pelvic lymph nodes‚Äô or ‚Äòmult iple liver metastases‚Äô).
2 RESPONSE CRITERIA
2.1 Evaluation of Target Lesions
ÔÇ∑Complete Response (CR): Disappearance o f all target lesio ns. Any pathological lymph nodes 
(whether target or non -target) m ust have reduct ion in short axi s to < 10 mm.
ÔÇ∑Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions,
taking as reference the baseline sum diameters.
Protocol Amendment No.: 04
Date: 22-Sep-2023 152
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
ÔÇ∑Progressive Disease (PD): At least a 20% increase in the sum of  diameters of target l esions, 
taking as reference the smallest sum on study  (this includes the baseline sum if that is the 
smallest on study ). In addit ion to the rel ative increase of 20%, the sum must also demonstrate 
an abso lute increase of at least 5 mm. (Note: the appearance of one or more new lesio ns is also 
considered progression).
ÔÇ∑Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify  for PD, taking as reference the smallest sum diameters while on study .
ÔÇ∑Not Evaluable (NE): If one or more target lesions cannot be measured or adequately assessed 
as either fully resolved or too sm all to measure (due to missing or poor quali ty images), and 
the sum of diameters of the remaining measured target lesions (if any) has not increased 
sufficient ly to meet Progressive Disease as defined above. 
2.1.1 Special Notes on the Assessment of Target Lesions
2.1.1.1 Lymph nodes
Lymph nodes ident ified as target lesions shoul d always have the actual short axis measurement 
recorded (m easured in the same anatomical plane as the baseline examinati on), even if the nodes 
regress to below 10 mm o n study. This means that when lymph nodes are included as target lesions, 
the ‚Äòsum‚Äô of lesions may not be zero even if compl ete response criteria are met, since a norm al 
lymph node is defined as having a short axis of < 10 mm. Case report forms or other data collectio n 
methods may therefore be designed to have target nodal lesio ns recorded in a separate sectio n 
where, in order to qualify  for CR, each node m ust achieve a short axis < 10 mm . For PR, SD ,and 
PD, the actual short axis measurement of the nodes is to be included in the sum of target lesio ns.
2.1.1.2 Target lesions that become ‚Äòtoo small to measure‚Äô
While on study , all lesions (nodal  and non-nodal ) recorded at baseline shoul d have their actual 
measurements recorded at each subsequent evaluation, even when very small (eg,2 mm). 
However, sometimes lesions or lymph nodes which are recorded as target lesions at baseline 
beco me so faint on CT scan that the radiologist may not feel comfortable assigning an exact 
measure and may report them as being ‚Äòtoo small to measure‚Äô. When this occurs it is important
that a value be recorded on the case report form. If it is the opinion o f the radio logist that the lesio n 
has likely disappeared, the measurement should be recorded as 0 mm . If the lesi on is believed to 
be present and is faint ly seen but too small to meas ure, a default value of 5 mm should be assigned
as the ref erence diameter. (Note: It is less likely that thi s rule will be used for lymph nodes since 
they usually  have a definable size when normal and are frequent ly surrounded by fat such as in the 
retrope ritoneum; however, if a lymph node is believed to be present and is faintly seen but too 
small to m easure, a def ault value of  5 mm shoul d be assigned in this circumstance as well). This 
defaul t value is derived fro m the 5 mm CT slice thickness (but should not be changed with varying 
CT slice thickness). The measurement of these lesions is potenti ally non-reproducible, therefore 
provi ding this default value will prevent false responses or progressions based upon measurement 
error. To rei terate, however, if t he radiologist i s able to provi de an actual  measure, that shoul d be 
recorded, even if it is below 5 mm.
Protocol Amendment No.: 04
Date: 22-Sep-2023 153
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
2.1.1.3 Lesions that split or coalesce on treatment
When non-nodal  lesions ‚Äòfragment‚Äô, the longest diameters of the fragmented portions shoul d be 
added together to calculate the target lesion sum. Similarly, as lesions coalesce, a plane between 
them may be maintained that would aid in obtaining maximal diameter measurements of each 
individual lesion. If the lesions have truly coalesced such that they are no longer separable, the 
vector of the longest diameter in this instance shoul d be the maximal longest diameter for the 
‚Äòcoal esced lesio n‚Äô.
2.2 Evaluation of Non -Target Lesions
This section provides the defini tions of the criteria used to de termine the tumor response for the 
group of non -target lesio ns. While some non -target lesio ns may actually be measurable, they need 
not be measured and instead shoul d be assessed only qualitatively at the time points specified in 
the protocol.
ÔÇ∑Complete Response (CR): Disappearance o f all non-target l esions. All lymph nodes must be 
non-patho logical in size (< 10mm short axis). 
ÔÇ∑Non-CR/Non -PD: Persistence of one or more non -target l esion(s)
ÔÇ∑Progressive Disease (PD): Unequivocal progressio n (see below) of existing non-target 
lesions.
2.2.1 Special Notes on Assessment of Progression of Non -Target Disease
The concept of progression of non -target di sease requi res addi tional explanati on as fo llows:
2.2.1.1 When the patient also has measurable disease
In this setting, to achieve ‚Äòunequivocal progressi on‚Äô on the basis of the non-target disease, there 
must be an overall level o f substant ial worsening in non -target di sease such that, even in presence 
of SD or PR in target disease, the overall tumor burden has increased sufficient ly to merit 
discontinuat ion of therapy (see examples in Appendix 2 and further details below). A modest 
‚Äòincrease‚Äô in the size of one or more non-target lesio ns is usually not sufficient to qualify for 
unequivocal progressi on status . Pleural effusio ns, pericardial effusi ons and ascites will not be 
followed as target or non-target lesions and will not contribute to response or progression. The 
designation of overall progressi on solely on the basis of change in non-target disease in the face 
of SD or PR of target disease will therefore be extremely rare.
2.2.1.2 When the patient has only non -measurable disease
This circumstance arises in so me trials when it is not a criterion of study entry to have measurable 
disease. The same general  concepts apply here as noted above, however, in this instance there is 
no measurable disease assessment to factor into the interpretati on of an increase in non -measurable 
disease burden. Because worsening in non -target disease cannot be easily quant ified (by defini tion: 
if all lesio ns are truly non -measurable) a useful test that can be applied when assessing patients for 
unequivocal progressi on is to consider if the increase in overall  disease burden based on the change 
in non-measurable disease is comparable in magnitude to the increase that would be requi red to 
declare PD for measurable disease: ie, an increase in tumor burden represent ing an addit ional 73% 
Protocol Amendment No.: 04
Date: 22-Sep-2023 154
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
increase in ‚Äòvolume‚Äô (which is equivalent to a 20% increase diameter in a measurable lesion). 
Examples includ e, an increase in lymphangit ic disease from localized to widespread, or may be 
described as ‚Äòsufficient to requi re a change in therapy‚Äô. If ‚Äòunequivocal  progressi on‚Äô is seen, the 
patient shoul d be considered to have had overall PD at that point. While it w ould be i deal to have 
objective criteria to apply to non-measurable disease, the very nature of that disease makes it 
impossible to do so; therefore the increase must be substant ial.
2.2.2 New Lesions
New bone lesio ns
New bone lesions shoul d be evaluated as per PCWG3 criteria.Bone lesions will be assessed by 
radionuclide bone scan only. Radiographic progressio n on bone scan is defined by the following 
criteria:
ÔÇ∑At least 2 new lesions on the first post -treatm ent bone scan, with at least two addit ional lesio ns
on the next scan (performed at least 6 weeks later) as compared to the first post -treatment bone 
scan. Date of progression is then the date of first post- treatm ent scan .
ÔÇ∑For scans after the first post-treatm ent scan, at least 2 new lesions relative to the first post-
treatm ent scan AND confirmed on a subsequent scan (perform ed at l east 6 weeks l ater). Date 
of progressi on is the date of the scan that fi rst docum ents at least 2 new lesi ons relat ive to the 
first post -treatm ent scan .
New soft tissue lesio ns
The appearance of new malignant soft tissue lesio ns denotes disease progression; therefore, some 
comments on detecti on of new lesions are important. There are no specific criteria for the 
ident ificat ion of new radiographic lesions; however, the finding of a new lesion shoul d be 
unequivocal: ie, not attributable to differences in scanning technique, change in imaging modalit y 
or findings thought to represent something other than tumor. This is particularly  important when 
the patient‚Äôs baseline lesions show partial or complete response. For example, necrosis of a  liver 
lesion may  be reported on a CT scan report as a ‚Äònew‚Äô cyst ic lesio n, which it is not.
NOTE: Fluid collect ions (pleural  effusio ns, pericardial  effusions, and ascites) will not be 
considered new l esions and will not contribute to response or progression. In the event a new fluid 
collect ion is seen on a post -baseline imaging exam, a comment m ay be made, but the appearance 
of a new fluid collect ion alone shoul d not resul t in an assessment of Progress ive Disease (PD). A 
lesion ident ified on a follow-up study  in an anatomical location that was not scanned at baseline 
is considered a new lesio n and will indicate disease progression. An example of this is the pat ient 
who has visceral disease at baseline and while on study has a CT or MRI brain ordered which 
reveals metastases. The patient‚Äôs brain metastases are considered to be evidence of PD even if 
he/she did not have brain imaging at baseline. A lesion ident ified on Chest X-Ray that was not 
present in p rior CT can be considered a new lesio n and will result in Progressive Disease (PD).
If a new lesio n is equivocal, for example because of it s small size, continued fo llow-up evaluat ion 
will clarify  if it represents truly new disease. If repeat scans confirm there is definitely  a  new 
lesion, then progressi on shoul d be declared using the date of the init ial scan.
Protocol Amendment No.: 04
Date: 22-Sep-2023 155
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
2.3 Response Assessment
2.3.1 Evaluation of Best Overall Response
The best overall response is the best response recorded from  the start of the study  treatm entuntil 
disease progressi on per PCWG3 criteria, or the last response recorded, taking into account any 
requi rement for confirmat ionand censoring rules regarding subsequent therapy . The patient‚Äôs best 
overall response assignment will depend on the findings of both target and non -target disease and 
will also take into consideration the appearance of new lesions. Furtherm ore, depending on the 
nature of the study  and the protocol  requi rements, it m ay also requi re confi rmatory  measurement.
2.3.2 Time Point Response
At each protocol -specified time point, a response assessment occurs. Table 2.3.2 -1provides a 
summary of the overall response status calculation at each time point for patients who have 
measurable disease at baseline. When patients have non -measurable (therefore non -target) disease 
only, Table 2.3.2 -2is to be used. 
Table 2.3.2 -1: Time Point Response
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/no n-PD No PR
CR Not evaluated No PR
PRNon-PD or not all 
evaluatedNo PR
SDNon-PD or not all 
evaluatedNo SD
Not all evaluated Non-PD No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease and NE = inevaluable
Table 2.3.2 -2: Time Point Response
Non-Target Lesions New Lesions Overall Response
CR No CR
Non-CR/no n-PD No Non-CR/no n-PDa
Not all evaluated No NE
Unequivocal PD Yes or No PD
Any Yes PD
CR = complete response, PD = progressive disease and NE = inevaluable
Protocol Amendment No.: 04
Date: 22-Sep-2023 156
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
aNon-CR/no n-PD is preferred over SD for non-target disease since SD is increasingly used as endpoint for 
assessment of efficacy in some trials so to assign this category when no lesions can be measured is not advised.
2.3.3 Best Overall Response 
Best response determination of complete or partial response requi res confirmation: Complete or 
partial responses may be claimed only if the criteria for each are met at a subsequent time point of 
ÔÇ≥4 weeks (28 days) later. In thi s circumstance, the best overall  response can be interpreted as in 
Table 2.3.3 -1. When SD is believed to be best response, it must meet the protocol -specified 
minimum t ime from the date of first treatment or rando mizat ion date.
For example, if the first scheduled follow-up imaging visit is Week 6 (ÔÇ±7 days) for a particular 
protocol , a Best Response of SD can only be made after the subject is on -study  for a minimum  of 
6 weeks (42 days) minus 7 days, for an absolute minimum time on-study  of 35 days from the 
reference start date (reference date is considered Day 1 on study). If the subject is not on -study  for 
at least this amount of time, any tumor assessment indicat ing stable disease before this time period 
will have a Best Response of NE unless PD is identified.
Special note on response assessment: When nodal disease is included in the sum o f target lesio ns 
and the nodes decrease to ‚Äònorm al‚Äô size (< 10 mm), they  may still have a measurement reported 
on scans. T his measurement should be recorded even though the nodes are normal in order not to 
overstate progression shoul d it be based on increase in size of the nodes. As noted earlier, this 
means that patients with CR may not have a total sum of ‚Äòzero‚Äô on the case report form (CRF).
Table 2.3.3 -1: Best Overall Response (Confirmation of CR&PR Required)
Overall Response 
First Time PointOverall Response 
Subsequent Time PointBEST Overall Response
CR CR CR
CR PR SD, PD OR PRa
CR SDSD provided minimum criteria for SD duration met, otherwise, 
PD
CR PDSD provided minimum criteria for SD duration met, otherwise, 
PD
CR NESD provided minimum criteria for SD duration met, otherwise, 
NE
PR CR PR
PR PR PR
PR SD SD
PR PDSD provided minimum criteria for SD duration met, otherwise, 
PD
PR NESD provided minimum criteria for SD duration met, otherwise, 
NE
NE NE NE
Protocol Amendment No.: 04
Date: 22-Sep-2023 157
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, and NE = inevaluable
aIf a CR is truly  met at first time point, then any  disease seen at a subsequent time point, even disease meeting PR 
criteria relative to baseline, makes the disease PD at that point (since disease must have reappeared after CR). Best 
response would depend on w hether minimum duration for SD was met. However, sometimes ‚ÄòCR‚Äô may be claimed 
when subsequent scans suggest small lesions were likel y still present and in fact the patient had PR, not CR  at the 
first time point. Under these circumstances, the original CR should be changed to PR and the best response is PR.
2.3.4 Confirmation Scans
Verification of Response: To be assi gned a status of CR or PR, changes in tumor m easurements 
must be confi rmed by consecut ive or subsequent repeat assessments that should be performed no 
less than 28days after the criteria for response are first met. Subsequent documentation of a CR 
may provi de confirmat ion of aprevi ously ident ified CR even with an intervening NEor PR 
(eg,CR NE CR or CR PR CR ).Subsequent documentation of a PR may provide confirmat ion of 
apreviously ident ified PR even with an intervening NE 
or SD (eg, PR NE PR or PR SD PR). 
However, only one (1) intervening time point will be allowed between PR /CRs for confirmat ion.
Verification of Progression :Progressi on of disease should be verified in cases where progression 
is equivocal. If repeat scans confirm PD, then progressio n should be declared using the date of the 
initial scan. If repeat scans do not confirm PD, then the subject is considered to nothave 
progressive disease.
REFERENCES
1Scher HI, Morris MJ, Stadl er WM et al. Trial design and objectives for castrati on-resistant 
prostate cancer: Updated recommendat ions from the Prostate Cancer Clinical Tri als Working 
Group 3. J Clin Onco l 2016, 34(12):1402 -
18.
Protocol Amendment No.: 04
Date: 22-Sep-2023 158
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
APPENDIX 6 MANAGEMENT ALGORITHM S FOR STUDIES UNDER NCI 
CTCAE VERSION 5
These general  guidelines const itute guidance to the Invest igator and may be supplemented by 
discussio ns with the Medical Moni tor representing the Sponsor. The guidance applies to all 
immuno -oncol ogy agents and regimens.
A general princi ple is that different ial diagnoses shoul d be diligent ly evaluated according to 
standard medical pract ice. Non-inflammatory etiologies shoul d be considered and appropriately 
treated.
Corti costeroi ds are a primary ther apy for immuno -oncol ogy drug -related adverse events. The oral 
equivalent of the recommended IV doses may be considered for ambulatory  patients with 
low-grade toxi city. The lower bioavailabilit y of oral corti costeroi ds shoul d be taken into account 
when swit ching to the equivalent dose of oral corticosteroids.
Consultat ion with a medical or surgi cal specialist , especially prior to an invasive diagnostic or 
procedure, is reco mmended.
The frequency and severit y of the rel ated adverse events covered by  these alg orithms will  depend 
on the immuno -oncol ogy agent or regimen being used.
Protocol Amendment No.: 04
Date: 22-Sep-2023 159
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
B M S - 936558 nivolumab
6HS
Protocol Amendment No.: 04
Date: 22-Sep-2023 160
6.0 A pproved 930142083 5.0 v A pproved 1.0 v
Clinical Protocol CA2097DX
B M S - 936558 nivolumab
6HS
Protocol Amendment No.: 04
Date: 22-Sep-2023 161
6.0 A pproved 930142083 5.0 v A pproved 1.0 v
Clinical Protocol CA2097DX
B M S - 936558 nivolumab
6HS
Protocol Amendment No.: 04
Date: 22-Sep-2023 162
6.0 A pproved 930142083 5.0 v A pproved 1.0 v
Clinical Protocol CA2097DX
B M S - 936558 nivolumab
6HS
Protocol Amendment No.: 04
Date: 22-Sep-2023 163
6.0 A pproved 930142083 5.0 v A pproved 1.0 v
Clinical Protocol CA2097DX
B M S - 936558 nivolumab
6HS
Protocol Amendment No.: 04
Date: 22-Sep-2023 164
6.0 A pproved 930142083 5.0 v A pproved 1.0 v
Clinical Protocol CA2097DX
B M S - 936558 nivolumab
6HS
Protocol Amendment No.: 04
Date: 22-Sep-2023 165
6.0 A pproved 930142083 5.0 v A pproved 1.0 v
Clinical Protocol CA2097DX
B M S - 936558 nivolumab
6HS
Protocol Amendment No.: 04
Date: 22-Sep-2023 166
6.0 A pproved 930142083 5.0 v A pproved 1.0 v
Clinical Protocol CA2097DX
B M S - 936558 nivolumab
6HS
Protocol Amendment No.: 04
Date: 22-Sep-2023 167
6.0 A pproved 930142083 5.0 v A pproved 1.0 v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
APPENDIX 7 CYP3A4 STRONG INHIBI TOR AND INDUCER GUID ANCE
The lists below are not m eant to be all  inclusive. Please consult individual drug labels for further 
inform ation. Addit ional information is also available at:
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractio
nsLabeling/ucm093664.htm
Table 7-1: Representative examples of Drugs that are strong CYP3A4 
Inhibitors or Inducers
CYP EnzymeStrong Inhibitorsa
ÔÇ≥5 fold Increase in AUC
Or > 80% Decrease in CLStrong Inducers 
ÔÇ≥80% Decrease in AUC
CYP3ABoceprevir, clarithromycin, conivaptan, 
grapefruit juiceb, indinavir, itraconazole, 
ketoconazole, lopinavir/ritonavir, mibefradilc, 
nefazodone, nelfinavir, posaconazo le, rito navir, 
saquinavir, telaprevir, telithromycin, voriconazoleAvasimibed, carbamazepine, phenytoin, 
rifampin, St. Johns Worte
Abbreviations: AUC = area under the concentration time curve; ; CL = clearance; CYP = cytochrome P450
aA stro ng inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a substrate fo r that CYP 
by equal o r more than 5 -fold.
bThe effect of grapefruit juice varies widely among brands and is concentration, dose, and preparation dependent. 
Studies have shown that it can beclassified as a ‚Äústrong CYP3A inhibitor‚Äù when a certain preparatio n was used 
(eg, high dose, double strength) or as a ‚Äúmoderate CYP3A inhibitor‚Äù when another preparation was used (eg, low 
dose, single strength).
cWithdrawn from the U nited States market because of safety reasons.
dNot a marketed Drug .
eTheeffect of St John‚Äôs Wort varies widely and is preparation dependent .
Protocol Amendment No.: 04
Date: 22-Sep-2023 168
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
APPENDIX 8 ECOG PERFORMANCE STATUS
ECOG PERFORMANCE STATUSa
0 Fully  active, able to carry on all pre -disease performance without restriction
1Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, e g, light house work, office work
2Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and 
about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5 Dead
aOken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, and Carbone PP. Toxicity and Res ponse 
Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649 -655.
Protocol Amendment No.: 04
Date: 22-Sep-2023 169
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS-936558 nivolumab
APPENDIX 9 C OUNTRY SPECIFIC AMENDMENTS: HIV TESTING
Criteria for exclusion of HIV-positive subjects in  Argentina, Czech Republic, Germany, and any 
other countries where exclusion of HIV-pos itive participants is locally mandated:
Table 2-1 Screening Procedural Outline 
(CA2097DX)Add ÕÜHIV testing Õáto list of laboratory tests.
Section 6.2  Exclusion Criteria, 1) 
Medical Conditions i)Replace ÕÜKnown history of a positive test for human 
immunodeficiency virus (HIV) or known acquired immunodeficiency 
syndrome (AIDS). Note: Testing for HIV must be performed at all sites in Germany and where mandated by locally‚Äù with ‚ÄúPos itive test for 
HIV‚Äù
Section 9.6.1Clinical Safety Laboratory AssessmentsReplace ÕÜTesting for HIV must be performed at sites where mandated
locally‚Äù with ‚ÄúTesting for HIV must be performed. Õá
Protocol Amendment No.: 04
Date: 22-Sep-2023 170
6.0 Approved 930142083 5.0 v Approved 1.0 v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
APPENDIX 10 PROTOCOL AMENDMENT SUMMARY OF CHANGE HISTORY
Overall Rationale for the Protocol Amendment 03, 13-Sep-2022
Protocol  Amendment 03 includes changes to expand the radiographic progressi on-free survival 
(rPFS) analysis populat ion and 
clarify censoring rules for rPFS  
,and clarificat ion of pharmacokinet ic (PK) sampling at follow-up visits, and 
clarificati on of severe acute respi ratory  syndrome coronavirus 2 (SARS -CoV -2)serology at 
follow-up as opti onal. 
Main changes have been included in the statist ical analysis sect ion,in which the population for the 
number ofrPFS analysis has been changed from the first 544 randomized participants to all 
rando mized  for expansio n to Intent ion-to-treat (ITT) . By incorporating the 
delayed treatm ent effect , the number ofrPFS events has been increased from 433 to 530, the 
number of andthe number of overall survival (OS) events has been increased from 615 to 690 for 
final analysis .Addit ional revisio ns in the stati stical analysis section have been added to align and 
clarify the populati ons f oranalysis.  
Addit ional revisi ons, including to secti ons of  the Synopsis, have been made to ali gn the protocol 
with respect to these changes. This protocol amendment applies to all participants.
Summary of key changes f or Protocol 
Amendment 03
Section Number & Title Description of Change Brief Rationale
Title Page Changed one of the  
Medical Monitor from  
to .
Changed  from  
 to .To reflect updated personnel
Section 4 Objectives and 
Endpoints. Table 4-1Added clarification of the censoring rules 
for rPFS
Section 5.3 Number of 
ParticipantsAdded wording regarding global 
recruitment completion and China 
continuatio nof enrollmentTo clarify recruitment status at the 
moment of the global amendment 
Section 9.6 
Pharmacokinetics. Table 
9.6-1: Pharmacokinetic 
Sampling Schedule for All 
ArmsNotes added to collection follow -up to 
clarify  this is 30 or 100 days from the 
discontinuation of nivolumabTo clarify PK collection when 
nivolumab is discontinued during the 
treatment period but not docetaxel, 
making clear that PK collection is 
always related to nivolumab infusion
Section 10.1 Sample Size
Determination , and Table 
10.1-1Expanded rPFS analysis population from 
first 544 to all global randomized, and 
changed the number of target rPFS events 
from 433 to 530. OS events increased from 
615 to 690. Updated enrollment rate. rPFS an alysis was
expanded to the entire Intention -to-
treat (ITT) population. Another 
rationale for this change that is based 
on the curent observed event rate, it 
is not feasible to observe 433 events 
in the first 544 randomized 
participants . Based on previous 
observed delayed effect of nivolumab 
Protocol Amendment No.: 04
Date: 22-Sep-2023 171
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of key changes f or Protocol A mendment 03
Section Number & Title Description of Change Brief Rationale
and ipilimumab across tumors, 
implementation of delayed treatment 
effect was applied for both rPFS and 
OS resulting in modification to the 
number of target events. Enrollment 
rate was updated because current 
enrollment rate significantly deviates 
from that of the previous protocol.
Table 10.3.1 -1Efficacy 
Statistical Analyses Updated statistical analysis method to 
increase population for rPFS analysis from 
first 544 to all randomized  Updated rPFS 
censoring rule to include censoring at the 
date of last tumor assessment prior to the 
missed tumor assessments for participants 
who had progressive disease (PD) or death 
immediately after more than one 
consecutive missed tumor assessments.Updated to stay consistent with 
changes made in Table 10.1-1
Section 10.3.7.1 Interim 
Analy sis for OS Reduced % OS events estimated for the 
first interim analysis from  59% to 47%Updated to stay consistent with 
changes made in Table 10.1-1
All Minor formatting and typographical 
correct ionsTo correct minor errors
Overall Rationale for the Protocol Amendment 02, 17 -Mar -2021
Protocol  Amendment 02 includes changes  
 
to allow inclusio n of pat ients who have received prior radium -223. 
Dose modificat ion criteria and immuno -oncol ogy (IO) agent management algorithms have been 
aligned with National Cancer Institute Commo n Termino logy Criteria for Adverse Event s
(NCI 
CTCAE) versio n 5. Serologic testing for severe acute respiratory syndrome coronavirus 2 (SARS -
CoV -2) statushas been added . Addit ional updates have been incorporated in order to improve 
alignment between protocol  sections and clarify  remote monitoring, prior malignancy window, 
thyroid testing, and ma le contraception requirements. 
Addit ional revisi ons, including to secti ons of  the Synopsis, have been made to ali gn the protocol 
with respect to these changes. This protocol amendment applies to all participants.
Summary of key changes for Protocol Amendment 02
Section Number & Title Description of Change Brief Rationale
Title P age Updated contact information . To reflect changes in study personnel 
and align with changes in the BMS 
protocol model document .
Synopsis Updated synopsis to align with changes to 
protocol .To align with changes to protocol .
Protocol Amendment No.: 04
Date: 22-Sep-2023 172
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of key changes for Protocol Amendment 02
Section Number & Title Description of Change Brief Rationale
Section 2 :Schedule of 
Activities Table 2-1 and Table 2-2: U pdated notes for 
AE/SAE assessment to include SARS -
CoV-2.
Tables 2 -1 an d Table 2-2:Added SARS 
CoV-
2 serology procedure .Serum and AE/SAE collection in the 
context of SARS -CoV -2 was added 
in the event that coronavirus disease 
2019 (COVID -19) sequelae may 
increase toxicity or impact 
interpretation of study events/results .
Table 2-2: I ncluded Subsequent Cancer 
Therapy  row. To clarify requirements for reporting 
subsequent systemic therapies .
Table 2-2: U pdated notes for Brain 
Imaging .To clarify timing of brain MRI .
Table 2-2: Updated health outcome 
questionnaire requirements .To clarify timing of questionnaire 
completion .
Section 2 :Schedule of 
ActivitiesAdded minor clarifications and references 
to the notes across Tables 2 -1 and 
Table 2-2.To improve understanding of the 
procedures .
Section 3.3 :Benefit/Risk 
AssessmentUpdated source information for nivolumab 
clinical activity in various malignancies .To clarify source information of 
clinical activity for nivolumab . 
Section 4 :Objectives and 
Endpoints
Table 4-1: Objectives and 
EndpointsTable 4-1: Added SARS-CoV -2 
exploratory objective and endpoint . 
related to SARS -CoV -2.
Section 5.1.1 : Screening 
Phase 
Section 6.1 :Inclusion 
CriteriaUpdated criterion 2i to specify allowed 
prior cancer vaccine therapy ( eg, 
sipuleucel -T), and radium -223 therapy, 
and clarify the time require d between the To provide examples of prior prostate 
cancer vaccine therapy allowed in the 
study.
Protocol Amendment No.: 04
Date: 22-Sep-2023 173
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of key changes for Protocol Amendment 02
Section Number & Title Description of Change Brief Rationale
2) Ty pe of Participant and 
Target Disease 
Characteristicsprior therapy and the beginning of the 
study treatment.
 
 
Section 6.1 :Inclusion 
Criteria
3)Age and Reproductive 
StatusUpdated criterion 3b to reflect 
contraception requirements for males 
treated with docetaxel (ie, 6 months after 
the last dose of docetaxel).To update contraceptive requirements 
based on current safety information .
Section 6.2 :Exclusion 
Criteria
1)Medical ConditionsRem oved criterion 1a, as not applicable 
per Protocol Amendment 02, and replaced 
with criterion 1m, which clarifies study 
eligibility based on prior and/or concurrent 
malignancies . To update requirements for inclusion 
of patients with concurrent or prior 
malignancies and prior SARS -CoV -2 
infection .
Updated criterion 1kto include eligibility 
conditio n for participants with prior 
SARS -CoV -2 infection .To clarify of eligibility condition for 
participants with prior SARS -CoV -2 
infection .
Section 6.2 :Exclusion 
Criteria
2)Prior/Concomitant 
TherapyRem oved criterion 2d, as not appli cable 
per Protocol Amendment 02.To allow inclusion of patients who 
have received prior radium -223 or 
other radiopharmaceuticals, as da ta 
suggest that prior treatment with 
these agents does not affect safety of 
subsequent docetaxel treatmen t.
Updated criterion 2e to clarify use of 
complementary medication s.To clarify use of complementary 
medications .
Added criterion 2f, w hichclarifies 
eligibility of participants who received 
products designed to treat or prevent 
COVID -19. To clarify eligibility  ofparticipants 
currently  in other interventional 
trials, including those for COVID -19.
Section 6.2 :Exclusion 
Criteria
3) Physical and Laboratory 
Test FindingsAdded cl arification for eligibility of 
participants with symptomatic or 
asymptomatic SARS -CoV -2 infection .Included language to clarify 
expectations for eligibility and 
retesting for participants with 
suspected or confirmed symptomatic 
COVID -19.
Section 7.4:Dosage 
Modification 
Tables 7.4 -1 and 
Table 7.4-2 Added Table 7.4 -1:Adverse Event Criteria 
to Delay, R esume, or Discontinue 
Nivolumab/ Placebo and Table 7.4-2:
Adverse Event Criteria to Delay, Reduce, 
Resume, or Discontinue Docetaxel. To align with NCI CTCAE version 5. 
Protocol Amendment No.: 04
Date: 22-Sep-2023 174
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of key changes for Protocol Amendment 02
Section Number & Title Description of Change Brief Rationale
Updated entire section to align with new 
tables and remove redundant content. 
Section 7.4.2 : Docetaxel 
Dose Reduction
Section 7.4.3: Dose Delay 
Criteria
Section 7.4.4 : Criteria to 
Resume Study Treatment
Section 7.4.5 : Management 
Algorithms for Nivolumab
Section 7.4.6: Treatment of 
Related Infusion Reacti onsRem oved redundant content, updated 
section title, aligned content with CTCAE 
version 5, added SARS -CoV -2 language, 
and renumbered sections as needed .
Updated Section 7.4.2 to include one 
allowed dose reduction.
Updated Section 7.4.3 to align with Table
7.4-1 and Table 7.4 -2.
Updated Section 7.4.4 to align with Table 
7.4-1 and to provide criteria for resuming 
treatment after SARS -CoV -2 infection.
Updated Section 7.4.6 title to align with 
Table 7.4 -1To align with NCI CTCAE version 5 
and include SARS -CoV -2 language. 
Section 7.6.2: Other 
Restrictions and 
Precautions
Section 7.7: Concomitant 
TherapyRem oved r edundant content . Revised to align with NCI CTCAE 
version 5. 
Section 7.7.1: Prohibited 
and/or Restricted 
TreatmentsUpdated to clarify use of complementary 
medication s.To clarify use of complementary 
medications .
Section 7.7.4: Treatment 
Beyond ProgressionUpdated to specify permitted treatment up 
to a maximum of 24 months from date of 
first dose .To clarify treatment beyond 
progression .
Section 8.1.1: 
Discontinuation of Specific 
Study TreatmentsUpdated to align with Table 7.4 -1 and 
Table 7.4 -2.To align with Table 7.4-1 and Table 
7.4-2.
Section 8.1.2: Post Study 
Treatment  -Study Follow -
upUpdated to clarify collection of survival 
data.To align with Section 5.1.3.
Section 9: Study 
Assessments and 
ProceduresAdded clarification for additional 
measures and procedures .Included language for AE/SAE 
follow -up in the context of SARS -
CoV-2 in the event that COVID -19 
sequelae may increase toxicity or 
impact interpretation of study 
events/results.
Section 9.1.3: Patient -
Reported OutcomesAdded clarification for alternative 
administration methods .To clarify alternative administration 
methods . 
Section 9.2.1: The 5 -Level 
EQ-5DMade necessary clarifications and 
corrections .To clarify content .
Section 9.3: Adverse 
EventsMade necessar y clarifications and 
correction s.To clarify content . 
Protocol Amendment No.: 04
Date: 22-Sep-2023 175
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of key changes for Protocol Amendment 02
Section Number & Title Description of Change Brief Rationale
Section 9.3.1 : Time Period 
and Frequency for 
Collecting AE and SAE 
Information
Section 9.3.3: Follow -up of 
AEs and SAEsUpdated to include details related to 
follow -up of SAEs and nonserious AEs 
associated with confirmed or suspected 
SARS -CoV -2 infection.Included language for AE/SAE 
follow -up in the context of SARS -
CoV-2 in the event that COVID -19 
sequelae may increase toxicity or 
impact interpretation of study 
events/results .
Table 9.6 -1 
Pharmacokinetic Sampling 
Schedule for all ArmsUpdated foot note c to provide detailed 
instructio ns for PK blood sampling at the 
end of nivolumab infusion.To align with EPE version 6.
Section 9.6.1: Clinical 
Safety Laboratory 
AssessmentsUpdated table and footnotes to clarify T3
sampling requirements.To allow total T3 when free T3 is not 
available .
Section 11:References Updated r eferences to reflect changes in 
the content .To align with updated protocol 
content. 
Appendix 1: Abbreviations 
and Trademarks Updated abbreviations to reflect changes in 
the content .To align with updated protocol 
content .
Appendix 2: Study 
Governanc e 
Considerations Made necessary clarifications and 
corrections.To clarify content. 
Appendix 4: Childbearing 
Potential Definitions and 
Methods of Contraceptio nUpdated contraception guidance for male 
participants with partners of childbearing 
potential to reflect requirements for 
participants treated with docetaxel. 
Changed definition of relevant systemic Toalign methods of contraception 
with updates made to male 
contraceptive requirements in 
Section 6.1.
Protocol Amendment No.: 04
Date: 22-Sep-2023 176
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of key changes for Protocol Amendment 02
Section Number & Title Description of Change Brief Rationale
exposure to 6 months after end of 
docetaxel treatment. 
Appendix 6: Management 
Algorithms for Studies 
UnderNCI CTCAE 
version 5Updated title to include NCI. Replaced IO 
agent management algorithms with those 
aligned with NCI CTCAE v ersio n 5.Updated management algorithms for 
immune-mediated AEs to align with 
NCI CTCAE version 5and 
nivolumab Inv estigator Brochure.
All Minor formatting, typographical and style 
corrections. These changes are minor and 
therefore have not been summarized. 
Overall Rationale for the Revised Protocol 01, 06-May -2020
Revised Protocol 01 includes changes  
 
to clarify the inclusion criteria for current evidence of metastatic 
disease and prior treatment with NAT, and to clarify lesions that do not qualify as visceral disea se.
Frequency of tumor assessment was revised to enhance precisio n of the radiographic 
progression -free survival (rPFS) endpo intand thecriteria for stable disease (SD)was revised based 
on frequency of tumor assessments. The statist ical secti on now speci fies sample size for rPFS.
In addition Revised Protocol  01 includes revisi ons made  
. These include provi ding guidance ontreatm ent of infusi on reactions for nivolumab 
and docetaxel , clarifying the purpose of 30-minute observat ion period between nivolumab and 
docetaxel, mandating discontinuation of docetaxel for cystoid macular oedema (CMO) and for 
GradeÔÇ≥3 hypersensit ivity react ion
,and modifying the rules for dose reducti on of docetaxel to 
align with docetaxe l labeling .In addition to changes made for clarityand alignment with 
nivolumab program- wide standards , changes were also made to explicit ly state the time period for 
collect ion for all non-serious adverse events and to exclude participants with HIV, as described 
below.
Summary of Key C hanges for Revised Protocol 01
Section Number & Title Description of Change Brief Rationale
Title page BMS Research and 
Development address changed. Administrative correction. 
ÔÇ∑Synopsis Key Inclusio n 
Criteria
ÔÇ∑Secti on 2: Schedule of 
Activities: Table 2 -1, 
Screening Procedural 
Outline (CA2097DX); 
Eligibilit y Assessments: 
 Update of text that specifies 
requi red evidence of metastatic 
disease 
Added specificat ion that if the 
same NAT is given more than 
once in the context of a different 
disease setting, these NAT will Clarified pati ent eligibilit y
 
 
 
 
 
 
Protocol Amendment No.: 04
Date: 22-Sep-2023 177
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of Key C hanges for Revised Protocol 01
Section Number & Title Description of Change Brief Rationale
 
ÔÇ∑Secti on 6.1 Incl usion 
Criteria 2) Ty pe of 
Parti cipant and Target 
Disease Characteristics 
b), f), h) and j).be considered as separate NAT 
regimens
 
 
 
 
 
 
ÔÇ∑Synopsis Key Inclusio n 
Criteria
ÔÇ∑Secti on 6.1 Incl usion 
Criteria 2) Ty pe of 
Parti cipant and Target 
Disease Characteristics b) 
and e) The cri terion presented below is 
now moved (synopsis) and 
numbered separately (Section
6.1) as 2) b  i and deleted fro m 
criterion 2 e) ii
Parti cipants whose di sease 
spread i s limited to regional 
pelvic lymph nodes (N1) 
measuring at least 2 cm in short 
axis will be considered eligibleRevised for clari ty. 
ÔÇ∑Synopsis Key Inclusio n 
Criteria
ÔÇ∑Section 6.1 Incl usion 
Criteria 2) Ty pe of 
Parti cipant and Target 
Disease Characteristics i) Added to criterion: second -
generat ion horm onal 
manipulat ions (eg, abiraterone 
acetate, enzalutamide, 
apalutamide, and darol utamide) .
Radiation therapy , previ ously  
included in this criterion is 
moved to and clarified in Section 
6.2: Exclusio n Cri teria Medical 
Condi tions 1) d)Clarificat ion.
ÔÇ∑Synopsis Key Exclusio n 
Criteria
ÔÇ∑Secti on 6.2: Excl usion 
Criteria Medical 
Condi tions 1) a)Added th e following 
clarificati onto prior malignancy 
active wit hin the previous 3 
years : (i.e. participants wi th a 
history  of prior m alignancy are 
eligible if treatment was Clarificat ion
Protocol Amendment No.: 04
Date: 22-Sep-2023 178
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of Key C hanges for Revised Protocol 01
Section Number & Title Description of Change Brief Rationale
completed at l east 3 y ears before 
enrollment)
ÔÇ∑Synopsis Key Exclusio n 
Criteria
ÔÇ∑Secti on 6.2: Excl usion 
Criteria Medical 
Condi tions 1) d) Revised to: Prior radiat ion 
therapy  must be com pleted pri or 
to 2 weeks before start of study  
treatm ent and patients shoul d 
have recovered (Grade ÔÇ£1) from 
radiation-related toxi citiesClarificat ion of exclusio n 
for prior radiat iontherapy  
and recovery  from 
radiation-related toxi cities. 
ÔÇ∑Synopsis Key Exclusio n 
Criteria
ÔÇ∑Secti on 6.2: Excl usion 
Criteria, 1) Medical 
Condi tions i ) 
ÔÇ∑Secti on 9.4.4 Clinical 
Safety Laboratory  
Assessments Refere nce to Appendix 9 added Appendix 9 specifies 
modificati onsin specific 
protocol  sections regarding 
exclusio n of HIV -positive 
subjects in countri es where 
exclusio n of HIV -positive 
participants i s locally  
mandated.
ÔÇ∑Synopsis: 
Prior/Concomi tant 
Therapy
ÔÇ∑Secti on 6.2: Exclusio n 
Criteria, 2) 
Prior/Concomi tant 
TherapyBotani cal preparat ions intended 
for general healt h have been 
removed from  exclusio n 
criterion.Adjustment in program  
standard.
ÔÇ∑Synopsis: Overall Design
ÔÇ∑Secti on 5.1 Overall 
Design
ÔÇ∑Secti on 7.3 Method of 
Treatment AssignmentIn addit ion to bone and lymph 
node m etastases,  prostate lesio n 
(or bl adder/rectum if fro m direct 
invasion fro m prostate) are 
specified as not to be considered 
as visceral disease. To cl arify lesions that do 
not qualify as visceral
disease .
ÔÇ∑Synopsis : Number of 
Parti cipants
ÔÇ∑Secti on 10.1 Sam ple Size 
Determinat ion
ÔÇ∑Table 10.1-1: Sample 
Size Determinat ionText/table data added to state 
thatrPFS analysis will be based 
on the first 544 randomized
participants only. In addi tion, the 
number of  rPFS events for the 
rPFS analysis was changed from
372 to 433 .To cl arify the number of 
subjects for the rPFS 
analysis and correct the 
number of events needed 
for rPFS analysis.
ÔÇ∑Synopsis: Object ives and 
EndpointsMinor changes in endpoint text 
for rPFS.Aligned with specification 
that rPFS analysis will be 
Protocol Amendment No.: 04
Date: 22-Sep-2023 179
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of Key C hanges for Revised Protocol 01
Section Number & Title Description of Change Brief Rationale
ÔÇ∑Secti on 4. Object ives and 
Endpoints Table 4-1 
Object ives and Endpo intsbased on the first 544 
rando mized participants.
Secti on 2: Schedule of 
Activities  
Table 2- 1, Screening 
Procedural  Outline 
(CA2097DX): Eligibilit y 
Assessments: Brain Imaging 
and Body  ImagingMRI brain imaging for eligibilit y 
is required as part of screening, 
unless the participant has 
completed an imaging study  of 
the brain now within 28 days of 
rando mizat ion, rather than fro m
the beginning of study  drug 
administration  To cl arify t iming of 
screening MRI brain .
ÔÇ∑IRT Note specifies that once a 
participant is eligible for the 
study , IRT m ust be contac ted to 
rando mize the participant.Clarificat ion.
ÔÇ∑Secti on 2: Schedule of 
Activities 
Table 2- 1, Screening 
Procedural  Outline 
(CA2097DX) : 
Laboratory  Tests 
ÔÇ∑Secti on 2: Schedule of 
Activities Table 2 -2:On-
Study  Treatm ent and 
Follow
-up Procedural 
Outline for Arms A and 
B (CA2097DX) ; 
Laboratory  Tests
ÔÇ∑Secti on 9.4.4 Clinical 
Safety Laboratory  
AssessmentsRemoved urinalysis from 
laboratory  tests to be conducted 
at screening or on treatment. Alignment with specified 
program -wide laboratory  
tests.
Secti on 2: Schedule of 
ActivitiesFootnote added to specify that 
no dose escalat ion or reductions Clarificat ion.
Protocol Amendment No.: 04
Date: 22-Sep-2023 180
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of Key C hanges for Revised Protocol 01
Section Number & Title Description of Change Brief Rationale
Table 2-2: On-Study  
Treatment and Follow -up 
Procedural  Outline for Arms 
A and B (CA2097DX)
ÔÇ∑Study  Treatm ent: 
Dispense Study  
Treatmentfor nivo lumab are allowed. 
Addit ional details for Q3W and 
Q4W dosing are also included.
ÔÇ∑Safety: Assessment: AEs 
Assessment
ÔÇ∑Safety: Assessments: 
SAE AssessmentThe row was updated and text 
was added to the note for AE 
assessment to state that all non -
serious adverse e vents (not only 
those deemed to be treatment -
related) should be co llected 
continuously during the 
treatm ent peri od and for a 
minimum o f 100 day s following 
discontinuat ion of study  
treatm ent.
In addit ion to the exist ing row 
for AE assessment, a separate 
row was added for SAE 
assessment during treatment and 
follow-up periodsTo explicit ly state the time 
period for collect ion for 
non-serious AEs and SAEs.
Secti on 2: Schedule of 
Activities 
Table 2-2: On-Study  
Treatment and Follow -up 
Procedural  Outline for Arms 
A and B (CA2097DX)Assessment of concomitant 
medicat ion use has been 
removed as an assessment during 
survival fo llow-up.Aligned to program 
standard.
ÔÇ∑Secti on 2: Schedule of 
Activities: Table 2 -2:
On-Study  Treatm ent and 
Follow
-up Procedural 
Outline fo r Arm s A and 
B (CA2097DX)
Laboratory  Tests: 
Clinical Laboratory  Tests Note added to allow for labs to 
be conducted 72 hours prior to 
dosing for each cycle.Clarifies window to 
perform  labs pri or to each 
cycle.
Protocol Amendment No.: 04
Date: 22-Sep-2023 181
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of Key C hanges for Revised Protocol 01
Section Number & Title Description of Change Brief Rationale
Efficacy Assessments : 
Body  Imaging 
ÔÇ∑Secti on 5.1.2 Treatment 
Phase
ÔÇ∑Secti on 9.1.2 , BICR 
Confirmation o f 
Progression
(clarificat ion on imaging 
and subsequent therapy  
only) Tumor assessments shoul d occur 
every 9 weeks ( ÔÇ±7 day s) from 
first dose, regardl ess of 
treatm ent schedule or dose 
delays f or first 54 weeks , rather 
than for the first 28 weeks .
In addit ion, clarified that 
imaging must continue until 
radiographic progression per 
PCWG3 is confirmed by  BICR, 
even in cases where subsequent 
therapy  has begun.  
frequency of tumor 
assessment was revised to 
enhance precision o f the 
rPFS endpo int.
Clarificat ion. 
Secti on 2: Schedule of 
Activities 
Table 2-2: On-Study  
Treatment and Follow -up 
Procedural  Outline for Arms 
A and B (CA2097DX)
ÔÇ∑Footnote c [fo llow-up] 
ÔÇ∑Notes for Clinical 
Laboratory  Tests 
ÔÇ∑Secti on 9.4.4. Clinical 
Safety Laboratory  
AssessmentsIn Footnote c, Safet y Follow -up 
Visit 1 (FU1) can be performed 
on the date of discont inuat ion if 
that date is greater than 30 days
rather than 42 days from last 
dose. 
In addit ion, text or footnote 
added to indicate specific tests to 
be performed at FU2 only if 
toxicities are present .Revised in conjunct ion 
with nivo lumab standards.
Clarificat ion for study  
sites.
Secti on 2: Schedule of 
Activities 
Table 2-2: On-Study  
Treatment and Follow -up 
Procedural  Outline for Arms Text added to indicate 
assessments to be performed 
only at safet y FU1Clarificat ion for study  
sites.
Protocol Amendment No.: 04
Date: 22-Sep-2023 182
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of Key C hanges for Revised Protocol 01
Section Number & Title Description of Change Brief Rationale
A and B (CA2097DX) : 
Notes for the fo llowing 
assessments BPI -SF. FACT -
P, FACT -P PCS
Secti on 6.2 Excl usion 
Criteria 3)Physical and 
Laboratory  Test Findings i)Added as new exclusio n 
criterion: AST and/or ALT > 
1.5 x ULN concomita nt with 
alkaline phosphatase > 2.5 x 
ULNAligned with criteria in 
docetaxel labeling.
Secti on 7 Treatm ent Table 7 -
1, Study  Treatm ents for 
CA2097DXStudy  medicati ons have each 
been defined in -text as 
investigat ional product or non -
investigat ional productTo m ore clearly define 
study  treatm ents.
Placebos (0.9% sodium chloride 
and 5% dextrose for injection ) 
added to Table 7 -1To m ore clearly define 
study  treatm ents.
Secti on 7.1.1 Nivol umab or 
Placebo Combined with 
DocetaxelText describing nivo lumab 
monotherapy  or pl acebo dosing 
removed
Text describing mo nitoring for 
docetaxel infusio n reactions 
added.To better organize the 
inform ation in Sect ion 
7.1.1 to focus on Q3W 
nivolumab or placebo 
dosing in co mbinat ion with 
docetaxel and to add 
additional information on 
the purpose of 30 -minute 
observat ion peri od between 
the end of nivo lumab or 
placebo infusio n and the 
start of docetaxel infusio n.
ÔÇ∑Secti on 7.1.1 Nivol umab 
or Pl acebo Combined 
with Docetaxel .Specificat ion of 8 m g dose and 
clarificati on of  dexamethasone 
administr ation schedule .To align with 
dexamethasone 
Protocol Amendment No.: 04
Date: 22-Sep-2023 183
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of Key C hanges for Revised Protocol 01
Section Number & Title Description of Change Brief Rationale
ÔÇ∑Secti on 7.1.2 Nivo lumab 
or Pl acebo Dosingprem edicat ion specified in 
docetaxel product label.
Secti on 7.1.2 Nivol umab or 
Placebo DosingText describing nivo lumab 
monotherapy  or placebo dosing 
from Section 7.1.1 added
Text describing Q3W dosing 
removed .To better organize the 
inform ation in Sect ion 
7.1.2to focus on Q4 W
nivolumab monotherapy  or 
placebo dosing .
ÔÇ∑Secti on 7.4.2 Docetaxel 
Dose Reduction 
ÔÇ∑Table 7.4.2 -1: Dose 
Reductions for DocetaxelSecond dose reduction of 
docetaxel remo ved fro m text and 
from Table 7.4.2 -1. If a second 
dose reduction is required, the 
protocol  now indicates that the 
participant shoul d discontinue 
docetaxel treatment.
Reference to Section 8.1.1.2 
Docet axel Discont inuation addedTo align with docetaxel 
product label.
For cl arity.
Secti on 7.4.3.2 Docetaxel 
Dose DelayBulleted list reformatted Clarificat ion.
ÔÇ∑Secti on 7.4.3.2 Docetaxel 
Dose Delay
ÔÇ∑Section 8.1.1.2 Docetaxel 
DiscontinuationAddition of information on 
impaired vision and cystoid 
macular oedema (CMO) to the list 
of events for which docetaxel dose 
delay or permanently discontinued 
should be considered.Added to align with 
docetaxel label .
Secti on 7.4. 6Treatment of 
Nivo lumab-related Infusio n 
React ionsAddit ion of information for 
treatm entof infusio n react ions 
related to nivo lumabAlignment with standards 
for studi eswith nivo lumab. 
Secti on 7.4.7 Docetaxel -
related Infusio nReacti onsNew sect ion added Updated to align wit h the 
EU Sm PCfor docetaxel .
Secti on 7.7.1 Prohibited
and/or Restricted 
Treatments : 7.7.1.1 All 
Parti cipantsSpecificat ion added for 
restri ction/allowance of non-
palliat ive and palliat ive 
radiation.
Restriction o f botani cal 
preparati ons to provide 
supportive care ha s been 
removed from  this secti on.Adjustment in program  
standard .
Protocol Amendment No.: 04
Date: 22-Sep-2023 184
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of Key C hanges for Revised Protocol 01
Section Number & Title Description of Change Brief Rationale
Secti on 8.1 Discont inuat ion
from Study  Treatm entThe fo llowing text added :
Terminat ion of the study  by 
Bristol-Myers Squibb (BMS) for 
reasons including but not limited 
to the following: safet y 
concerns, terminat ion of drug 
development, lack o f efficacy, 
and lack of meet ing study 
objectives/endpo ints.To cl arify reasons for 
sponsor -mandated 
discontinuat ion.
Clinical progression has been 
deleted fro m criteria for 
discontinuat ion from  study  
treatm ent. For consistency wit h the 
protocol :discontinuat ion is 
only mandated for 
radiographic progression
ÔÇ∑Secti on 8.1 
Discontinuati onfrom 
Study  Treatm ent
ÔÇ∑Secti on 9.1.2, BICR 
Confirmation o f 
ProgressionText added to clarify  that PSA 
progression alo ne is not an 
indicat ion to stop treatment. 
Discontinuation from study  
treatm entis only mandated for 
radiographic progression per 
PCWGS criteria for measurable 
disease and/or bone disease.Clarificat ion. 
Secti on8.1.1. 2 Docetaxel 
Discontinuati onPerm anent discont inuat ion for 
any Grade ÔÇ≥3 drug-related 
hypersensit ivity react ion added .Updated to align wit h the 
EU Sm PCfor docetaxel . 
Secti on 9.1.1.2 Im aging and 
Clinical AssessmentA Best Overall Response (BOR) 
ofSD requires a minimum of 56 
days rather than 49 days on 
study  from date of first dose to 
the date of the first imaging 
assessmentClarificat ion ofminimum 
criteria for SDbased on 
frequency  of tumor 
assessments .
Secti on 9.2 Adverse Events Paragraph added :
Immune-mediated adverse 
events are AEs consistent with 
an immune -mediated m echanism  
or immune -mediated component 
for which non -inflammatory  
etiologies (eg, infection or tumor 
progression) have been ruled 
out. IMAEs can include events 
with an al ternate etiology  which Alignment with nivolumab 
standards.
Protocol Amendment No.: 04
Date: 22-Sep-2023 185
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of Key C hanges for Revised Protocol 01
Section Number & Title Description of Change Brief Rationale
were exacerbated by  the 
induct ion of autoimmunit y. 
Inform ation supporting the 
assessment will be co llected on 
the participant‚Äôs case report 
form.
Secti on 9.2.1
Time Period and Frequency  
for Collect ing AE and SAE 
Inform ationText added. For participants 
assigned to treatm entand never 
treated with study  drug, SAEs 
shoul d be collected for 30 day s 
from the date of treatment 
assignment.
Text was added to state that all 
non-serious adverse events (not 
only those deemed to be 
treatm ent-related) should be 
collected continuously during 
the treatment period and for a 
minimum o f 100 day s following 
discontinuat ion of study  
treatm ent.Alignment with nivo lumab 
standards .
To explicit ly state the time 
period for collection for 
non-serious adverse events.
Secti on 9.2.2 , Method of 
Detecting AEs and SAEsParagraph added .
Every  adverse event m ust be 
assessed by  the invest igator with 
regard to whether it is 
considered immune -mediated. 
For events which are potentially 
immune -mediated, addit ional 
inform ation will be co llected on 
the participant‚Äôs case report 
form.Alignment with nivo lumab 
program standard.
Secti on 9.4.4 Clinical Safety  
Laboratory  AssessmentsBUN orSerum Urea
Uric acid, creatine kinase, total 
protein, and direct bilirubin 
removed from  lab assessments. Revised to align with the 
most recent l anguage for 
BMS studies and to align 
with specified program -
wide laboratory  
assessments. 
Protocol Amendment No.: 04
Date: 22-Sep-2023 186
6.0
Approved
930142083
5.0
v
Approved
1.0
v
Clinical Protocol CA2097DX
BMS -936558 nivolumab
Summary of Key C hanges for Revised Protocol 01
Section Number & Title Description of Change Brief Rationale
Secti on 11. References References added. New references added in 
support of changes 
 
Appendix 1 Abbreviat ions
and Trademarks Addit ion of terms to align wit h 
protocol  contentUpdated for clarity.
Appendix 5 APPENDIX 5 :
Prostate Cancer Working 
Group 3 (P CWG3 ) 
Guidelines (Wit h Modified 
Response Evaluat ion Cri teria 
In Solid Tumors (R ECIST ) 
Criteria For Soft Ti ssue 
Lesio n Assessment)
Secti on 1.3 Speci al 
considerations regarding 
bone lesio nsAdded text to specify that bone 
lesionswill be assessed as non-
target lesio ns.Clarificat ion.
Appendix 9 Country  Specific 
Amendments : HIV TestingNew Appendix added that 
describes procedures for HIV 
testing to be performed in 
Germ any and any other site 
where exclusio n of HIV -positive 
participants i s mandatedAppendix 9 specifies 
modificati ons in specified 
protocol  sectionsregarding 
exclusio n of HI V-positive 
subjects in countri es where 
exclusio n of HIV -positive 
participants i s locally  
mandated.
Protocol Amendment No.: 04
Date: 22-Sep-2023 187
6.0
Approved
930142083
5.0
v
Approved
1.0
v